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ABSTRACT
Previous work has demonstrated the importance of neutrophil derived proteolytic enzymes in the
pathogenesis of acute pulmonary inflammation. The protease/anti-protease balance theory of lung
disease relies on the presence of substances within the lung which inhibit these enzymes. These
include alpha-1-antiprotease, secretory leukoprotease inhibitor (SLPI) and elafin. Indeed these
inhibitors have been used to modulate the inflammatory response both in vitro and in vivo. Whilst
only limited data currently exists in relation to the ovine orthologs of these inhibitors the potential of
this species as an intermediate model for lung-directed gene therapy has recently been highlighted and
warrants further applied research. This thesis is directed towards this aim.
The first section details the cloning and characterisation of the ovine forms of SLPI and elafin. The
ovine orthologs show many characteristics in common with the human forms of these proteins
including distributions at mucosal sites and activity against neutrophil elastase in vitro. The
identification of the sequences of the genes encoding ovine SLPI and elafin has expanded the current
knowledge based on members of the whey acidic protein (WAP) and Trappin families of protein.
The ovine elafin sequence facilitated the construction of a replication-deficient adenovirus (Ad-o-
elafin) for use as an efficient vector in lung-directed gene therapy in the context of lipopolysaccharide
(LPS)-mediated direct lung injury. The data demonstrates that local lung administration of Ad-o-elafin
up-regulates the innate immune response to intra-pulmonary LPS both within areas of the lung
directly exposed to the virus and also in spatially disparate lung segments not receiving adenovirus.
Additionally, the endobronchial administration of Ad-o-elafin abrogates the circulating leukocytosis
seen as a result of intra-pulmonary LPS instillation when compared to control adenovirus. This
suggests a role for local elafin up-regulation in the stimulation of the innate immune response with a
concomitant decrease in the systemic response.
These data expand a relatively narrow knowledge base in relation to lung-directed adenoviral-
mediated gene therapy in large animal models. In particular the extent of influence of a local gene
delivery has been highlighted and is potentially of direct relevance to the design of applied protocols
aimed at modulating the inflammatory response in the lung.
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This chapter will outline and discuss the literature which forms the background for the work presented
within this thesis.
The main objectives identified at the start of this work were:
1. To investigate and characterise the ovine orthologs of the anti-proteases elafin and
secretory leukoprotease inhibitor (SLPI), proteins which have been extensively
researched in man and other mammals.
2. To construct, characterise and optimise an adenoviral vector encoding one of these anti-
proteases.
3. To assess the effects of adenoviral up-regulation of the anti-protease shield in the sheep
lung on the response to local inflammation.
Component aims within objective 1 included (a) the isolation and sequencing of the cDNAs for these
proteins followed by the screening of an ovine bacterial artificial chromosome (BAC) library to allow
the sequencing of the relevant genes, (b) an assessment of the distribution of these anti-proteases in
the sheep at the RNA level, and (c) an appraisal of the functional activity of the ovine proteins by
transfection of mammalian cells with expression plasmids containing the anti-protease cDNAs, and
investigation of anti-protease activity in the culture supernatant.
Component aims within objective 2 included (a) the construction of an adenoviral vector encoding one
of these anti-proteases, (b) the optimisation of transfection efficiency in vitro and in vivo, and (c) the
characterisation of the immediate response to adenoviral vector instillation in the lung.
Finally, in objective 3 an ovine model of acute inflammation was developed in order to determine
whether adenoviral up-regulation of the anti-protease shield in the sheep lung would modulate aspects
of the local or systemic response to endotoxin.
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This introductory chapter will review important topics with relevance to the experimental work
detailed in chapters 3 to 7 of this thesis. A crucial concept within this thesis is that of the
protease/anti-protease balance in the lung and this is explained and discussed in the context of the
potential benefits of being able to artificially manipulate the balance.
The available evidence in relation to manipulating this balance through protein delivery or gene
transfer is reviewed and discussed prior to a short justification of the choice of the sheep as an




1.2. The proteinase/anti-proteinase balance in the lung
1.2.1. The role of neutrophil derived enzymes in lung inflammation.
The identification that the congenital deficiency of al-antitrypsin leads to premature development of
pulmonary emphysema (Laurell and Eriksson, 1963; Eriksson, 1964) coincided with work done to
model emphysematous changes by instilling the proteolytic enzyme papain into the lungs of rats
(Gross et al., 1965). This work led to the protease/anti-protease balance hypothesis of pulmonary
inflammation with regards chronic lung disease, specifically chronic bronchitis, emphysema and
chronic obstructive pulmonary disease (Kueppers et al., 1974 and 1978; Lieberman, 1976; Morse,
1978A and B; Janoff, 1985). The sources of proteases in lung disease include mast cells, neutrophils
and macrophages. The neutrophil derived enzymes neutrophil elastase, cathepsin G and proteinase 3
are of particular significance as a consequence of the large number of circulating neutrophils found
within the lung's vasculature and the critical role this cell plays in the progression of acute
inflammation. These proteases are contained within the neutrophilic azurophilic granules which also
contain myeloperoxidase and defensins. Neutrophils also contain specific granules (which harbour
collagenase, gelatinase, histaminase, lysozyme and lactoferrin) and other non-specific granules. The
proteolytic enzymes mentioned above are now discussed in more detail.
Human neutrophil elastase (HNE) is the major proteolytic enzyme contained within the azurophilic
granules and is a serine protease which degrades various substrates such as elastin (Reilly and Travis,
1980), proteoglycan and collagen (Starkey et al., 1977), matrix proteins found within the
alveolar/capillary membrane. HNE has a positive feedback function in the promotion of inflammation
and neutrophil influx as it stimulates the release of IL-8, which is a potent neutrophil chemokine
(Adams and Lloyd, 1997; Mukaida, 2003). In addition to both direct and indirect anti-bacterial
activities HNE also stimulates goblet and mucosal cell secretion, increases vascular permeability and
stimulates broncho-constriction (Smallman et al., 1984; Sommerhoff et al., 1990; Nadel, 1991; Suzuki
et al., 1996). Additional effects include cleavage of complement components on opsonised bacteria
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(Tosi et al., 1990), of lymphocyte surface markers (Doring et al., 1995), and of CD14 on Monocytes
(Le Barillec et al., 1999) and macrophages (Henriksen et al., 2004A). Exogenous HNE instillation into
the lungs of experimental animals causes the development of emphysematous lesions (Janoff et al.,
1977; Senior et al„ 1977).
Proteinase 3 (PR-3) is a cationic serine proteinase related to HNE which is more active than HNE in
acidic conditions (Kao et al., 1988). Like HNE, PR-3 can induce IL-8 (Berger et al., 1996) and can
cleave the anti-protease secretory leukoprotease inhibitor (SLPI) (Rao et al., 1993). PR-3 degrades
elastin, fibronectin, collagen type IV, laminin and vitronectin (Rao et al., 1991). PR-3 has been shown
to occur at higher concentrations than HNE in sputum from patients with cystic fibrosis and may be
more resistant to proteolytic degradation in vivo (Witko-Sarsat et al., 1999). Additionally, the
observation that DNA does not bind to and inhibit PR-3 (whereas this does occur with HNE and
cathepsin G) has prompted speculation that PR-3 could be the most important proteinase with activity
in the diseased lung (Duranton et al., 2000).
Cathepsin G is also related to HNE at the amino acid level but seems to be a relatively weak
proteolytic enzyme. It has stimulatory effects on the activity of HNE against elastin (Boudier et al.,
1981; Lucey et al., 1985). In common with HNE and PR-3, cathepsin G stimulates submucosal gland
secretion and increases vascular permeability (Somerhoff et al., 1990; Peterson et al., 1995).
1.2.2. The anti-elastase shield of the lung.
The balance hypothesis predicts the presence of mechanisms to control the proteolytic activity of the
enzymes discussed above. The major constituents of this anti-proteinase screen with respect to the
neutrophil-derived proteases are the proteins al-antiproteinase, elafin and secretory leukoprotease
inhibitor, and also in sheep the novel Kazal type anti-proteinase sheep lung elastase inhibitor (SLEI).
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al-Antiproteinase (al-antiprotease, al-antitrypsin) is a 52kDa glycoprotein (in man) synthesized and
secreted by the liver before entering the lung passively by diffusion from the circulation. It is a major
anti-proteinase in the lung with estimates of its contribution to the total anti-proteinase screen varying
between 50 and 90% (Gadek et al., 1981; Boudier et al., 1983; Sallenave et ah, 1999). al-
Antiproteinase shows characteristics of acute phase proteins and plasma levels increase during acute
inflammation (Dickson et al., 1974), though increases in production are seen secondary to IL-6 which
leads to a delayed increase compared to the situation seen with SLPI and elafin discussed below.
Within the lung al-antiproteinase is also secreted by monocytes, macrophages and epithelial cells
(Perlmutter et al., 1985; Sallenave et al., 1997A; Cichy et al., 1997). Functional modification of al-
antiproteinase may be an important effect of cigarette smoking due to the presence of an oxidation-
sensitive methionine residue in the active site (Carp et al., 1982). Equally oxidants from macrophages
and neutrophils have also been identified as a source of al-antiproteinase inactivation (Hubbard et al.,
1987; Wallaert et al., 1991 and 1993A and B). More than 75 mutations in the al-antiproteinase
protein have been identified, however the most important clinically is the Z mutation (Lomas and
Mahadeva, 2002). Mutations in the al-antiproteinase protein are associated with a reduction in the
functional capacity of this enzyme and the premature development of emphysema (Eriksson, 1996).
Interestingly, al-antiproteinase can protect against the effects of TNF and LPS possibly due to the
induction ofIL-1 receptor antagonist (Tilg etal., 1993; Libert et al., 1996).
Secretory leukoprotease inhibitor (SLPI) is a small (11.7kDa in human), cationic, secreted protein
found throughout mucosal sites in the body. In the lung SLPI is secreted by the serous cells of the
bronchial sub-mucosal glands, the non-ciliated epithelial cells of the airway walls and by alveolar
macrophages (Stolk and Hiemstra, 1999), and is also an important anti-protease in neutrophils
(Sallenave et al., 1997B). SLPI inhibits HNE, cathepsin G, trypsin, chymotrypsin and chymase (Fink
et al., 1986; Boudier and Bieth, 1992) via an active site in the second of two whey acidic protein
(WAP) domains found in the boomerang-shaped mature SLPI protein (Grutter et al., 1988; Eisenberg
et al., 1990). It is the WAP domains, containing 4 disulphide bonds each, which indicate a close
relationship with the very similar anti-proteinase elafin discussed below.
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Elafin (elastase-specific inhibitor, skin-derived antileukoprotease) is also a small (9.9kDa) secreted
cationic protein. SLPI and elafin can be regarded as members of the anti-leukoprotease family, though
it is more accurate to regard elafin as a member of the trappin family (Schalkwijk et al., 1999) due to
the presence of a sequence made up of repeats of the consensus sequence PVKGQD which constitute
the 'transglutaminase substrate domain'. Transglutaminase enzymes cross-link the lysine and glutamic
acid residues of these molecules to other matrix proteins (Steimert and Marekov, 1995; Nemes and
Steinert, 1999). Elafin has a more specific spectrum of activity than SLPI with human elafin inhibiting
HNE, PR-3 and porcine pancreatic elastase (PPE) (Schalkwijk et al., 1999).
Due to their similar characteristics SLPI and elafin can be regarded as a functionally discrete group of
low molecular weight cationic anti-proteases. Both have been termed 'alarm antiproteases' due to
their up-regulation by IL-1, TNF, HNE, defensins and bacterial LPS (Sallenave, 2000). In addition to
the well-recognised anti-proteinase activity of elafin and SLPI, several additional functions for these
proteins in the innate immune response have been postulated. SLPI has been shown to have
bactericidal activity against both Escherichia coli and Staphylococcus aureus representing both Gram-
negative and Gram-positive organisms respectively (Hiemstra et al., 1996), and elafin shows activity
against Pseudomonas aeruginosa (Gram-negative) and S. aureus (Gram positive) (Simpson et al.,
1999). In addition SLPI inhibits the replication of HIV-1 in monocytes (McNeely et al., 1995) and
also has anti-fungal properties (Tomee et al., 1997). SLPI has been characterised as a protein induced
by, and antagonistic to, bacterial LPS and can also be used in transfection experiments to render
macrophages hypo-responsive to LPS (Jin et al., 1997). Elafin modulates the LPS response in
endothelial cells and macrophages (Henriksen et al., 2004B; McMichael et al., submitted manuscript).
SLPI also inhibits the production of metallo-proteases by monocytes and macrophages by the
inhibition of prostaglandin synthetase-2 (Zhang et al., 1997). These emerging roles for both SLPI and
elafin in the innate immune response represent an exciting and interesting field which is of great
relevance to potential therapeutic applications.
A final serine proteinase inhibitor has been isolated and characterised from the bronchoalveolar lavage
fluid of the sheep. This is a Kazal-type inhibitor (Mistry et al., 1997) and is known as Sheep Lung
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Elastase inhibitor (SLEI) and is a glycosylated anionic protein with a molecular weight of 16.8-
17.3kDa produced locally within the lung. SLEI inhibits human neutrophil elastase and porcine
pancreatic elastase but not cathepsin G. The median molar ratio of SLEI to al-antiproteinase in the
sheep BALF (3.2 to 1) indicates its potential importance in the ovine lung.
Preliminary work in man has suggested the presence of an analogous inhibitor in the BALF (Bingle et
ah, 1995).
1.3. The modulation of the lungfe inflammatory response
1.3.1. Therapeutic manipulation of the anti-elastase shield.
Prior literature in relation to the therapeutic effects of these anti-proteinases on the pathophysiology of
the inflamed lung concern either the direct administration of protein to the lung or the use of gene
transfer (or gene therapy) techniques to deliver the anti-proteinase cDNA to the lung.
Most studies involving protein delivery have focused on potential benefits with respect to
emphysematous lung damage associated with deficiency of al-antiproteinase. Protocols of protein
delivery have varied from the use of fractionated human plasma (MacDonald and Johnson, 1995)
through to recombinant protein produced by transgenic animals (Colman, 1999; Tebbutt, 2000). The
results of studies in human patients have been equivocal. Evidence from North America and
Scandinavia suggests that protein treatment using recombinant al-antiproteinase does indeed slow the
decline of FEV, (Eriksson, 1996; The Alpha-1-Antitrypsin Deficiency Registry Study Group, 1998)
although other studies have disputed this (Dirksen et al., 1999). The seemingly disappointing response
to al-antiproteinase may relate to the protein's sensitivity to oxidation or an inability to access the
interstitial site of proteolytic activity (Campbell and Campbell, 1988). In cystic fibrosis patients,
nebulized al-antiproteinase augments neutrophil-mediated killing of Pseudomonas aeruginosa by
epithelial lining fluid (McElvaney et al., 1991). Beneficial effects have also been shown in the
modulation of allergic lung inflammation in sheep whereby pre-treatment with aerosolised al-
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antiproteinase inhibited antigen-induced broncho-constriction, possibly as a result of a modulation of
tissue kallikrein activity (Forteza et al., 1996).
Recombinant SLPI has also been delivered by aerosolisation to sheep with allergic lung inflammation
as a consequence of sensitisation and challenge with Ascaris suum. Administration for 4 days prior to
antigen challenge inhibited both early and late phase broncho-constriction, inhibited hyper-sensitivity
to carbachol and also inhibited the antigen-induced decrease in tracheal mucus velocity (Wright et ah,
1999). The same group also demonstrated that SLPI inhibited airway hyper-responsiveness induced
by histamine in ovalbumin sensitised guinea pigs, and allergen-induced influx of leukocytes into the
lung in a murine model (Wright et ah, 1999). rSLPI has also been shown to modulate the effects of the
neutrophil influx seen after immune complex deposition in the rat lung. In this latter case rSLPI
significantly decreased the lung damage as assessed by haemorrhage and vascular permeability
(Mulligan et ah, 1993).
Studies involving the use of elafin protein in the lung are limited to the work by Tremblay et ah who
have shown that the intra-tracheal administration of human pre-elafin (the 117 amino acid form
including the signal sequence) to Golden Syrian hamsters inhibited HNE-induced lung haemorrhage
(Tremblay et ah, 2002). Further work by the same group demonstrated that pre-elafin instillation led
to a dose-dependent inhibition of LPS-induced neutrophil influx in C57BL/6 mice and significantly
decreased gelatinase activity, macrophage inflammatory protein-2 and KC levels in the
bronchoalveolar lavage fluid (Vachon et ah, 2002).
Work performed within this laboratory has so far focused on the in vivo administration of human
elafin to murine models, using adenoviral vectors. Principally, Simpson et ah, (2001 A) investigated
the effects of an adenovirus encoding human elafin (Ad-elafin) on the progression of pneumonia in
mice induced by the intra-tracheal instillation of Pseudomonas aeruginosa. The same workers had
previously shown that purified human elafin protein had anti-microbial effects against Staphylococcus
aureus and Pseudomonas aeruginosa (Simpson et ah, 1999). The instillation of Ad-elafin 5 days prior
to the intra-tracheal administration of P. aeruginosa led to a significant decrease in recovered bacterial
colonies isolated from the BALF 24 hours later, with a concomitant decrease in BALF total protein,
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when compared to both a PBS control and the instillation of the control adenovirus Ad-lacZ, encoding
for the beta-galactosidase gene (Simpson et al., 2001A).
Importantly, in preliminary experiments the same group could not show any detectable human elafin
in the serum of animals that received Ad-elafin administered intra-tracheally indicating that transgene
expression in an anatomically and physiologically discrete lung compartment led to an improved
outcome in bacterial clearance.
1.3.2. Models to investigate the modulation of the lung's innate immune response.
The experimental work of Simpson et ah (2001A) referred to in section 1.3.1 was of great importance
in providing in vivo experimental evidence to support the existence of a link between the anti-protease
shield and the innate immune system within the lung. This potential link has led to the concept that
elafin may have a role in the compartmentalisation of the immune response within the lung (Sallenave
et ah, 2003). In addition to the direct bacterial infection of the lung (Simpson et ah, 2001A), acute
lung injury may also occur secondary to systemic sepsis. In this context the adult respiratory distress
syndrome (ARDS) may occur (Fein et ah, 1983; Fowler at ah, 1983; Montgomery et ah, 1985;
Niederman and Fein, 1990). During sepsis the pro-inflammatory cytokine TNF-a (TNF) is elevated
and the levels are correlated with severity (van der Poll and Lowry, 1995; Calandra et ah, 1990).
Equally TNF administration can mimic some of the deleterious effects of sepsis (Natanson et ah,
1989). Conversely, the blockade of TNF in patients leads to a worsened prognosis (Fisher et ah,
1996). This paradox may reflect a role for TNF in the innate immune response and indeed TNF has
been shown to activate the phagocytosis and microbicidal activity of alveolar macrophages and
neutrophils in vitro (Le and Vilcek, 1987; Tan et ah, 1995). This background information led Chen et
ah (2000) to examine the influence of adenoviral transfer of murine TNF cDNA in a murine model of
experimentally induced sepsis. The model involved caecal ligation and puncture (CLP) followed by
instillation of Pseudomonas aeruginosa into the lungs. The study showed that mice benefited from
receiving Ad-TNF intra-tracheally relative to those receiving control virus or vehicle alone.
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Additionally the Ad-TNF treated animals yielded significantly fewer P. aeruginosa colonies 24 hours
after bacterial instillation compared to control adenovirus. Alveolar macrophages (AMs) from Ad-
TNF treated mice also showed a higher phagocytic index compared to AMs from control adenovirus
treated animals when cultured ex vivo with bacteria. This compartmental activation of the innate
immune system by local adenovirus-mediated expression of a pro-inflammatory cytokine has
interesting and important implications for the delivery of other potentially immuno-stimulatory
cDNAs to the lung.
Of particular interest is the use of 11-10 in models of localised inflammation which has shown
differing effects dependent upon the site of administration. 11-10 has been demonstrated to inhibit the
clearance of bacteria from the murine lung with a concomitant increase in mortality (van der Poll et
al., 1996) and equally the neutralisation of 11-10 leads to an improved survival and increased bacterial
clearance (Greenberger et ah, 1995). In contrast, the systemic administration of 11-10 appears to be
protective in models of respiratory tract infection and sepsis (Sawa at ah, 1997; Kurahashi et ah,
1999). Morrison et ah (2000) showed that the intra-tracheal delivery of an adenovirus encoding for IL-
10 could ameliorate lung damage in a porcine model of pneumonia caused by Actinobacillus
pleuropneumoniae although this work looked at a single time-point 24 hours post-bacterial infection.
Additional data utilising gene transfer techniques in pneumonia models have demonstrated a
beneficial effect with regards bacterial clearance by IL-12 (Greenberger et ah, 1996) and IFN-y (Lei et
ah, 1997).
The lung's innate immune response is orchestrated by a complex balance of 'pro' and 'anti'
inflammatory cytokines. The investigation of techniques allowing the manipulation of the anti-
protease shield within the inflamed lung may yield important information with respect to a link
between this protective barrier and the stimulation or otherwise of the innate immune response.
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1.3.3. Large animals as models for lung-directed gene therapy.
Large animals have played an important role in the development of comparative models of diseases
affecting the lung and the investigation of therapeutic strategies therein.
The reasons that prompt research in larger species are various but are frequently related to either
particular species-specific similarities to human subjects in relation to host responses in the context of
either natural or experimentally induced disease or are related to issues surrounding the development
of delivery protocols of relevance to human clinical medicine.
Predominant within the literature are studies using dogs in models of lung cancer both by the topical
application of known carcinogens (Okita et al., 1977; Shors et al., 1980; Benfield et al., 1981) or by
the transfer of tumour tissue (Ahrar et al., 2002). Equally dogs have been used to investigate therapies
for lung tumours including chemotherapy, radiotherapy and radiofrequency ablation (Pass et al., 1987;
Hershey et al., 1999; de Boer et al., 1999; Demmy et al., 2002; Ahrar et al., 2003). However, other
mammalian species have been utilised in the majority of gene transfer techniques to the respiratory
tract. For example the pig has been used in several studies using both plasmid DNA formulations
(Nabel et al., 1992) and adenoviruses (Chapelier et al., 1996; Morrison et al., 2000). Interestingly,
Hackett et al. (2000) showed that 90% of adenoviral vector injected intravenously in the pig localised
to the lung which is in stark contrast to the situation seen in rodent studies where vector localises to
the liver illustrating an important difference between rodent and larger animal models.
By far the majority of gene transfer studies have utilised primates. Several studies relevant to viral
gene transfer to the respiratory tract have been performed by the group of Dr. James Wilson of The
Gene Therapy Programme at the University of the Pennsylvania School of Medicine. These have
investigated the adenoviral delivery of the cystic fibrosis transmembrane conductance regulator
(CFTR) cDNA to primate lungs (Engelhardt et al„ 1993; Simon et al., 1993; Goldman et al., 1995;
Chirmule et al., 1998) as a preface to human clinical trials, and also the blockade of CD-40
interactions with its ligand to abolish the mucosal IgA response to the vector (Chirmule et al., 2000).
Brody et al. (1994) demonstrated a dose-dependent inflammatory response to adenovirus which could
persist for up to 2 months, and Sene et al. (1995) and Lerondel et al. (2001) developed a novel aerosol
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based delivery protocol for adenovirus. Finally, primates have also been used to optimize the in vivo
delivery of the use of aerosolised DNA/lipid complexes (McDonald et al., 1998).
The sheep has gained popularity as a model for human lung disease for a variety of reasons not least
of which being the broadly comparable lung volumes shared by these species (the average lung
volume for a 50kg young adult female human is approximately 5.5 litres compared to approximately 4
litres for a sheep of equivalent weight). Sheep have become widely used in surgical science (Borrie
and Mitchell, 1960; Hecker, 1974; Zrunek et al., 1988; Ingenito et al., 2001 and 2003) with their size
and docile nature facilitating general ease of handling. They are also amenable to experimental
interventions such as repeated venepuncture and don't represent any particular anaesthetic risk. With
regards the respiratory system, sheep are a good model for the human system on account of a similar
anatomy (McLaughlin et al., 1961; Plopper et al., 1983; Mariassy and Plopper, 1983). Indeed this
similarity extends to the histochemical and cytochemical characteristics of the secretory cells within
the respiratory tract (Mariassy et al., 1988). The ovine respiratory tract has also proved more relevant
when compared to that of dogs in the study of gaseous exchange (Werlen et al., 1984).
Early physiological data indicating the utility of the sheep as a model for studying basic lung biology
and pathophysiology (Halmagyi and Colebatch, 1961A and B; Colebatch and Halmagyi, 1961 and
1963; Halmagyi et al., 1963) led to further use of the sheep in numerous disease models, including
asbestosis (Begin et al., 1983A and B).
Further studies illustrate the physiological similarities with man. Estimates of static compliance in the
ovine lung vary from approximately 4.1 to 4.9ml/cm.H20/kg (Wanner et al., 1978; Begin et al., 1981)
which is closer to the situation in man which is estimated at between 2.4ml/cm.H20/kg (Butler and
Smith, 1956) and 3.9ml/cm.H20/kg (Turner et al., 1968) than that seen in other primates (9.1 to
9.4ml/cm.H20/kg - Kosch and Gillespie, 1977; Pare et al., 1978), and compares favourably to that seen
in the dog (4.0 to 5.0ml/cm.H20/kg - Mead and Collier, 1959; Robinson and Gillespie, 1973).
Equally, ovine lung resistance has been estimated at between 1.2 and 3.5cm.H20/l/s (Wheeler et al.,
1990; Kleeberger et al., 1985) compared to 2.19 to 5.1cm.H20/l/s in man (Saunders et al., 1977; Dohi
and Gold, 1979). These similarities have also led to a more recent interest in the development of an




In summary, the ovine lung shares structural and functional similarities with the human lung.
A comprehensive and detailed expertise in ovine respiratory research has developed at the R(D)SVS
over the last two decades. This work initially focused on the characterization of the clinical pathology
of Maedi-Visna infection (Watt et al., 1992; Collie et ah, 1993, 1994 and 1995; Begara et ah, 1995
and 1996; Lujan et ah, 1995) and led on to investigation of allergic responses in the lung (Sture et ah,
1995; Pemberton et ah, 2000; Collie et ah, 2001; Collie, 2003). Workers have also used ovine models
to study broncho-constrictor activity within the lung (Corcoran and Haigh, 1992, 1993 and 1995).
Finally recent advances have been made with regards gene transfer to the pulmonary epithelium by
segmental delivery of plasmid DNA to the airways (Emerson et ah, 2003).
This background of knowledge combined with current local expertise in low molecular weight anti-
proteases (discussed in section 1.2.2) and plasmid mediated transfer of genes to the ovine respiratory
epithelium, led to our recognition of the potential utility of this model system in exploring the effects







2.1. EXPERIMENTAL PROCEDURES -CLONING AND SEQENCING OF
OINE ELAFIN AND SLPI GENES
2.1.1. Molecular biology reagents.
Primers were synthesised and supplied by MWG-Biotech AG (Ebersberg, Deuch.): Elafin gene-
specific reverse primer (GSP1) 5'- CAT GGC GCA CCG GAT CA - 3'; Elafin gene-specific forward
primer (GSP2) 5'- ATG AAG ACC AGA AGC TTC TTG GTC C - 3'; Full length reverse primer (r-
el) 5'- CTG GGG ATC CAT ACA GGT CTT - 3'; Bgl II forward elafin primer (Bgl-f-el) 5'- GCC
GGA GAT CTG ACA ACA TGA AGA CCA GAA GCT TCT TGG TC - 3' (Bgl II site underlined;
Kozak sequence in bold); Sac I elafin reverse primer (Sac-r-el) 5'- TAC GTG AGC TCT CAT CAC
TGG GGA TCC ATA CAG GTC TT - 3' (Sac 1 site underlined); Forward BAC primer (fBAC) 5'-
TGA AAA GGG TCC AAT CAA CG - 3'; Reverse BAC primer (rBAC) 5'- GAG CCA CGC TTA
GTG AGG AG - 3'; Reverse Inverse elafin primer (r-inv-el) 5'- GCC CCT AAC AAC CTC TCC TC
- 3'; Forward elafin promoter primer (f-el(prom) 5'- ATT CCA CCT TCC CTA TT - 3'; Forward
SLPI 5' primer (fSLPI) 5'- CTC ACC ATG AAG TTC AGT GGG CTC TTC C - 3'; Forward SLPI
primer 2 (fSLPI2) 5'- CCC TCC TAG AAA ATC TGC CC - 3'; Reverse SLPI primer 1 (rSLPIl) 5'-
TCA GGC TTT CAC AGG CGA AAG GGC - 3'; Reverse SLPI primer 2 (rSLPI2) 5'- CAC TGG
ACA CGT CCC AGG CTT CT - 3'; Bgl II forward SLPI primer (Bgl-f-SLPI) 5'- GCC GGA GAT
CTC TCA CCA TGA AGT TCA GTG GGC TCT TC - 3' (Bgl II site underlined; Kozak sequence in
bold); Sac I SLPI reverse primer (Sac-r-SLPI) 5'- TAC GTG AGC TCT CAG GCT TTC ACA GGG
GAA AGG CA - 3' (Sac I site underlined); Reverse FLAG SLPI primer (r-FLAG-SLPI) 5'- TCA
TCA CTT GTC ATC GTC GTC CTT GTA GTC GGC TTT CAC AGG GGA AAG - 3' (FLAG
epitope in bold); Sac I FLAG SLPI reverse primer (Sac-r-FLAG-SLPI) 5'- TA CGT GAG CTC TCA
TCA CTT GTC ATC GTC GTC CTT GTA GTC GGC TTT CAC - 3' (Sac I site underlined;
FLAG epitope in bold).
Taq DNA polymerase, magnesium chloride 25mM, DNA polymerase buffer, dNTPs, oligo (dT)
primer, EcoRl, Buffer FI for EcoRl, Bglll, Buffer D for Bglll, Sac I, Buffer J for SacI, M-MLV
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reverse transcriptase, 5x M-MLV RT buffer were supplied by Promega UK (Southampton, UK).
Shuttle vector pDC516 was obtained from Microbix Biosystems Inc. (Toronto, Canada). Shuttle
vector pIRES-GFP#3 was kindly donated by Dr. Mary Hitt (Dept. of Pathology and Molecular
Medicine, McMaster University, Hamilton, Ontario, Canada).
2.1.2. RNA preparation.
Ovine tissues were obtained from 5 month old crossbred lambs (Moredun Institute, Roslin,
Edinburgh). The tissue samples obtained from sheep organs were treated as follows. Samples of each
tissue were removed at autopsy and frozen at -80°C. Approximately one gram of each of these was
then homogenised and the RNA extracted using Trizol (Life Technologies). RNA quality was
assessed by running lOpl on a 1% agarose gel. Quantification of RNA in samples was by dual
wavelength spectrophotometry.
2.1.3. Elafin RACE-PCR.
RACE-PCR for ovine elafin was performed using ovine tracheal mucosal RNA. Firstly 5' RACE was
performed by using the primer GSP1 (derived from partial sequence already obtained from
preliminary experiments) and the 5' forward Generace Primer (GRP1). This was followed by a nested
PCR using GSP1 with nested 5' forward Generace Primer (nGRPl). PCRs were carried out using a
PTC-200 DNA engine (MJ Research) in 50pl mixtures. The following conditions were used: 10% Taq
DNA polymerase lOx buffer, l.lmM magnesium sulphate, 0.2mM for each dNTP, 2.5 units Taq DNA
polymerase, and approximately 20pmol of each primer.
Cycling parameters were as follows: initial incubation of 92°C for 5 minutes, followed by 92°C 1
minute, 55°C 1 minute, and 72°C for I minute (30 cycles followed by a final amplification step of
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72°C). Products were run out on a 1% agarose gel. These conditions were used for both the original
and nested PCRs.
To perform the 3'RACE a slightly different strategy was used. Reverse transcription of the original
RNA sample was performed using the Generace oligo-dT supplied in the Generacer™ kit and M-
MLV RT (Promega). PCR was then performed using the forward primer GSP2 and the reverse
Generace™ primer (GRP2) in order to obtain the full-length cDNA sequence. GSP2 was designed
from the sequence derived from the 5'RACE procedure. PCR conditions were similar to those above
except for a magnesium chloride concentration of 2.2mM. This was followed by a nested PCR using
GSP2 and nested reverse Generace™ primer (nGRP2).
2.1.4. SLPI RACE-PCR.
Ovine SLPI full-length cDNA sequence was obtained using the following technique. Rapid
amplification of cDNA ends (RACE) was performed using the Invitrogen™ Generacer™ kit as
recommended by the manufacter. Using ovine kidney RNA, 5'RACE was performed using forward
Generace Primer (GRP1) and the reverse primer rSLPIl (derived from preliminary sequence - not
shown) followed by nested PCR using nGRPl and rSLPI2. This was followed by a full length PCR of
cDNA using fSLPI and rSLPI. Cycling parameters were as follows: initial incubation of 92°C for 5
minutes, followed by 92°C 1 minute, 60°C 1 minute, and 72°C for 1 minute (35 cycles followed by a
final amplification step of 72°C). Products were run out on a 1% agarose gel.
No 3'RACE was performed (sequence already available in house - Mistry, personal communication).
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2.1.5 Extraction of PCR products and cloning reactions.
All PCR products were run on 1% agarose gels and bands of interest were cut out and purified using
the QIAQuick Gel Extraction Kit (Qiagen, Crawley, W. Sussex).
Cloning of the extracted RACE cDNA fragments was achieved by using the TOPO TA CloningR Kit
for Sequencing included with the GeneRacer™ kit. The cDNAs were ligated into pCRR4-TOPOR
plasmid which was transformed into TOP 10 E.coli cells. Plasmid DNA was purified with the Promega
SV Miniprep system.
2.1.6. Sequence analysis.
Sequence analysis was done both in house and by MWG-Biotech AG, and the sequence data analysed
with the on-line computer software packages NCBI Open Reading frame finder (NCB1), NCB1 Blast
(NCBI) and BCM Multiple Sequence Alignment tools (BCM).
2.1.7. Bacterial artificial chromosome (BAC) library screening and subcloning.
An ovine BAC library was screened using primers fSLPI2 and rSLPI2 (for SLPI) and fBAC and
rBAC (for elafin) by Dr. F. Piumi at Institut National de la Recherche Agronomique (INRA),
Laboratoire mixte INRA-CEA de Radiobiologie et d'Etude du Genome (LREG), Jouy-en-Josas,
France. Positive clones (one for elafin and one for SLPI) were isolated and DNA prepared with
Qiagen Plasmid Maxi Kit (Qiagen, Crawley, UK), lpg of each BAC positive clone was digested with
EcoRl, run out on a 1% agarose gel, and blotted onto GeneScreen™ membranes (PerkinElmer
Biosciences, Inc.). These were probed for one hour with [a-32P]dCTP labelled full length cDNAs
coding for ovine elafin or ovine SLPI, using Express-Hyb (Clontech) following the manufacturers
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protocol. Positive bands were identified with a Storm Phosphoimager system (Amersham) and further
subcloned into plasmid PDC516 for sequencing using various internal primers.
2.1.8. Tissue distribution of elafin and SLPI by Northern Blot analysis and RT-PCR.
Twenty pg of each tissue RNA sample were denatured in 50% formamide, 16% formaldehyde, 20mM
MOPS, pH 7.0, 5mM sodium acetate, and ImM EDTA, for 15 mins at 65 , electrophoresed in a 1%
agarose gel containing 2.2M formaldehyde and transferred to GeneScreen membrane. The membrane
was hybridised with [a-32P]dCTP labelled full length cDNA coding for ovine elafin in ExpressHyb™
(Clontech) following the manufacturer's recommendations. The membrane was then visualised on a
Storm™ Phosphoimager system (Amersham).
One pg of each tissue RNA sample was used in a reverse transcriptase reaction using M-MLV RT
(Promega). Product from this reaction was split into two PCRs, using either forward and reverse 13-
actin primers or the full length elafin primers GSP-2 and r-el. The process was repeated for SLPI
using the 13-actin primers and the partial length primers fSLPI and rSLPI2. Conditions were as for the
RACE elafin PCR except for there being 35 cycles for elafin and SLPI, and 28 cycles for the 13-actin.
2.1.9. Genomic DNA preparation.
DNA was extracted from lung and liver samples by proteinase K digestion in NTES (50mM Tris,
50mM EDTA, lOOmM NaCl, 1% SDS). Following phenol/chloroform extraction, washing with 100%




2.1.10. Comparison of ovine elafin products synthesised by PCR from the positive BAC clone, the
genomic DNA and RT-PCR synthesised cDNA.
In order to compare the elafin cDNA, identified by the RACE procedure, with the gene sequence
identified by BAC screening (see above) and with genomic ovine DNA, PCR was performed using as
template purified elafin BAC DNA and ovine liver DNA alongside cDNA synthesised from ovine
skin and pIRES-GFP-ovine elafin, using the non intron-spanning primers fBAC and rBAC. PCR
parameters were as for the RACE elafin PCR. Products from the genomic DNA PCR were ligated into
pCRR4-TOPOR plasmid which was transformed into TOPIO E.coli cells. Plasmid was extracted with
Promega SV Miniprep system and sequenced using internal primers.
An additional PCR was performed on ovine genomic DNA using the primers f-el and GSP2. Products
from this PCR were also cloned into pCRR4-TOPORas above and sequenced.
2.1.11. Construction of ovine elafin and ovine SLP1 expression constructs.
Full-length elafin cDNA coding for a protein of 220 amino acids in pCRR4-TOPOR was used as a
template for PCR with Bgl-f-el and Sac-r-el (to give Bglll-elafin-SacI). PCR conditions were as for
the RACE PCR for elafin.
Full-length SLPI cDNA coding for a protein of 132 amino acids in pCRR4-TOPOR was used as a
template for PCR with Bgl-f-SLPI and Sac-r-SLPI (to give Bglll-SLPl-SacI). The same template was
used for PCR with Bgl-f-SLPl and r-FLAG-SLPI, followed by a nested PCR of this product with Bgl-
f-SLPI and Sac-r-FLAG-SLPl (to give Bglll-SLPI-FLAG-SacI). PCR conditions were as for the
RACE PCR for SLPI.
These PCR products were ligated into the expression vector pIRES-GFP#3 using standard ligation
techniques producing pIRES-GFP-ovine elafin, pIRES-GFP-ovine SLPI and pIRES-GFP-ovine SLPI-
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FLAG. These plasmids were used to transform XLl-BIue subcloning grade E. coli (Stratagene).
Plasmid was purified with the Qiagen Plasmid Maxi Kit (Qiagen, Crawley, UK).
2.1.12. Transfection of 293 cells with ovine elafin and ovine SLPI expression constructs.
293 cells (Microbix Biosystems Inc.) were cultured in Dulbecco's Modified Eagle's Medium
(DMEM) containing 10% foetal calf serum (FCS), penicillin G (final concentration lOOU/ml),
streptomycin sulphate (final concentration lOOpg/ml) and L-glutamine (final concentration 2pM) in
6cm plastic tissue culture dishes and incubated at 37°C in a humidified incubator containing 5% C02
until fully confluent. 6pg plasmid DNA was suspended in 15pl 3M CaCl2 and made up to 225pl with
distilled water. This was then added to an equivalent volume of 2xHBSS (1.5mN Na2HPO4(Fl20)2,
lOmM KC1, 280mM NaCl, 12mM D-Glucose, 50mM HEPES, pH 7.05) and mixed for 1 minute. This
was combined with 4ml of DMEM containing 10% FCS, lOOU/ml penicillin G, lOOpg/ml
streptomycin sulphate and 2pM L-glutamine and added to 293 cells which had been washed with PBS
twice and the cells incubated at 37°C overnight. After 24hrs the medium was removed, the cells
washed twice with PBS and medium replaced with fresh DMEM as above but containing no FCS.
Medium was removed after a further 3 days, cells spun out at 1000G for 4 minutes and the
conditioned medium stored at -20°C.
2.1.13. Anti-elastase activity of ovine elafin and ovine SLPI transfectants.
Anti-elastase assays were performed in 96 well microtitre plates. lOng human neutrophil elastase
(FINE, diluted in 50mM Tris, 0.1% Triton, 0.5M NaCl, pH 8.0) was incubated, at 37°C for 30
minutes, alone or with increasing volumes of conditioned medium from untransfected cells or from
cells transfected with pIRES-GFP-ovine elafin or pIRES-GFP-ovine SLPI (final volumes 50ul).
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Residual HNE activity was measured by change in absorbance at 405nm of the chromogenic substrate
N-methoxysuccinyl-ala-ala-pro-val-p-nitroanilide over 10 minutes at room temperature. Rate of
change in absorbance was directly correlated with HNE activity. The percentage of residual HNE
activity (y-axis) was plotted against the volume of conditioned medium used (x-axis) and the point
where the linear part of the curve crossed the x-axis was used to calculate elastase inhibitory capacity
(EIC) of the medium (Sallenave et al., 1991).
2.1.14. Western blot analysis of ovine elafin and ovine SLPI transfectants.
Supernatants from untransfected and plasmid transfected 293 cells were analysed by SDS-PAGE
(reducing conditions, 15% acrylamide gel). Pre-stained molecular weight markers were included.
Proteins were transferred to PVDF membrane in 25mM Tris, 192mM glycine, 10% methanol, at 100V
for 60 minutes at 4°C. Membranes were blocked overnight at 4°C in TPBS (0.01% Tween 20 in PBS)
with 5% dried skimmed milk then incubated in a 1:1000 dilution of primary antibody (anti-elafin
Trab-20 monoclonal antibody directed against the PVKGQD repeats (Hycult, Nl), or anti-FLAG
monoclonal antibody (Sigma-Aldrich) or polyclonal anti-human SLPI antibody (Sallenave et ah,
1992) with 5% skimmed milk powder for 1 hour at room temperature. Membranes were then washed
with TPBS and incubated in a 1:2000 dilution of either anti-mouse IgG conjugated to peroxidase (for
Trab-20 and anti-FLAG monoclonal primary antibodies) or anti-rabbit IgG conjugated to peroxidase
(for anti-human SLPI polyclonal primary) (both antibodies supplied by DakoCytomation, CA) for 45
minutes at room temperature. After washing in TPBS, membranes were developed using Western
Lightning™ Chemiluminescent Reagent Plus (PerkinElmer Life Sciences, Inc.) and exposed on X-
omat radiograph-quality film (Kodak).




To investigate the phylogenetic relationships of the ovine forms of elafin a phylogenetic tree was
constructed by the neighbour-joining method (Saitou et al., 1987) using data from multiple alignment
of the amino acid sequences of the whey acidic protein (WAP) domains of members of the trappin
family, the known SLPI sequences (human, mouse, rat, pig and sheep), the murine elafin-like proteins
1 and 2 (Hagiwara et al., 2003), and the human vasopressin molecule which contains a rudimentary




2.2. EXPERIMENTAL PROCEDURES -THE CONSTRUCTION OF AN
ADENOIRUS EXPRESSING OWE ELAFIN AND INESTIGATION OF
INFECTION OPTIMISATION PROTOCOLS IN VITRO
2.2.1. Insertion of the ovine elafin cDNA into the shuttle vector pDC516.
The cDNA coding for the short 220 amino acid form on ovine elafin (TOM-1) contained in the
expression vector pCRR4-TOPOR was used as template for two consecutive PCRs with firstly Bgl-f-el
and FLAG-r-el, followed by Bgl-f-el and Sac-r-FLAG-el (to yield Bglll-elafin-FLAG-SacI). PCR
conditions were as for the RACE PCR for ovine elafin. Final product from these PCRs was ligated
into shuttle vector pDC516 (which contains the murine cytomegalovirus (MCMV) promoter) using
standard ligation techniques to yield pDC516-o-elafin. Product from this reaction was used to
transform XL 1-Blue subcloning grade E. coli and a positive colony identified by restriction analysis.
Plasmid was isolated with the Qiagen Maxi-Prep kit. This plasmid is referred to as pDC516-o-elafin.
2.2.2. Co-transfection of 293 cells with shuttle plasmid and adenoviral vector plasmid.
Human embryonic kidney cells (HEK 293 cells) were grown in 6cm dishes until 80-90% confluence.
These cells were then co-transfected with pDC516-o-elafin and pBHGfrt(del)El,3FLP (a kind gift
from Dr. M. Hitt, McMaster University) at various ratios or with the single control plasmids pFG140
(as a positive control) and pDC516-o-elafin or pBHGfrt(del)El,3FLP (as negative controls) in the
following way. Plasmid DNA was added to 15pl 3M CaCl2 and the volume made up to 225pl with
sterile water. To this, 225pl 2xHBSS (8g NaCl, 5g HEPES, 0.27g KC1, O.lg Na2HP04, lg D-glucose,
pH 7.1, made up to 500ml with sterile water) was added and vortexed before adding to 5ml pre-
warmed 293 medium (MEM Eagles, 10% FCS, 1% Penicillin/Streptomycin, 1% L-Glutamine, 3%
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sodium bicarbonate). The resulting mixture was added to the 293 cells and incubated overnight before
replacing the medium. The cell monolayers were monitored daily for signs of cytolysis. When
monolayers showed 90-100% cytolysis (including the positive control dish transfected with pFG140)
the contents of each dish were transferred to 14ml Falcon tubes and centrifuged at 1200rpm for 10
minutes at 4°C. The supernatant was then transferred to a fresh Falcon tube with 10% glycerol and
stored at -80°C. DNA was extracted from the cell pellet for Southern blot analysis as described below.
2.2.3. DNA extraction from CPE positive dishes and Southern blot analysis.
The cell pellet from the co-transfections which resulted in cytolysis (see above) were incubated
overnight at 37°C with 600pl lxPronase-SDS solution (200pl 5mg/ml Pronase, 40pl 500mM EDTA,
lOOpl 10% SDS, 1.66ml lOmM Tris-HCl, pH 7.5). The resultant lysate was extracted twice with
500pl buffer-saturated phenol followed by centrifugation at 13,000rpm for 10 minutes at room
temperature.
The aqueous layer was then added to 50pl of 3M sodium acetate and 1ml absolute ethanol and mixed
several times by inversion. This was centrifuged at 13,000rpm for 10 minutes at room temperature to
pellet the DNA and the supernatant discarded. The pellet was washed in 95% ethanol then air dried
before being dissolved in lOOpl O.lxSSC (17.53g NaCl, 8.82g sodium citrate made up to 100ml with
water, pH 7.0 then dissolved 1:200 in water).
lOpl of this DNA solution was digested with Hind III overnight at 37°C and run out on a 1% agarose
gel after which the gel was photographed to examine possible banding patterns. This gel was then
transferred to Genescreen™ membrane and probed using ovine elafin cDNA in a Southern blot
analysis as described in 2.1.7.




Stored supernatant (Section 2.2.2) was diluted 1 in 106 and 1 in 107 in PBS ++ (PBS with 0.01%
CaCl2 and 0.01% MgCl2) and added to fresh 293 cells in 6cm dishes. The dishes were then incubated
at 37°C for 45 minutes after which 10ml of an overlay solution (1% agarose in water, melted and
maintained at 42°C, added to 1.6xMEM Eagles, 10%FCS, 0.1% yeast extract, 2%
Penicillin/streptomycin, 2% L-Glutamine, 0.45% sodium bicarbonate, 1% fungizone) was added to
the monolayer. The overlay was left to solidify for 10 minutes before being returned to the incubator.
Plaques appeared within 5-7 days. Several well isolated plaques (>3mm diameter) were selected by
removing an agar plug core with the broad end of a sterile PI000 pipette tip. The cores were placed
into 1ml PBS ++ and 10% glycerol and stored at -80°C.
2.2.5. Re-infection of 293 cells with plaque lysate.
The plaques isolated in section 2.2.4 were subjected to 3 rounds of freeze-thaw lysis after which 200pl
of the lysate was used to infect fresh 293 cells in 6cm dishes. After 100% cytolysis the dishes were
treated as in section 2.2.3 above to isolate the DNA. This DNA was again digested with Hind III and
the resultant DNA run on a 1% agarose gel to examine the banding pattern for possible transgene
insertion. The supernatants from this experiment were used to screen for secreted ovine elafin by
Western blot analysis in the same manner as described in 2.1.14 above and probed with Trab-20
monoclonal antibody (Hycult, Nl), or anti-FLAG monoclonal antibody (Sigma-Aldrich) diluted 1 in
1000 in PBS/0.1% Tween and 5% skimmed milk powder. The secondary antibody and detection by
chemi-luminescence were as desribed in 2.1.14.
Further amplification and titration of one positive plaque was performed as described elsewhere




2.2.6. Optimising adenoviral infection efficiency in vitro.
A549 cells were plated out in 48 well plates at 80,000 cells per well. Ad-GFP at MOI 1 and 10 was
applied to the monolayers in fresh medium (DMEM plus 1% pencillin/streptomycin, 1% L-
Glutamine) for one hour. Additionally, Ad-GFP that had been complexed with polyethylenimine
(PEI) at a ratio of 500 molecules of PEI to one viral particle in fresh medium and Ad-GFP which had
been complexed with calcium phosphate co-precipitates (formed by adding 2.14pl 2.5M CaCl2 per ml
EMEM medium and vortexed well before incubating with adenovirus for 20 minutes) was added to
the cells. After one hour the medium containing the Ad-GFP was removed and the monolayers were
washed twice with sterile PBS. Fresh medium (DMEM plus 10% FCS, 1% pencillin/streptomycin, 1%
L-Glutamine) was then added to the wells. The wells were examined for the presence ofGFP 24 hours
later by fluorescent microscopy and images captured using Openlab 3.0.0 image capturing software
(Improvision Ltd., Coventry, UK). GFP positive pixel counts were measured using ImageJ software
(http://rsb.info.nih.gov/ii/).
In a second experiment Ad-o-elafin was used to infect A549 cells in the same plate format as above at
MOI 10 either alone or after pre-complexing with PEI (500 molecules PEI per viral particle) or
calcium phosphate. Additionally, cells were infected with virus alone in hypotonic EGTA (lOOmM
EGTA in 37.5mosm/l PBS). After one hour the medium was replaced with fresh DMEM plus 10%
FCS, 1% pencillin/streptomycin, 1% L-Glutamine. Bacterial lipopolysaccharide (LPS) (lOpg/ml of
LPS purified from E. coli L28 B8) was added to the culture supernatant in one set of wells on day 3.
On day 4 the medium was removed from all wells, cellular debris removed by centrifugation at
13,000rpm for 10 minutes at 4°C and the supernatant assayed for secreted elafin by direct ELISA as
detailed below in 2.2.7.
Further experiments examined the effects on infection efficiency and cell death of varying the contact
times between the adenovirus/calcium phosphate co-precipitates and the A549 cells. This experiment
was performed using the same cells and well format as above and using Ad-GFP at an MOI of 10 with
or without calcium phosphate co-precipitation (as detailed in the above section) with contact times
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with the cells varying from 1 to 60 minutes before medium was replaced. Image J analysis of
photomicrographs taken at 24 hours post-infection allowed GFP positive pixels to be quantified. The
cells which were in contact with the virus alone or virus and calcium phosphate for 1 hour were also
stained with trypan blue to assess viability after 24 hours.
2.2.7. Direct ELISA for secreted ovine elafin.
Secreted elafin in the culture supernatant was detected by a direct ELISA protocol in the following
manner. A 96 well assay plate (CostarR) was used to bind the different supernatants from the above
experiments (neat and 1 in 10 dilutions) over night at 4°C. Test supernatants were compared against
supernatants from cells transfected with plasmid containing the ovine elafin cDNA. The latter had
been accurately titrated for elafin content by anti-elastase activity and were used as standards.
Supernatants were removed on the following day and the wells rinsed 3 times with PBS-T (PBS plus
0.1% Tween 20) before adding Trab-20 monoclonal antibody (Hycult Biotechnology, Nl.) at a
dilution of 1 in 1000 in PBS-T. After 2 hours the antibody solution was removed and the wells washed
3 times with PBS-T. Goat anti mouse monoclonal antibody conjugated to peroxidase was added at a
dilution of 1 in 2000 in PBS-T for 1 hour. The wells were washed 3 times with PBS-T. Substrate was
added (sodium acetate citrate pH 4.9 with 1% 3,3',5,5'-tetramethylbenzidine and 0.05% H202) and a
blue colour allowed to develop before the reaction was 'stopped' with 1M H2S04 The colour was
read at 490nm with reference readings taken at 560nm. The absorbances for each sample were cross-
referenced with those from the known standards to allow the amount of secreted elafin in each sample
to be calculated.





Ovine alveolar macrophages (and other mobile cells) collected at routine bronchoalveolar lavage (see
section 2.3.2.) were cultured in 24 well plates at a seeding density of 250,000 per well in RPMI
containing 10% foetal calf serum (FCS), penicillin G (final concentration lOOU/ml), streptomycin
sulphate (final concentration lOOpg/ml), L-glutamine (final concentration 2pM) and amphotericin B
(0.5%). After 6 hours non-adherent cells were washed off the wells and fresh medium was added to
each well. Ad-GFP MOI 100 with or without calcium phosphate co-precipitation was applied to the
cells for 20 minutes before removal and replacement of medium. 24 hours later the monolayers were
photographed and infection efficiency assessed by visualisation of GFP. The cells in contact with
virus alone or virus and calcium phosphate for 20 minutes at an MOI of 100 were also stained with
trypan blue to assess viability after 24 hours. In this experiment alveolar macrophages from 3 different
donor sheep were used.
Additionally, Ad-o-elafin was used at MOIs of 100 and 200 both with and without co-precipitation
with calcium phosphate in the same way as above. This time the culture medium was collected after 4




2.3. EXPERIMENTAL PROCEDURES - IN VIVO EXPERIMENTATION.
2.3.1. Anaesthesia and ventilation of sheep for experimental procedures.
Food was withheld for 12 hours prior to anaesthesia which was achieved by intravenous
administration of a single bolus of thiopentone sodium (Intraval sodium; Rhone Merieux Ltd.) at a
dose rate of 20 mg/kg bodyweight. Following this the sheep was intubated and anaesthesia maintained
with gaseous halothane (2-3 per cent) in oxygen and nitrous oxide. The sheep was placed in a large
plexiglass whole body respirator (internal volume: 388 litres) in sternal recumbency. The proximal
end of the endotracheal tube was connected to the anaesthetic circuit through a connector in the wall
of the box. Negative pressure ventilation was achieved by connection to a large bellows pump
(Cuirass; Cape Warwick, Warwick, U.K.) which induced a sinusoidal tidal respiratory pattern, the rate
and magnitude of which could be controlled by adjustment of the pump itself. A tidal volume of
lOml/kg bodyweight was maintained. Respiratory rate was adjusted to maintain end-tidal C02
measurements in the range 4.5-5.5% (Oxicap Monitor Model 4700; Ohmeda, Louisville, CO, USA).
2.3.2. Bronchoalveolar lavage.
Two 20ml aliquots of normal saline (0.9% NaCl solution) were used to lavage lung segments after
wedging a flexible fibre-optic bronchoscope (5.3mm OD) (Model FG-16X; Pentax U.K. Ltd.) in
selected segmental bronchi.
Bronchoalveolar lavage (BALF) was passed through sterile gauze into a sterile Falcon tube and





BALF was spun at 400g for seven minutes to separate out the cellular fraction. The resultant pellet
was re-suspended in sterile phosphate buffered saline and the total cell number counted before
subsequent preparation of cytospins for differential cytology. Supernatants were re-centrifuged at
1,000 x g at 4°C for 20 min. The samples were stored at -70°C.
2.3.4. Differential cytology.
Cells were counted using a Neubauer haemocytometer and values expressed per millilitre BALF.
Cytocentrifuge slides were prepared and stained using Diff Quick stain for differential counts on 500
cells. Cells were classified as neutrophils, macrophages, eosinophils, lymphocytes, mast cells or
'other' cells according to standard morphological criteria.
2.3.5. LPS-induced up-regulation of ovine elafin and SLPI in bronchoalveolar lavage fluid.
Bronchoalveolar lavage fluid collected by colleagues as part of a related protocol (Tate et al., 2004;
submitted manuscript) provided the means to assess the regulation of ovine elafin and SLPI following
local lung challenge with LPS. Briefly, in this protocol twelve cross-bred sheep (10 female and 2
male) were anaesthetised with 20mg/kg intravenous thipoentone (Intraval sodium, Merial Animal
Health Ltd., Harlow, Essex, UK), intubated and maintained on 2-3% halothane in oxygen and nitrous
oxide, lmg lipopolysaccharide (LPS) from E. coli 026:B6 diluted in 5ml distilled water was instilled
via bronchoscope into random segments. Bronchoalveolar lavages from these sheep were collected a
week prior to the experiment and 6, 24 and 168 hours after the administration of LPS. The lavages
were spun at 400g for 7 minutes and the supernatant stored.
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The stored supernatant (200pl) was used in a dot blot onto GeneScreen™ membrane and blocked with
5% milk powder in TPBS. The membrane was then probed with either polyclonal anti-human SLPI
antibody (Sallenave et al., 1992) or monoclonal Trab-20 anti-elafin antibody (Hycult, Nl). After
exposure to X-omat radiograph-quality film, resultant films were scanned and densitometry
measurements taken using a UVP white light Transilluminator (UVP, Inc. Upland, CA USA). Control
membranes probed with secondary antibody alone showed no detectable protein (not shown).
2.3.6. Instillation of Adenovirus or Adenovirus/calcium phosphate co-precipitates into the ovine lung.
The anaesthetised and intubated animal was placed in sternal recumbency in the whole body respirator
as above and maintained with 2-3% halothane in oxygen and nitrous oxide. The fibreoptic endoscope
(5.3mm OD) (Model FG-16X; Pentax U.K. Ltd.) was advanced and wedged in selected segmental
bronchi. The adenovirus was diluted from stock solution into 5ml sterile PBS in order to achieve the
required number of active particles (plaque forming units or pfu). This 5ml volume was then instilled
into the segment, through a polyethylene catheter passed through the giving port of the endoscope and
passed as far into the chosen segment as possible without damaging the lung. Instillation was
performed in a controlled manner in order to avoid flooding proximal to the tip of the endoscope and
to facilitate dispersion of the adenovirus/PBS into the subtended segment. This was usually
accomplished within approximately 30-60 seconds. At the end of the instillation air was allowed to
enter the giving port of the endoscope to allow equilibration of pressures in the segment and the
endoscope carefully withdrawn while monitoring and managing any reflux of the adenovirus/PBS.
Adenovirus/calcium phosphate co-precipitates were formed by incubating, with gentle intermittent
agitation, the specific amount of stock adenovirus solution (calculated to yield the requisite pfu) with
lml of the freshly made calcium phosphate solution (2.14pl 2.5M CaCl2 added per ml EMEM
medium and vortexed well) at room temperature for 20 minutes before dilution to 5ml with sterile




2.3.7. Culture of harvested alveolar macrophages.
After counting the total cells and making the cytospins for differential cytology, mobile cells were
plated out in 48 well tissue culture plates at 50,000 cells per well in RPMI containing 10% foetal calf
serum (FCS), penicillin G (final concentration lOOU/ml), streptomycin sulphate (final concentration
lOOpg/ml), L-glutamine (final concentration 2pM) and amphotericin B (0.5%). After 6 hours non¬
adherent cells were washed off the wells and the adherent cells cultured for a further 7 days in fresh
medium. Supernatants were then collected, spun at 13,000rpm for 1 minute to remove cellular
contamination, and stored at -30°C. After 24 hours in fresh medium the number of GFP+ve cells was
assayed by direct visualization of the wells using UV-microscopy.
2.3.8. Western blot analysis of cell culture supernatants.
25pi of supernatant along with known amounts of purified ovine elafin protein were reduced with 1%
dithiothreitol and loaded on 4-12% gradient polyacrylamide gel using the Invitrogen NuPage gel
system as recommended by the manufacturer. After running the gel proteins were transferred to
Hybond ECL Nitrocellulose membrane (Amersham Pharmacia). Resultant membranes were blocked
in 5% skimmed milk powder in TPBS (Phosphate buffered saline and 0.1% Tween 20). Membranes
were probed overnight at 4°C with Trab-20 diluted 1 in 500-1000 in TPBS or anti-FLAG monoclonal
antibody diluted 1 in 1000 in TPBS. Membranes were then washed in PBS-T before the secondary
antibody was applied (Goat anti mouse IgG conjugated to F1RP). This was followed by final washing,
addition of Western Lightning™ Chemiluminescent Reagent Plus (PerkinElmer Life Sciences, Inc.),
and exposure to X-omat radiograph-quality film (Kodak). Densitometry measurements were made on




2.3.9. Post-mortem visualisation of GFP+ve cells in the ovine lung.
48 hours after lung segmental instillation of Ad-GFP the animals were euthenased and exsanguinated
by severing both carotid arteries. The lungs were removed and inflated for 2 hours with 4%
paraformaldehyde at room temperature. The lungs were then rinsed twice with sterile PBS and
inflated with 30% sucrose overnight at 4°C. Small representative portions of lung were carefully
dissected and stored at 4°C in 30% sucrose. Small pieces of these portions were then mounted in
optimal cutting temperature medium (OCT) and 10pm sections cut and mounted on lysine-coated
slides. The residual OCT was rinsed off with sterile PBS and then the slides were dipped in absolute
alcohol to remove salts. The slides were subsequently dipped into lpg/ml DAPI (4',6-diamidino-2-
phenylindole) in methanol for 2 seconds and then immediately dipped firstly into PBS and then into
absolute ethanol before being air-dried. Cover slips were then affixed with DPX mounting fluid and
GFP+ve cells counted by direct visualisation with UV-microscopy.
2.3.10. Total protein content of bronchoalveolar lavage fluid.
The total protein content of the BALF supernatant was assayed using the bicinchoninic acid method




2.3.11. Serum neutralising anti-adenovirus titres.
Whole blood was collected into plain vacutainers by jugular venepuncture.and left to clot at room
temperature for 2 hours before separation of the serum by centrifugation at 13,000rpm for ten minutes.
lOgl of undiluted serum, or of a 1 in 10 or 1 in 100 dilution, was added to 90pl DMEM medium which
in turn was added to 85gl of DMEM containing a specific number of adenovirus particles encoding
for beta galactosidase (Ad-lacZ). The number of Ad-lacZ particles was calculated to give a
multiplicity of infection (MOI 100) when previously cultured A549 cells were infected in 48 well
plates. The virus/serum/medium mixtures were incubated at 37°C for 90 minutes and then applied to
the washed A549 cells in 48 well plates for 20 hours at 37°C. The monolayers were washed and then
lysed by applying 200pl sterile distilled water and passing the cells through 2 freeze-thaw cycles.
Finally all the cells were disrupted by repeated passage through a P200 tip along with scraping of the
final residual cells from the well. This crude protein solution was transferred into a 1.5ml eppendorf
and vortexed for 30 seconds. Finally the insoluble debris was centrifuged out at 13,000rpm for 5
minutes. The resultant clear cell lysate was removed from the isoluble matter for further analysis. This
lysate was assayed for beta galactosidase activity by using the p-Galactosidase Enzyme Assay System
with Reporter Lysis Buffer (Promega). Beta galactosidase activity was compared to control infections
using MOI 100 but no incubation with ovine serum and also a negative control using no Ad-lacZ
infection. At each dilution the residual beta galactosidase activity was calculated as a percentage of
the positive control cells activity and hence the percentage inhibition calculated. The titre for each
time-point was calculated by graphing the inhibition of beta galactosidase activity (y axis) against
volume of serum used (x axis). The point where the linear portion of the resultant curve crossed the x
axis was used to calculate the volume of serum needed to inhibit 100% of the Ad-lacZ particles. The
titre was hence calculated by dividing the volume of the total virus containing solution (185 pi) with
the volume of serum calculated to be necessary to inhibit the Ad-lacZ 100%.
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2.3.12. Modulation of the local and systemic responses to bacterial LPS by the segmental
administration of recombinant adenovirus.
A flow diagram outlining the experimental protocol is depicted in figure 1. Virus was administered
either once only (at day 0) or twice (at day 0 and then again at day 14). 1x10s plaque forming units
(pfu) were co-precipitated and instilled into 3 discrete segments in the right lung. Animals received
either Ad-o-elafin or Ad-GFP, no animals received both. At 3, 7 and 10 days after instillation
bronchoalveolar lavage fluid (BALF) was collected from one of the administered segments and one
'naive' segment in the left lung.
4 animals in each group (Ad-o-elafin and Ad-GFP treated) received instillations at both day 0 and day
14 (fig. 1, left branch). BALF was therefore obtained from these animals on days 3, 7, 10, 14 (nai've
segment only), 17, 21 and 24. Each of these BALF samples was used for analysis of total cell count
numbers, differential cytology and total protein content.
A second group of animals was used to assess the response to bacterial LPS after a single dose of
recombinant adenovirus (fig. 1, right branch). Virus was instilled into three segments in the right lung
and BALF collected from both the right lung (virus treated segments) and the left lung (naive
segments) at day 3, 7 and 10. These BALF samples were used for assessment of total cell counts,
differential cell counts and total protein content. At day 10 after virus instillation M. haemolytica LPS
(3ml of a sterile solution in water at 150pg/ml) was instilled into both a virus treated segment in the
right lung and a naive segment in the left lung. The sheep were euthenased on day 14 and BALF
samples obtained from the LPS instilled segments along with a further 'naive' segment. This BALF
was assessed as above for total cell counts, differential cell counts and total protein content.
The BALF samples from this second group were also used to isolate and culture alveolar macrophages
as previously described and culture supernatants used in Western blot analysis after 1 week. The
alveolar macrophages were also checked for GFP content after 24 hours as described above.
A more detailed outline of the experimental protocols is shown in fig. 2.
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Fig. 2. Protocol for the repeated administration of adenovirus and
also the modulation of the LPS response in the ovine lung.
The diagram shows the times of the administration of either Ad-o-elafin or Ad-
GFP to the ovine lung and subsequent sampling by broncho-alveolar lavage and
airway brushing. A represents the protocol for animals 188-192; B the protocol
for animals 193-196; C the protocol for animals 453, 468, 809, 897 and 909; D
the protocol for animals 472, 478, and 920.
(In protocols C and D, examining the effects of Ad-o-elafin and Ad-GFP on the
response to bacterial LPS within the lung and also systemically, segment a
represents Ad-/LPS+ segments, segment b represents Ad+/LPS+ segments and
segment h represents Ad-/LPS- segments as discussed in section 7.3.5).
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2.3.13. Production ofMannheimia haemolytica LPS.
A 0.5ml aliquot of M. haemolytica was inoculated into 50ml of Nutrient Broth and incubated at 37°C
overnight. 30ml of this culture was then used to inoculate 3 litres of Nutrient Broth and incubated at
37°C for 18 hours in an orbital shaker at lOOrpm. The bacteria were then pelleted at 5000g for 30
minutes and re-suspended in 50ml of sterile distilled water. This suspension was then warmed to 68°C
and an equal volume of 90% aqueous phenol at 68°C was added. The resultant mixture was
maintained at 68°C for 10 minutes after which it was placed on ice to allow phase separation. After
centrifugation at 5000g for 30 minutes at 4°C the upper aqueous phase was collected and dialysed for
36 hours against several changes of distilled water using Spectra/PorR dialysis tubing (3,500 molecular
weight cut-off). The resultant solution was then lyophilized and diluted in sterile water to a final
concentration of 150pg/ml.
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CHAPTER 3
THE IDENTIFICATION AND CHARACTERISATION OF THE
OVINE ORTHOLOG OF ELAFIN
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3.1. INTRODUCTION
The human elastase-specific inhibitor elafin (Skin derived antileukoprotease/SKALP) has been
studied extensively with regards gene/cDNA sequence (Sallenave and Silva, 1993), tissue distribution
and antimicrobial activity (Simpson et al., 1999). Simian, bovine and porcine orthologs have also been
characterized at the gene and cDNA level (Zeeuwen et al. 1997; Tamechika et ah, 1996).
Historically, human elafin was first isolated from bronchial mucus (Hochstrasser et ah, 1981; Kramps
and Klasen, 1985; Sallenave and Ryle, 1991) and psoriatic skin (Wiedow et ah, 1990; Molhuizen et
ah, 1993). Elafin messenger RNA has been demonstrated by Northern blot analysis in epiglottis,
pharynx, vocal fold and psoriatic skin (Pfundt et ah, 1996). This is similar to porcine elafin's
distribution where elafin has been shown to be expressed in the trachea and large intestine by RNAse
protection assay (Tamechika et ah, 1996) and furthermore shown to be secreted by goblet cells in the
tracheal mucosa and large intestinal crypts by in-situ hybridization (Suzuki et ah, 2000). Human elafin
has also been shown to be produced by alveolar macrophages (Mihaila and Tremblay, 2001) and Type
II epithelial cells (Bingle et ah, 2001). It is thought that this general distribution seen for currently
known elafin orthologs, i.e. a distribution at mucosal sites and in inflamed epithelia, possibly reflects
an immuno-regulatory function for elafin over and above its classically described anti-elastase activity
(Simpson et ah, 1999; Sallenave, 2000). The distribution of the known elafin orthologs will be looked
at in more detail in chapter 5.
The human elafin gene has been studied in detail. It is found on chromosome 20 and spans
approximately 2.2 kbps. The gene itself is made up of 3 exons and 2 introns and codes for a protein of
117 amino acids. This being a secreted protein, it has a signal peptide of 22 amino acids followed by
two functional domains. The first is a transglutaminase substrate domain made up of five repeats of
consensus sequence PVKGQD. This region has been termed 'cementoin' (Nara et ah, 1994) in the
trappin family of proteins (Schalkwijk et ah, 1999) which the elafin members belong to. This
glutamine and lysine rich region is thought to be involved in a transglutaminase reaction resulting in
s-(y-glutamyl)lysine covalent bonds between the repeat region and matrix proteins such as loricrin and
keratin-1, to promote the anchorage of the molecule to the interstitium, at least in the skin (Steinert
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and Marekov, 1995; Nemes and Steinert., 1999). The second domain of o-elafin is composed of a
whey acidic protein (WAP) domain which contains the anti-elastase site (Sallenave and Silva, 1993;
Tsunemi et al., 1996).
Simpson et al. (2001A) showed the potential of human elafin cDNA delivery by an adenoviral vector
(Ad-elafin) to the murine lung in a model of Pseudomonas induced acute lung injury. Here the
delivery of Ad-elafin significantly improved survival rates compared to delivery of a control
adenovirus encoding for beta galactosidase (Ad-lac Z). Additionally it was shown that human elafin
protein had a chemo-attractant property for neutrophils both in vitro and in vivo in lungs stimulated
with bacterial LPS. Overall the authors reported a beneficial outcome for animals pre-treated with Ad-
elafin compared to pre-treatment with control virus or indeed with PBS.
An interest in ovine models of inflammatory lung disease has led to the current investigation into the
ovine orthologs of elafin with regards the sequence of the ovine elafin gene and cDNA and the tissue
distribution of the ovine elafin cDNA.
Once an ovine elafin ortholog had been shown to exist and dependent upon there being evidence for a
similar function to human elafin, an expression plasmid expressing the ovine elafin protein could then
be constructed. This would allow the investigation in vitro of the potential anti-protease activity of
ovine elafin.
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3.2. AIMS
The work presented in this chapter was aimed at:
1. Isolating cDNA species from ovine tissue that show homology with the cDNA for human elafin and
hence represent an ovine ortholog of this protein.
2. Screening of an ovine genomic library (specifically a Bacterial Artificial Chromosome library) in
order to obtain full gene sequence for an ovine elafin ortholog.
3. Screening a panel of ovine tissues to show ovine elafin expression at the RNA level by RT-PCR
and Northern Blot techniques.
4. The construction of an expression plasmid containing the ovine elafin cDNA allowing transfection
of lung derived epithelial cells in vitro to assess the functional activity of ovine elafin as an anti-
elastase and also to investigate possible methods of detection of protein.
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3.3. RESULTS
3.3.1. Isolation and sequence alignment of ovine elafin cDNA.
Using ovine tracheal mucosal RNA, and PCR primers GSP1 (indicated in fig. 1 and 2 and annealing
to a portion of the ovine elafin sequence already available (Mistry, unpublished)) and forward primers
annealing to sequences corresponding to the GeneracerR oligo ligated to the 5' terminus of the mRNA
(GRP1 and nGRPl), 5' RACE PCR produced a product of approximately 610bps (fig. 2) which was
cloned into pCRR4-TOPOR plasmid for sequencing. A selection of colonies was grown in LB broth
and plasmid purified from these broths. Three sequences were obtained from positive colonies as
shown in fig. 3. All of these products contained the sequence corresponding to the GeneracerR oligo
ligated to the 5' terminus of the mRNA followed by 18bps of 5'UTR and then sequence
corresponding to ovine elafin through to the priming site for GSP1. This information allowed 3'
RACE to proceed using the forward primer GSP2 (indicated in fig. 3) and a reverse primer annealing
to the GeneracerR oligo dT used in the reverse transcription step of the RACE procedure. This yielded
a product of 887bps (fig. 4) which was also cloned into pCRR4-TOPOR plasmid for sequencing and
was shown to contain sequence 3' of the stop codon corresponding to 3' UTR through to the
polyadenylation signal. This product terminated with the sequence corresponding to the GeneracerR
oligo dT sequence used in the reverse transcription step of the RACE procedure. Altogether, the 5'
and 3' RACE procedure facilitated the identification of an open reading frame for a protein of 220
amino acids which showed homology with human, simian and porcine elafin (see fig. 5) and will be
referred to as ovine elafin. The protein consists of a putative hydrophobic signal sequence of 23 amino
acids at the N terminus followed by a distinct region of hexapeptide repeats of consensus sequence
PVKGQD which corresponds to a potential transglutaminase substrate domain (Zeeuwen et al., 1997).
The C terminal portion contains a presumed disulphide core region with eight cysteine residues in
positions corresponding to those in the human elafin protein. This latter region corresponds to the
ancestral whey acid protein domain (Schalkwijk et al., 1999).
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1 15 16 30 31 45 46 60 61 75 76 90
O-Elafin 2 AGTCAATGGAC 11
O-Elafin 3 AGGTCCAGTCAAAGG ACAAGATCCAGTCAA AGGTCAAGATCCAGT CAAAGGTCAAGATCC AGTCAAAGGGACAAG ATCCAGCCAAAGGTC 90
O-Elafin 4 0
O-Elaf in 1 0
91 105 106 120 121 135 136 150 151 165 166 180
O-Elafin 2 AAGATCCAGTCAAAG GACAAGATCCAGTCA AAGGTCAAGATCCAG TCAAAGGACAAGATC CAGTCAAAGGTCAAG A-TCCAGTCAAAGGT 100
O-Elafin 3 AAGATCCAGTGAAAG GTCAAGATCCAGTCA AAGGTCAAGATCCAG TCAAAGGACAAGATC CAGTCAAAGGTCAAG A-TCCAGTCAAAGGA 17 9
O-Elafin 4 0
O-Elafin 1 CAGTCAAAGGACAAG GGTCCAGTCAAGGGA 30
181 195 196 210 211 225 226 240 241 255 256 270
O-Elafin 2 CAAGGTCTAGTCAAG GGT-CAAGGTCCAGT CAAGGGACAAGATCC AGTCAAAGGTCAAGA TCCAGTCAAAGGTCA AGATCCAGTCAAAGG 189
O-Elafin 3 CAAGATCCAGTCAAA GGT-CAAGATCCAGT CAAAGGACAAGATCC AGTCAAAGGTCAAGA TCCAGTCAAAGGTCA AGATCCAGTCAAAGG 268
O-Elafin 4 GGTCCAGT CAAGGGACAAGATCC AGTCAAAGGTCAAGA TCCAGTCAAAGGTCA AGATCCAGTCAAAGG 68
O-Elafin 1 CAAGATCCAGTCAAA GGGACATGGTCCAGT CAAGGGACAAGATCC CGTTAAAGGACAAGT TTCAGTTAAAGGTCA AGATAAAGTCAAAGC 120
271 285 286 300 301 315 316 330 331 345 346 360
O-Elafin 2 ACAAGAC-CGAGTCA GAAGTCCACTCCTCA CTAAGCGTGGCTCCT GCCCCAGGGTTCTGA TCCGGTGCGCCATGA TGAACCCCCCTAACC 278
O-Elafin 3 ACAAGAC-CGAGTCA GAAGTCCACTCCTCA CTAAGCGTGGCTCCT GCCCCAGGGTTCTGA TCCGGTGCGCCATGA TGAACCCCCCTAACC 357
O-Elafin 4 ACAAGAC-CGAGTCA GAAGTCCACTCCTCA CTAAGCGTGGCTCCT GCCCCAGGGTTCTGA TCCGGTGCGCCATGT TGAACCCCC-TAACC 156
O-Elafin 1 GCAAGAAGCCAGTCA AAGGTCCAGTCTCCA CTAAGCCTGGCTCCT GCCCCATTATCTTGA TCCGGTGCGCCATGT TGAATCCCCCTAACC 210
«-GSP1
361 375 376 390 391 405 406
O-Elafin 2 GGTGTCTGAGAGATG CTCAGTGCCCAGGGG TCAGAAGTGCTGTGA AGGCT 328
O-Elafin 3 GGTGTCTGAGAGATG CTCAGTGCCCAGGG- TCAGAAATGCTGTTA AAGCT 406
O-Elafin 4 GCTGCTTGAAAGATA CTGACTGCCCAGGAA TCAGAAGTGCTGTGA AGGCT 206
O-Elafin 1 GCTGCTTGAAAGATA CTGACTGCCCAGGAA TCAGAAGTGCTGTGA AGGCT 260
choose an area of homology for use as an annealing site for a primer in 5'RACE-
Fig. 1. Multiple sequence alignment of possible ovine elafin cDNAs
already hown.
Four partial length ovine elafin cDNA clones (o-elafin 1 to 4) were aligned to
I
PCR. The annealing site for this primer (GSP1) is shown underlined.
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Fig. 2. 5'ovine elafin sequence was derived by 5'RACE-PCR using
cDNA derived from tracheal mucosa.
A. Schematic representation of the 5' RACE procedure for ovine elafin using
primers annealing to a known portion of the ovine elafin cDNA (GSP-1) and the
ligated GeneRacer™ Oligo (GRP-1 and nGRP-1).
B. Agarose gel of the products from the 5' RACE PCRs.
I. and IV. lkb ladder.
II. PCR performed on cDNA derived from ovine tracheal mucosa using P-actin
primers P-actin 1 and 2.
III. PCR performed on cDNA derived from ovine tracheal mucosa using GSP-1
and GRP-1.
V. PCR performed on product in lane C using GSP-1 and nGRP-1.
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1 15 16 30 31 45 46 60 61 75 76 90
Clone 1 MKTRSFLVQVWLLI LGTLVAEAAIIRGRP KGQGTKKTNVLVNEK GPINGQYPVKRPNPV KGQGPVKGQDPVKGQ DPVKGQDPVKGQDPV
Clone 2 MKTRSFLVQVWLLI LGTLVAEAAI IRGRP KGQGTKKTNVLVNEK GPINGQYPVK GQDPVKGQ DPVKGQDPVKGQGPV
Clone 3 MKTRSFLVQVWLL- LGTLVAEAAI IRGRP KGQGTKKTNVLVNEK GPINGQYPVKRPNPV KGQGPVKGQDPVKGQ DPVKGQDPVKGQDPV
GSP2—>
91 105 106 120 121 135 136 150 151 165 166 180
Clone 1 KGQDPVKGQDPVKGQ DPVKGQDPVKG
Clone 2 KGQDPVKGQDPVKGQ DPVKGQGPVKGQDPV KGQ DPVKGQDPVKGQ DRVRSPLLTKRGSCP
Clone 3 KGQDPVKGQDPVKGQ DPVKGQDPVKGQDPV KGQDPVKGQDPVKG- DPVKGQGPVKGQDPV KGQDPVKGQDPVKGQ DRVRSPLPH
181 195 196 210 211 225
Clone 1 116
Clone 2 RVLIRCAM 14 6
Clone 3 172
<—GSP1
Fig. 3. Amino acid sequence for 3 clones derived by 5RACE-PCR.
5' RACE PCR was performed using cDNA derived from ovine tracheal mucosa
and primers GSP1 and primers annealing to the 5' GeneRacer™ oligo. Product
was cloned into pCR4-TOPO™ which was used to transform TOP 10 E. coli
cells. Positive colonies were grown up in broth and plasmid purified and
sequenced. Three clones contained the 5' portion of an open reading frame
showing homology with human and porcine elafin. The amino acid sequence of
the open reading frames for these clones are shown aligned. Underlined are the
priming sites for GSP1 (used in the 5'RACE-PCR) and GSP2 (to be used in the
full-length PCR to follow).
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Fig. 4. PCR of full length ovine elafin using cDNA derived from
tracheal mucosa.
A. Schematic representation of the full length RACE procedure for ovine elafin
using primers annealing to a known portion of the 5' end of the ovine elafin
cDNA (GSP-2) and the GeneRacer1 Oligo-dT region (GRP-2 and nGRP-2).
B. Agarose gel of the products from the full length RACE PCRs.
I. and IV. lkb ladder.
II. PCR performed on cDNA derived from ovine tracheal mucosa using p-actin
primers p-actin 1 and 2.
III. PCR performed on cDNA derived from ovine tracheal mucosa using GSP-2
and GRP-2.
V. PCR performed on product in lane III using GSP-2 and nGRP-2.
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porcine MRSRSFLVLVWFLICGTLVAQA AGRIRRPKGKGTKKILALVK 43
ovine MKTRSFLVQVWLLILGTLVAEA AIIRGRPKGQGTKKTNVLVNEKGPINGQYPVKRPNP 60
human MRASSFLI-VWFLIAGTLVLEA AVT G 26
Transglutaminase Substrate
porcine -GQG PVRGKDQVKGQG PVKGQDLGKSQDPVKAQLPDKGQD 82
ovine IGQGPVKGQDPVKGQDPVKGQDPVKGQDPVKGQDPVKGQDPVKGQDPVKGQDPVKGQDP 120
human VPVKGQDTVKGRVPFNGQD PVKGQVSVKGQD 57
-> 4-
porcine —LG--KGEDSVKGQDPFKAQLPDKLQDPVKAQPAIK RLII L
ovine kgqgpvkgqdpvkgqdpvkgqgpvkgqdpvkgqdpvkgqdpvkgqdrvrspiJl

















Fig. 5. The complete ovine elafin amino acid sequence shows high
degree of homology with porcine and human orthologs.
PCR was performed on cDNA derived from ovine tracheal RNA using forward
primer GSP2 and the reverse GeneRace™ primer GRP2. This was followed by a
semi-nested PCR using GSP2 and the nested GeneRace™ primer nGRP2. PCR
product was purified and ligated into pCRR4-TOPO™ which was used to
transform TOP 10 E. coli cells. Positive colonies were grown up in broth and
plasmid purified and sequenced. PCR product contained an open reading frame
coding for a protein of 220 amino acids (ovine elafin). The amino acid sequence
of the encoded protein is shown aligned with that for porcine and human elafin.
The three domains are shown in separate boxed areas. The glutamic acid and
lysine residues involved in the transglutaminase-mediated covalent bonding are
indicated in bold type. indicates a conserved residue, indicates a conserved
substitution and indicates a semi-conserved substitution.
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3.3.2. Sequence analysis of ovine elafin gene
Screening of an ovine BAC library was performed at the Institut National de la Recherche
Agronomique (INRA) using probes generated by PCR (see materials and methods). This screening
identified one clone for elafin. Southern blot analysis using lpg of BAC clone DNA allowed
identification of a positive EcoRl band of approximately 15kb from the elafin clone (see fig. 6). This
band was purified and subcloned into PDC516 (Microbix Biosystems Inc., Ca) for sequencing with
sequential internal primers through to the polyadenylation signal at the 3' end and proximally through
towards the promoter region. Unfortunately when this approach was applied to the 15kB EcoRl
fragment containing the elafin gene, we were only able to obtain full 3' sequence information (up to
the polyA signal) and no 5' information. Because the BAC library was generated by partial Hind III
digestion, and since the elafin signal peptide coding region contains a Hind III site (not shown), we
were unable to obtain 5' information using this methodology and only obtained sequence from this
restriction site forwards.
The promoter region sequence was obtained for the elafin gene by using PCR (with ovine genomic
DNA as template obtained locally - see Chapter 2) with primer f-el(prom) annealing to the 5' end of
the ovine elafin promoter (see fig. 7) along with a reverse primer annealing to a portion of the first
intron of the ovine elafin gene (r-inv-el). This PCR product (fig. 8) was cloned into pCRR4-TOPOR
and sequenced (fig. 9). This enabled us to obtain the rest of the elafin gene and we were able to show
that the elafin gene spans approximately 2.5kb and is split into 3 exons and 2 introns. Positions of the
exon/intron boundaries and other features of interest are shown in fig. 10.
3.3.3. Tissue distribution of ovine elafin.
Total RNA was extracted from multiple ovine tissues and analysed by Northern blot. A 750bp ovine
elafin RNA species was detected in tongue, trachea, small intestine, large intestine (strongest signal)
and skin (see fig. 11).
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Fig. 6. Southern blot of ovine BAC DNA probed for ovine elafin.
1 pg ofBAC DNA was digested with restriction enzymes (Xho I, XBa I, Bgl II
and EcoRI), fractionated on a 0.8% agarose gel, then blotted onto a nylon
membrane. The membrane was probed with radiolabelled full length cDNA
corresponding to the coding sequence ofTOM-1. The size of the bands seen
are indicated.
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ovine 0 ATACATCTTCTTGACAACATGAAGACCAGAAGC 33
porcine 592 TGGCCTCAGCTCTCAGCCATCCACCTTCCTGACAACATGAGGTCCAGAAGC 643
human 480 TGGCCTTAGCTCTTAGCCAAACACCTTCCTGACACCATGAGGGCCAGCAGC 531
Fig. 7. Design of primers for sequencing of ovine elafin promoter region.
The known promoter sequence for the human and porcine elafin genes were aligned with
the 5' sequence for ovine elafin. A primer was designed based on the porcine sequence
which anneals to the underlined portion of the porcine sequence. This primer (f-
el)prom)) was used in PCR along with R Inv 1 primer. Template used was ovine
genomic DNA. The start codons for the three sequences aligned here are shown in bold.
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Fig. 8. PCR of ovine elafin promoter.
PCR was performed on ovine genomic DNA using the primers f-el(prom) and r-inv-
el. Product was run out on 0.8% agarose gel.
I. lkb ladder.
II. PCR performed on ovine genomic DNA using f-el(prom) and r-inv-el primers.
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Fig. 9. Ovine elafin promoter region sequence.
Sequence derived from the product ofPCR reaction with 5' elafin and R Inv 1
primers using genomic ovine DNA as template. The 5' elafin primer annealed
directly 5' to the 1st base shown. The start codon of the ovine elafin cDNA is shown
in bold. The putative TATA box and Kozak sequence are underlined.
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Fig. 10. Sequence for the gene coding for ovine elafin.
The 'tata' box, 5' Kozak sequence and 3' polyadenylation signal sequence are
boxed. Exons are underlined. Predicted signal cleavage site is between amino
acids 23 and 23 (between A and A). Annealing sites for the primers GSP1,
GSP2, r-el (used in RACE-PCR), fBAC, rBAC (used in PCR screening of BAC
library) and r-inv-el (used to amplify the promoter region) are indicated.
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Fig.11. Tissue distribution of ovine elafin RNA as assessed by
Northern Blot (loading of 20g of total RNA).
Ribosomal 18S and 28S RNA sub-units are indicated by arrows (A). The
membrane was probed with the full length cDNA (660bps) corresponding to the
coding portion of the gene for ovine elafin (B). Quantitative analysis of tissue
expression of ovine elafin by densitometry of blot intensity relative to 28S RNA
bands (C).
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RT-PCR reaction using primers GSP2 and r-el (shown in fig. 10) for ovine elafin was performed using
the same RNA samples (see fig. 12). Consistent with the Northern blot analysis, we found RNA to be
present in tongue, trachea, small intestine, large intestine and skin. Interestingly, products of two
different lengths were obtained, approximately 660bp (the expected size from fig. 10) and 800 bp.
Two forms of ovine elafin are therefore being transcribed in the tissues analysed, the 660bp form
shown and isolated by RACE-PCR and predicted by the BAC screening as shown in figs. 10, and an
additional longer form of 800bp.
3.3.4. Genomic PCR for ovine elafin using a combination of non introns-spanning and introns-
spanning primers.
On account of isolating two different ovine elafin mRNA products by RT-PCR (see fig. 12), although
only one gene was isolated from the BAC library screening, we performed additional PCR reactions
using non-intron spanning primers and a variety of templates to determine whether these RNA
products are splice variants from a single gene or products of different/allelic genes. Fig.l3A shows
the PCR products when fBAC and rBAC primers are used with various templates: genomic ovine
DNA (obtained locally), cDNA synthesised by RT-PCR from ovine skin RNA (shown to be positive
for elafin expression), DNA extracted from the elafin positive BAC clone, and finally DNA extracted
from the expression plasmid pIRES-GFP#3 containing the cDNA for ovine elafin isolated by RACE-
PCR (see above). Two bands were seen with the first two templates (approximately 400bps and
525bps). The low molecular weight band corresponded to the ovine elafin cDNA product isolated by
RACE-PCR (coding for a 220 amino acid protein) and present in the pIRES-GFP#3 plasmid
containing the ovine elafin cDNA. The higher molecular weight band was of unknown origin. The
two products obtained with the genomic DNA template were isolated and cloned into pCRR4-TOPOR
and sequenced. As predicted, the low molecular weight product sequence matched exactly the
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Fig. 12. Tissue distribution of ovine elafin expression by reverse
transcription and PCR (RT-PCR).
RT-PCR for (A) B-actin and (B) ovine elafin from RNA extracted from the
various organs indicated. The position ofmolecular weight markers is indicated.
Primers used for amplification of ovine elafin GSP2 and r-el yielding two
products of approximately 660bps and approximately 800bps.
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Fig 13. The Ovine Elafin gene exists as two alleles.
A. PCR was performed using the non intron-spanning primers fBAC and rBAC as detailed
in the text. Templates used were ovine genomic DNA, cDNA synthesised by reverse
transcription ofRNA isolated from ovine skin, DNA isolated from an ovine BAC clone
positive by PCR for the elafin gene, and the expression plasmid pIRES-GFP#3 containing
the cDNA for ovine elafin (TOM-1). The lower molecular weight product of approximately
400bps is due to amplification of exon 2 of the ovine elafin gene or cDNA (and also
inserted into pIRES-GFP#3); the longer product of approximately 525 bps corresponds to
amplification of a longer form of ovine elafin.
B. 20pg of genomic ovine DNA was digested with restriction enzymes (Xbal, SacI, EcoRl
and BamHl), fractionated on a 0.8% agarose gel, then blotted onto a nylon membrane. The
membrane was probed with radiolabeled full length cDNA corresponding to the coding
sequence ofTOM-1. The size of the bands seen are indicated.
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sequence from the ovine elafin original sequence (fig. 10) while the high molecular weight product
sequence showed an increase in number in PVKGQD repeats (26 instead of 19). The existence of two
different genomic forms was further confirmed using a different set of PCR primers (GSP2 and f-el),
yielding 2 distinct products of approximately 1500 and 1600bps (not shown). These products were
cloned into pCRR4-TOPOR and sequenced and confirmed the presence of a second, heavier form of
the ovine elafin gene coding for 26 PVKGQD repeats (instead of 19) but otherwise identical to the
original gene isolated by BAC library screening and above. The original form of the gene described in
Fig. 10 will here after be referred to as Trappin Ovine Molecule-1 (TOM-1) and the higher molecular
weight form, coding for the longer form of ovine elafin of 262 amino acids, will be referred to as
TOM-2. Alignment of TOM-1 and the known region of TOM-2 are shown in a diagrammatic
representation in fig. 14.
Southern Blot analysis of ovine genomic DNA (from the same animal as the RNA used in the RT-
PCR fig. 12) is shown in fig. 13B and indicates the presence of only one ovine elafin gene showing
that indeed TOM-1 and TOM-2 are two allelic forms of the same gene.
3.3.5 Construction of expression plasmid encoding for ovine elafin.
The TOM-1 cDNA was successfully ligated into pIRES-GFP#3 (fig. 15) at three different insert to
vector ratios as seen in Fig. 16. Product from the reaction between 7.5ng vector and lOng insert was
used to transform XLl-Blue subcloning grade E. coli. Positive clones were grown up in broth and
plasmid isolated with the Qiagen Maxi-Prep kit. One such clone was chosen based on correct
restriction enzyme analysis and sequencing. This plasmid will now be known as pIRES-GFP#3-ovine
elafin.
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Fig.14. Figure showing the relationship between the two ovine elafin
alleles (TOM-1 and TOM-2) coding for proteins of 220 amino acids
and 262 amino acids respectively.
The promoter sequence and 3' sequence is known for the gene TOM-1 only (see
Fig. 10). 100% homology exists between the known portion ofTOM-2 and the
corresponding portion ofTOM-1, except for the fact that TOM-2 contains 7
extra repeats with the consensus PVKGQD as shown. Numbers below the
representation of TOM-1 denote base-pairs from the start of the sequence shown
in Fig. 10. TOM-2 has been sequenced after PCR of ovine genomic DNA using
the primers GSP 2 and R-el as shown.
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Fig. 15. Insertion of TOM-1 cDNA into pIRES-GFPS.
PCR product consisting of the cDNA coding for TOM-1 with the addition of Bgl
II and Sac I restriction sites (Bgl II-o-elafin-Sac I) was purified from agarose gel,
digested with Bgl II and Sac I then re-purified and inserted into pIRES-GFP#3
expression vector which had also been purified post digestion with Bgl II and
Sac I. This allowed the construction ofpIRES-GFP-o-elafin.
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A B C D E F
Vector 7.5ng 22ng 30ng 30ng 30ng
insert 10ng 10ng 10ng - 10ng
Ligase + + + +
Fig. 16. Ligation of TOM-1 cDNA into pIRES-GFPS.
Bgl II and Sac I digested TOM-1 cDNA was ligated into digested pIRES-GFP#3
with varying ratios of insert to vector as shown above and the products run on an
0.8% agarose gel.
A lkb ladder.
B,C,D Vector and insert at varying ratios and T4 DNA ligase
E Vector and T4 DNA ligase showing minimal recircularisation of vector
F Vector and insert with no T4 DNA ligase
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3.3.6. Transfection of 293 cells with an ovine-elafin plasmid construct.
In order to show potential anti-elastase activity attributable to the protein encoded for by the ovine
elafin cDNA, supernatants were collected from 293 cells transfected with an expression plasmid
encoding for ovine elafin (pIRES-GFP#3-ovine elafin containing the TOM-1 cDNA).
Supernatant from 293 cells either untransfected or transfected with pIRES-GFP-ovine elafin were
collected and submitted to Western Blot analysis (see Fig. 17). The ovine elafin transfected cell
supernatant contains a protein that reacts with the anti-elafin Trab-20 antibody and migrates at a
molecular weight of approximately 38kDa. The untransfected cell supernatant does not contain any
protein cross reacting to the Trab-20 antibody.
An anti-elastase assay was performed on this supernatant and on supernatant from untransfected 293
cells. Results are presented in fig. 18 as overall Elastase Inhibitory Capacity (EIC) i.e. the amount of
pure human neutrophil elastase inhibited by the supernatant expressed as nmol/ml. The elafin plasmid
transfected cell supernatant has a higher EIC compared to the untransfected cell supernatant.
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A B C D
Fig.17. Western blot analysis of supernatants from plasmid-
transfected 293 cells.
23p.l of supernatant from A. untransfected 293 cells, B. pIRES-ovine elafin plasmid
transfected 293 cells, or C. pIRES-ovine SLP1-FLAG transfected 293 cells was
used in Western blot analysis. Membrane was probed with the anti-elafin Trab-20
monoclonal antibody directed against the repeat sequence PVKGQD. Recombinant










EIC = 2.60 nmol
HNE ml"1
Fig. 18. Anti-human neutrophil elastase (HNE) activity of
conditioned medium from 293 cells transfected with pIRES-ovine
elafin plasmid.
1 Ong HNE was incubated for 30 minutes alone or with 40pl, 30pl, 20pl, 1 Opl,
5pl and 1 fxl of conditioned medium from untransfected 293 cells or from 293
cells transfected with pIRES-ovine elafin and resultant elastase activity assessed
with MeO-succinyl-alanine(2)-proline-valine-p-nitroanilide as substrate. The rate
of change of absorbance at 405nm was followed for ten minutes. Results shown
as means of HNE activity over the ten minutes of the assay for two replicates
against the volume of supernatant used. The dashed lines represent the line of
best fit for the linear part of the curve from which we calculated the
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3.4. DISCUSSION
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Neutrophil elastase inhibitors have been shown to be important endogenous molecules involved in
limiting neutrophil-derived excess inflammation in humans, as well as in a variety of animal models
(Laurell and Erikkson, 1963; Gross et al., 1965; Stolk et al., 1991; Rudolphus et al., 1993). Significant
among these inhibitors is elafin, a member of the trappin multigene family (Wiedow et al., 1990;
Sallenave et al., 1991). The 'trappin' name has been coined by Schalkwijk and collaborators
(Zeeuwen et al., 1997; Schalkwijk et al., 1999) as an acronym for TRansglutaminase substrate and
wAP (whey acidic protein) domain containing ProteIN, to illustrate its property of being 'trapped' in
a tissue and therefore potentially acting as an anchored protein. Trappins are constituted of an N-
terminal transglutaminase substrate domain with hexapeptide repeats (PVKGQD), and a C-terminal
four disulphide core, containing, in some members, the anti-elastase activity (Schalkwijk et al., 1999).
The members of this family show similarities in their WAP domains with those seen in another
elastase inhibitor, the secretory leukocyte proteinase inhibitor (SLPI), which has a broader spectrum
of enzyme inhibition (Boudier and Bieth, 1992). Trappin members have been isolated from a number
of animal species, including man, but no studies until now had identified the ovine orthologs of elafin
and SLPI.
We have in the present study isolated both the genes and cDNA coding for the ovine orthologs of
elafin.
Using RACE-PCR techniques, we have isolated from a tracheal sample a cDNA encoding for ovine
elafin (o-elafin) which is composed of 220 amino acids, inclusive of a 23 amino acid signal peptide
indicating that the protein is, like other species orthologs, a secreted protein. Following this signal
peptide, we identified a region containing nineteen hexapeptide repeats of the consensus sequence
PVKGQD. A similar region of repeats has been termed 'cementoin' (Nara et al., 1994) in the trappin
family of proteins (Schalkwijk et al., 1999) which the elafin members belong to (see above). This
glutamine and lysine rich region is thought to be involved in a transglutaminase reaction resulting in
s-(y-glutamyl)lysine covalent bonds between the repeat region and matrix proteins such as loricrin and
keratin-1, to promote the anchorage of the molecule to the interstitium, at least in the skin (Steinert
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and Marekov, 1995; Nemes and Steinert, 1999). The second domain of o-elafin is composed of a 4
disulphide core region, named the WAP domain (see above), which, based on the sequence, contains
the anti-elastase site (see below).
The predicted size for o-elafin after cleavage of the putative signal was 20.8 kDa. However a different
migration profile on SDS PAGE was noted after over-expression of the o-elafin cDNA in 293 cells. It
is anticipated that this is most likely due to the highly positive nature of the mature protein (16 net
positive) as the protein will not be rendered anionic by the SDS to the same extent as a neutral protein
of equivalent molecular weight. Hence the less anionic resultant protein will not migrate as quickly to
the anode and hence will appear 'heavier' than it actually is. Alternatively the ovine elafin may be
being cross-linked in the 293 cell supernatant to an un-identified protein, possibly by the action of a
transglutaminase (Molhuizen et al., 1993; Schalkwijk et ah, 1999).
When the biological activity of supernatant from 293 cells transfected with o-elafin was assessed (fig.
18), it was shown to have an elastase inhibitory capacity (EIC) for human neutrophil elastase (HNE)
of 21.05nM. If we make the assumption that ovine elafin inhibits HNE with the same stoichiometry as
human elafin i.e. one molecule of elafin interacts with one molecule of elastase (Sallenave and Ryle,
1991), then this equates to 437ng/ml of'active o-elafin'. The protein sequence of the predicted active
site is identical to bovine elafin (Zeeuwen et ah, 1997). However, no spectrum of anti-protease
activity is available for this protein.
Using both the ovine genomic BAC library described above and genomic DNA obtained locally, we
also isolated the o-elafin gene (fig. 10), which sequence predicted exactly the cDNA sequence
obtained from tracheal RNA. The gene structure is similar to that for human elafin (Saheki et ah,
1992; Sallenave and Silva, 1993) in that the gene contains 3 exons and 2 introns with similar
intron/exon boundaries.
The promoter region shown contains a 'tata' box at bp 463 but no sequence identifiable as a 'caat'
box. An ATG initiation codon was observed, directly 3' of a consensus Kozak's sequence (Kozak,
1984). The o-elafin leader sequence coding for the signal peptide was found to be very similar to other
species' orthologs.
RT-PCR and Northern blot analysis using RNA from various ovine tissues showed o-elafin to be
present in tongue, trachea, small intestine, large intestine and skin. This is similar to porcine elafin's
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distribution where elafin has been shown by in-situ hybridisation to be secreted by goblet cells in the
tracheal mucosa and large intestinal crypts (Suzuki et al., 2000) and human elafin which was first
isolated from bronchial mucus (Hochstrasser et al. 1981; Kramps and Klasen, 1985; Sallenave and
Ryle, 1991) and psoriatic skin (Wiedow et al., 1990). Messenger RNA for human elafin has been
demonstrated by Northern blot analysis in epiglottis, pharynx, vocal fold and in psoriatic skin (Pfundt
et al., 1996). The mainly mucosal distribution of o-elafin is consistent with it being, like its human
ortholog, an antimicrobial 'defensin-like' molecule (Simpson et al., 1999) with potential further
functions in the regulation of the innate immune response (Sallenave, 2000; Sohn et al., 2003).
Interestingly, we obtained either one or two o-elafin products, by RT-PCR, depending on the tissues
(fig. 12). The size of the smallest one (660bps) matched well with the size expected from the cDNA
derived from the elafin gene isolated from the BAC library (hereafter named TOM-1). The origin of
the longest (approximately 750bps) obtained from the tongue, small intestine and large intestine was
investigated further, using locally obtained ovine genomic DNA. Southern blot and genomic PCR
analysis allowed us to rule out the existence of splicing forms of the o-elafin gene as well as the
existence of two genes and showed, instead, that the two cDNAs derived from allelic forms of the
same gene (TOM-1 and TOM-2). When the two genomic alleles were sequenced, we found them to be
identical but for the addition of 126bps coding for seven extra PVKGQD repeats in the longest form
(fig. 14). The reason why we only obtained TOM-1 from the BAC library analysis while both TOM-1
and TOM-2 were obtained later probably lies with the origin of the samples: the INRA (France) BAC
library used was derived from a different ovine breed (Romanov breed, Vaiman et al., 1999) from the
one used for the RNA and subsequent analysis (Suffolk crosses from the UK). Our results suggest that
the Romanov breed animal used to construct the BAC library only has TOM-1 while the Suffolk
breed has both TOM-1 and TOM-2. The source of the RNA and DNA used in the RACE procedure
and subsequent analysis was the UK commercial lowland flock (in this case Suffolk crosses as
mentioned above) and as such were the result of much interbreeding between a variety of sheep
breeds. It is possible that this will have an influence on the number of allelic forms of o-elafin and as
such a 'screening' experiment involving PCR of a panel of individual animals from a variety of ovine
breeds would be of undoubted interest.
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Due to the high number of trappin family members identified so far, particularly in the hooved
mammals compared to primates (Furutani et al., 1998), there has been interest in the evolution of the
individual proteins and in the reasons that there are multiple trappins in one species but not in another.
One cis acting element that has been implicated in the gene multiplication is the region of PVKGQD
repeats in the transglutaminase substrate-coding region of the gene. Furutani et al. (1998) identify a
correlation between number of repeats and number of trappin family members i.e. fewest repeats in
human and peccary which have only one member each. When we apply this rationale to the ovine
elafin gene we predict from the fact that we have at least 19 repeats in the ovine elafin gene first
sequenced that there will be multiple trappin family members. This is the first time a trappin family
member gene has been shown to be present in more than one allelic form.
The large transglutaminase substrate domain present within the ovine elafin molecule is of interest
with regards interactions with other tissue components. As mentioned above this region is thought to
be involved in cross-linking to extracellular matrix proteins. Human elafin has been shown to be
cross-linked in this way to the cornified envelope of keratinocytes (Nakane et al., 2002; Steinert and
Marekov, 1995). Human elafin contains 5 repeats loosely based on the consensus sequence
PVKGQD. The ovine elafin equivalents discussed here contain 19 or 26 repeats with far higher
conservation of the consensus sequence. This may mean there is a difference in the quantity and
quality of transglutaminase-mediated cross-linking. Recent work has implicated transglutaminase
repeats to be of importance in inhibiting tissue transglutaminase and in turn phospholipase-A2 hence
leading to a down-regulation of pro-inflammatory mediators in a hypersensitivity model (Sohn et al.,
2003). The extensive transglutaminase substrate region of the ovine elafin proteins may therefore have
a beneficial effect in this regard also with an improved efficacy at down regulating the two enzymes
compared to human elafin. This will be considered further in chapter 5.
It is important to note that the work identifying the o-elafin cDNA presented here has been based on
products of PCR and as such may have preferentially isolated certain ovine trappins due to primer
design. However, we also see only one DNA species by Southern blot analysis with full length o-
elafin cDNA. If multiple trappin genes were present, we would expect to see multiple DNA species
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annealing to this probe with varying degrees of homology with the probe. Further work needs to be
performed to be certain that o-elafin is the only trappin gene present in ovines.
3.5. CONCLUSIONS
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In summary, the genes encoding for the ovine ortholog of elafin have been successfully identified and
cloned and its tissue expression has been determined at the RNA level. In addition, by over-expressing
the o-elafin cDNA, it has been shown that the ovine elafin molecule is correctly processed and has
anti-elastase activity. Ovine elafin is a member of the trappin family of genes that exists in two
distinct allelic forms, each of which encodes a separate protein with different transglutaminase domain
length. Although the significance of the existence of these 2 alleles is unclear, the particularly high
number of repeats in either allele of o-elafin is interesting and may have physiological bearing.
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CHAPTER 4
THE IDENTIFICATION AND CHARACTERISATION OF THE
OVINE ORTHOLOG OF SECRETORY LEUKOCYTE PROTEASE
INHIBITOR
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4.1. INTRODUCTION
Secretory leukoprotease inhibitor (SLPI) is a non-glycosylated anti-protease first described in man
(Stetler et ah, 1986; Heinzel et al., 1986; Thompson and Ohlsson, 1986; Seemuller et al., 1986) which
is expressed at multiple mucosal sites and is thought to be an important inhibitor of human neutrophil
elastase but also shows activity against cathepsin G, chymotrypsin, trypsin and chymase. The pattern
of secretion at mucosal sites reflects that already mentioned for elafin as discussed in chapter 3, and
similarly prompts speculation that in addition to anti-protease functions SLPI may have a role in the
innate immune response. Indeed human SLPI has been shown to have bactericidal activity against E.
coli and S. aureus (Hiemstra et al., 1996). In addition recombinant human SLPI can kill A. fimigatus
and C. albicans in a dose dependent manner providing the fungal cells are metabolically active
(Tomee et ah, 1997). In both these situations the anti-microbial activity was localised to the N-
terminus of the protein. The combination of anti-microbial activity and an improved resistance to
degradation by bacterial proteases (Sponer et ah, 1991) has made SLPI a potentially attractive protein
for use in inhalation therapy for lung inflammation (Bingle and Tetley, 1996).
The importance of SLPI in the human has led to the characterization of SLPI homologs in the mouse
(Zitnik et ah, 1997), rat (Gipson et ah, 1999; Song et ah, 1999) and pig (Farmer et ah, 1990). In all the
different species studied so far there is a high degree of homology at the protein level and the lengths
of the proteins vary between 115 (porcine SLPI) and 132 amino acids (human SLPI). The porcine
SLPI is shorter than others due to it lacking an obvious signal peptide (Farmer et ah, 1990). The SLPI
orthologs are all made up of two whey acidic protein (WAP) domains (Drenth et ah, 1980). These
domains consist of a conserved disulphide bonded region containing 8 cysteine residues. The second
WAP domain contains the active anti-protease site.
SLPI has been shown to modulate the LPS response in the lung (Rudolphus et ah, 1993; Stolk et ah,
1993) and in macrophages (Jin et ah, 1997). The effects that SLPI has on the LPS response may at
least partially be explained by the inhibition of IkBoi degradation (Taggart et ah, 2002). My interest in
the modulation of lung inflammation in a large animal model of lung inflammation has prompted this
investigation of the ovine form of SLPI.
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Prior to the work presented in this chapter, I already had access to the 3' cDNA sequence of a possible
candidate for the ovine form of SLPI. This allowed the work presented to progress as outlined
overleaf.
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4.2. AIMS
The work presented in this chapter was aimed at:
1. The isolation of the full-length cDNA encoding for the ovine form of secretory leukoprotease
inhibitor (SLPI).
2. The screening of an ovine genomic BAC library in order to obtain full gene sequence for an ovine
SLPI ortholog.
3. The investigation of the distribution of the expression of ovine SLPI at the mRNA level by RT-
PCR and Northern Blot techniques using a panel of ovine tissues.
4. The construction of an expression plasmid containing the ovine SLPI cDNA allowing transfection
of cells in vitro to assess the functional activity of ovine SLPI as an anti-elastase and also to
investigate possible methods of detection of this protein.
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4.3. RESULTS
4.3.1. Isolation and sequence alignment of ovine SLPI cDNA.
Using ovine kidney RNA, and PCR primers rSLPIland rSLPI2 (indicated in fig. 1 and 2 and
annealing to a portion of the ovine SLPI sequence already available (Mistry, unpublished)) and
forward primers annealing to sequences corresponding to the GeneracerR oligo ligated to the 5'
terminus of the mRNA (GRP1 and nGRPl), 5' RACE PCR produced a major product of
approximately 300bps (fig. 2) which was cloned into pCRR4-TOPOR plasmid for sequencing. A
selection of colonies was grown in LB broth and plasmid purified from these broths. Plasmid was
purified and contained sequence corresponding to the GeneracerR oligo ligated to the 5' terminus of
the mRNA followed by 15bps of 5'UTR and then sequence corresponding to ovine elafin through to
the priming site for rSLPI2. This information allowed full length PCR to be performed using the
forward primer fSLPI (indicated in fig. 3) and reverse primer rSLPI annealing to the 3' end of the
SLPI cDNA. This yielded a product of 405bps (fig. 3) which was also cloned into pCRR4-TOPOR
plasmid for sequencing. Altogether, the 5' RACE and full length PCR procedures allowed us to
identify an open reading frame for a protein of 132 amino acids which showed homology with human,
murine, rat and porcine SLPI (see fig. 4) and will be referred to as ovine SLPI. This protein consists of
a putative 24 amino acid hydrophobic signal sequence followed by two regions, each based on a whey
acidic protein (WAP) domain with 8 conserved cysteine residues in each.
4.3.2. Sequence analysis of ovine SLPI gene
Screening of an ovine BAC library was performed at the Institut National de la Recherche
Agronomique (INRA) using probes generated by PCR (see materials and methods). This screening
identified one clone for SLPI. Southern blot analysis using lpg of BAC clone DNA allowed
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1 15 16 30 31 45 46 60 61 75 76 90
human CAGAGTCACTCCTGC CTTCACCjAT^AAGTC CAGCGGCCTCTTCCC CTTCCTGGTGCTGCT TGCCCTGGGAACTCT GG-CACCTTGGGCTG
murine TCACC^QAAGTC CTGCGGCCTTTTACC TTTCACGGTGCTCCT TGCTCTGGGGATCCT GG-CACCCTGGACTG
porcine GG CAGGGGCCTCTTGCC CTTCGTG CTTCT TGCCCTGGGAATCflA TCjGCACCTTGGGCCG
ovine T GG-CACCCTGGCACG
91 105 106 120 121 135 136 150 151 165 166 180
human TGGAAG GCTCTG GAAAG TCCTTCA AAGCTGGAGTCTGTC CTCCTAAGAAATCTG CCCAGTGCCTTAGAT ACAAGAAACCTGAGT
murine TGGAAGGAGGCAAAA ATGAT GCTATCA AAATCGGAGCCTGCC CTGCTAAAAAGCCTG CCCAGTGCCTTAAGC TTGAGAAGCCACAAT
porcine TGGAAG GTGCTG AAAAT GCTTTGA AAGGGGGAGCCTGCC CTCCTAGAAAAATTG TCCAGTGCCTTAGAT ATGAGAAACCCAAGT
ovine TGGAAG—GTGCTG AAAATGAAGCTTTGA AAGCTGGGGCCTGCC CTCCTAGAAAATCTG CCCAGTGCTTTGGAA ATGAGAAACCCAGGT
181 195 196 210 211 225 226 240 241 255 256 270
human GCCAGAGTGACTGGC AGTGTCCAGGGAAGA AGAGATGTTGTCCTG ACACTTGTGGCATCA AATGCCTGGATCCTG TTGACACCCCAAACC
murine GCCGTACTGACTGGG AGTGCCCGGGAAAGC AGAGGTGCTGCCAAG ATGCTTGCGGTTCCA AGTGCGTGAATCCTG TTCCCATTCGCAAAC
porcine GCACAAGTGACTGGC AGTGTCCAGACAAGA AGAAATGTTGCCGAG ATACTTGCGCAATCA AATGCCTGAACCCTG TTGCTATCACGAACC
ovine GCAGTAGTGACTGGC AGTGCCCGCACAAGA AGAAATGTTGCCTCG ACGCTTGCGGAACCG AATGTCTGGACCCTG TCAACATCACAAACC
271 285 286 300 301 315 316 330 331 345 346 360
human CAACAAGGAGGAAGC CTGGGAAGTGCCCAG TGACTTATGGCCAAT GTTTGATGCTTAACC CCCCCAATTTCTGTG AGATGGATGGCCAGT
murine CAGTGTGGAGGAAGC CTGGGAGGTGCGTCA AAACTCAGGCAAGAT GTATGATGCTTAACC CTCCCAATGTCTGCC AGAGGGACGGGCAGT
porcine CAGTTAAGGTGAAGC CTGGGAAGTGTCCAG TGGTCTATGGCCAGT GTATGATGCTCAACC CCCCCAATCACTGCA AGACAGACAGCCAGT
ovine CAGTTAAGAAGAAGC CTGGGACGTGTCCAG TGATCCATGGCCAAT GTCTGATGCTTAAAC CCCTCAATCACTGTG AGACAGAYGACCAGT
361 375 376 390 391 405 406 420 421 435 436 450
human GCAAGCGTGACTTGA AGTGTTGCATGGGCA TGTGTGGGAAATCCT GCGTTTCCCCTGTGA AAGCTTGATTCCTGC CATATGGAGGAGGCT
murine GTGACGGCAAATACA AGTGCTGTGAGGGTA TATGTGGGAAAGTCT GCCTGCCCCCGATGT GAGCCTGATCCCTGA CATTGG-CGCCGGCT
porcine GCCTGGGTGACTTAA AATGCTGCAAGAGCA TGTGCGGGAAAGTCT GCCTCACCCCTGTGA AAGCCTGATTCCTGC CATTTAGAAGAGGCT
ovine GCATAGGTGCATTAA AGTGCTGCAAGGCCA TGTGTGGGAAAGTCT GCCTTTCYCCTGTGA AAGCCTGATTCCTGC TGTTTGGGAGAGTCT
451 465 466 480 481 495 496 510 511 525 526 540
human CTGGAGTCCTGCTCT GTGTGGTCCAGG TCCTTTCCACC CTGAGACTTGGCTCC A C
murine CTGGACTCGTGCTCG GTGTGCTCTGGAAAC TACTTCCCTGCTCCC AGGCGTCCCTGCTCC GGGTTCCATGGC-TC CCGGCTCCCTGTATC
porcine CTGGATTCCTACTTT GTGCTGTCTGGG AATTCCATTTCCACT CCCAGACGTGGATCC CTGGGGCAGGCCGTG ATAAAGACTTGGTTC
ovine CTGGATTCTTATGCT GTGTGGTGTGGG AATWCCAYTTCTACA CCCAGGCTTGAATCA CT CCGTG GCGAAGACTTGGTTC
541 555 556 570 571 585 586 600 601 615 616 630
human CACTGATATCCTCCT TTGGGGAAAG GCTT GGCACACAGCAGGCT TTCAAGAAGTGCCAG
murine CCAGGCTTGGATCCT GTGGACCAGGGTTAC TGTTTTACCACTAAC ATCTCCTTTTGGCTC AGCATTCACCGATCT TTAGGGAAATGCTG-
porcine TACCACCACCATCTA CTTTGCAGAACAT CTC AGCACCCTGTAGGCT TCCAGGACATGCCTG
ovine TAACACCAATATCTT CTYTGCAGAAK A-A G—CCAAC AAATGCCTG
631 645 646 660 661 675 676 690
human TTGATCAATGAATAA ATAAACGAGCCTATT TCTCTTTGCAC 598
murine TTGGAGAGCAAATAA ATAAACGCATTCATT TCTCTATGCAAAAAA AAAAAAAAAAAAA 664
porcine TTGATTGGTGCATCA ATAAATAAGCATATT TCTCTCTGT 600
ovine TTGACTTATCAATAA 509
Fig. 1. Multiple sequence alignment of the hown mammalian SLPI
cDNAs.
The known nucleotide sequences for the human, murine and porcine forms of
SLPI are shown aligned with the known portion of the ovine form of SLPI. Start
codons for the known full-length cDNAs are boxed.
Chapter 4










476 485 1844 1869 1942 1968
TCACCATGAAG .AGAAGCCTGGGACGTGTCCAGTGATC AAQTGCTGCAAGGCCATGTGTGGGAAA
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Fig. 2. 5RACE-PCR for ovine SLPI.
A. Schematic representation of the 5' RACE procedure for ovine SLPI using primers
annealing to a known portion of the ovine elafin cDNA (rSLPIl and 2) and the
ligated GeneRacer™ Oligo (GRP-1 and nGRP-1).
B. Agarose gel of the products from the 5' RACE PCRs.
I. and IV. lkb ladder.
II. PCR performed with no template using GRP-1 and rSLPIl.
III. PCR performed on cDNA derived from ovine kidney using GRP-1 and rSLPIl.
V. PCR performed with no template using nGRP-1 and rSLPI2.
VI. PCR performed on the product from lane III using nGRP-1 and rSLPI2.
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A
1 15 16 30 31 45 46 60 61 75 76 90
5'OVINE SLPI ACCCCTGCCCTCACC ATGAAGTTCAGTGGG CTCTTCCCCTTCCTG CTTCTTGCCCTGGGA ACCCTGGCACTTTGG GCTGTGGAAGGTGCT 87
-»fSLPI
91 105 106 120 121 135 136 150 151 165 166 180
5'OVINE SLPI GAAAATGAAGCTTTG AAAGCTGGGGCCTGC CCTCCTAGAAAATCT GCCCAGTGCTTTGGA AATGAGAAACCCAGG TGCAGTAGTGACTGG 177
181 195 196 210 211 225 226 240 241 255 256 270
5'OVINE SLPI CAGTGCCCGCACAAG AAGAAATGTTGCCTC GACACTTGCGGAACC GAATGTCTGGACCCT GTCAACATCACAAAC CCAGTTAAGAAGAAG 2 67
271 285 286

























Fig. 3. cDNA sequence of ovine SLPI.
A. Sequence derived by 5'RACE PCR. Underlined are the priming sites for
rSLPI2 (used in 5'RACE PCR) and fSLPI (used in full length PCR shown in B.).
B. Full length cDNA of ovine SLPI.
The Gel shows in lane I lkb ladder and lane II the PCR product using cDNA
derived from ovine kidney and primers fSLPI and rSLPI. Nucleotide and amino
acid sequence (predicted by sequence analysis software) is also shown.
Underlined are the priming sites for fSLPI and rSLPI (used in full length PCR),
fSLPI2 (used in screening the BAC library), rSLPIl (used in 5'RACE PCR) and
rSLPI2 (used in 5'RACE PCR and screening the BAC library. Start codon and
stop codon are boxed.
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colony identified by restriction analysis and plasmid isolated again with the Qiagen Maxi-Prep kit.
This plasmid will be known as plRES-GFP#3-ovine SLPI-FLAG.
4.3.5. Transfection of 293 cells with an ovine SLPI plasmid construct.
In order to show potential anti-elastase activity attributable to the protein encoded for by the ovine
SLPI cDNA, supernatants were collected from 293 cells transfected with an expression plasmid
encoding for ovine SLPI (pIRES-GFP#3-ovine SLPI-FLAG).
Supernatants from 293 cells either untransfected, or transfected with pIRES-GFP-ovine SLPI-FLAG
were collected and submitted to Western Blot analysis (see Fig. 9). The ovine SLPI transfected cell
supernatant contained 2 positive protein bands that reacted with the anti-FLAG antibody and migrated
at molecular weights of approximately 12 and 20kDa. The untransfected cell supernatant does not
contain any protein cross reacting to the anti-FLAG antibody.
An anti-elastase assay was performed on this supernatant and on supernatant from untransfected 293
cells. Results are presented in fig. 10 as overall Elastase Inhibitory Capacity (EIC). The SLPI plasmid
transfected cell supernatant has a higher EIC compared to the untransfected cell supernatant.
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Fig.9. Western blot analysis of supernatants from plasmid-
transfected 293 cells.
23(Jl of supernatant from A. untransfected 293 cells, B. pIRES-ovine elafin
plasmid transfected 293 cells, or C. pIRES-ovine SLPI-FLAG transfected 293
cells was used in Western blot analysis. Membrane was probed in lanes A. to C.
with the anti-FLAG monoclonal antibody M2. Lane D. was probed with
polyclonal anti-human SLPI antibody. Human recombinant SLPI in lane D runs
at 11,7kDa.
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Fig.10. Anti-human neutrophil elastase (HNE) activity of conditioned
medium from 293 cells transfected with pIRES-ovine SLPI plasmid.
10ng HNE was incubated for 30 minutes alone or with 40[Jl, 30[Jl, 20|_ll, lOpl,
5|Jl and l|Jl of conditioned medium from untransfected 293 cells or from 293
cells transfected with pIRES-ovine SLPI plasmid and resultant elastase activity
assessed with MeO-succinyl-alanine(2)-proline-valine-p-nitroanilide as
substrate. The rate of change of absorbance at 405nm was followed for ten
minutes. Results shown as means ofHNE activity over the ten minutes of the
assay for two replicates against the volume of supernatant used. The dashed lines
represent the line of best fit for the linear part of the curve from which we
calculated the supernatant's Elastase Inhibitory Capacity (EIC) by the method
described in Materials and Methods.
4.4. DISCUSSION
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I have isolated and cloned from ovine kidney a cDNA encoding for a protein of 132 amino acids with
a putative signal peptide of 24 amino acids. This protein shows good homology with the already
known orthologs of secretory leukoprotease inhibitor (SLPI) and shall be referred to as ovine SLPI.
The alignment of the known orthologs shown in fig. 4 renders some information as to the possible
structure and functional activity of the ovine SLPI protein. Firstly there is conservation of the 16
cysteine residues which take part in the intra-molecular disulphide bonding which has been shown in
the human SLPI protein by X-Ray crystallography (Grutter et al., 1988). These bonds are thought to
be important for the maintenance of the two discrete whey acidic protein (WAP) domains of the SLPI
protein. Indeed the human SLPI protein has been shown to be in a 'boomerang' shape with the two
WAP domains making up the globular ends of the protein. In addition to the cysteine residues, many
of the residues taking part in the inter-main-chain hydrogen bonds in the human SLPI protein are
conserved in ovine SLPI. This adds more credence to the prediction that ovine SLPI will also take on
a 'boomerang' shape in the secreted form.
The human SLPI protein has its anti-protease site/primary binding segment exposed on the outer
surface of a hairpin bend in the second WAP domain. The specific amino acid composition of this
segment is important with regards the specificity of protease inhibition (Grutter et al., 1988; Eisenberg
et al., 1990). Human SLPI inhibits human neutrophil elastase, trypsin, chymotrypsin, chymase and
cathepsin G (Boudier and Bieth, 1992). The Pi and Pf residues identified for protease binding are
Leu-72 and Met-73 (numbered after cleavage of the signal peptide hence in fig. 4 Leu-99 and Met-
100) in the human SLPI protein. As shown these residues are conserved in the ovine SLPI protein and
a similar spectrum of anti-protease activity can be predicted. Of interest is the Pi residue being leucine
in SLPI compared to alanine in the elafin protein. This difference in residue is thought to be the reason
for the lack of an inhibition against chymotrypsin for human elafin, as the alanine residue is not large
enough to fill the S, pocket of chymotrypsin (Tsunemi et al., 1996). This raises the interesting
possibility that porcine elafin which has a P| leucine, may have a similar anti-protease activity to
SLPI. Murine and porcine SLPI both have Pi methionine residues and this may well have profound
effects on their anti-protease activities. Indeed Zitnik at al. (1997) have shown that murine SLPI is less
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effective at inhibiting human neutrophil elastase, bovine chymotrypsin and human cathepsin G
compared to human SLPI. Also, the authors postulate that the Pi methionine renders murine SLPI
more susceptible to oxidative inactivation.
Interestingly, Junger et al. (1992) found that recombinant human SLPI had only a slightly reduced
association rate constant (A:on) for ovine neutrophil elastase (ONE) when compared to human
neutrophil elastase (HNE). This was in contrast to human recombinant eglin C which had a one
hundred-fold decreased kon for ONE compared to HNE. This highlights the importance of considering
the source of protease inhibitor as well as the source of the target enzyme when describing enzyme
inhibition studies.
The ovine SLPI cDNA isolated here has been shown to code for the secreted ovine SLPI protein
which, on expression, is correctly processed and folded as shown by its detection in 293 cell
supernatant after plasmid transfection. I have also shown functional data with a strong inhibition of
human neutrophil elastase by the secreted protein.
I have also, by the use of a BAC library, identified and sequenced the gene encoding for ovine SLPI.
The gene structure throughout the known mammalian SLPI orthologs seems to be well conserved
when the exon/intron relationships are considered. In common with human and murine SLPI, the
ovine gene is made up of 4 exons and 3 introns as shown in fig. 5. There is a signal peptide sequence
as predicted by the use of the SignalP online sequence analysis tool
(http://www.cbs.dtu.dk/services/SignalP/). This predicts cleavage of the signal peptide after Gly-24.
This correlates precisely with the cleavage of the signal peptide in human SLPI after Gly-25. The
putative regulatory 'caaf and 'tata' boxes were identified in the promoter region, at bp 192 and 435
respectively.
The distribution of ovine SLPI transcription was demonstrated by RT-PCR and RNA was found in the
tongue, trachea, kidney, bladder and liver. This distribution shows similarities with that of human
SLPI which has been shown by immunohistochemistry to be present in the lachrymal, respiratory,
proximal digestive and genital tracts (Franken et al., 1989), and more recently in the kidney (Ohlsson
et al., 2001). In addition, the mRNA for the murine ortholog of SLPI has been demonstrated in spleen
and lung and, to a lesser degree, in liver, kidney and testis (Zitnik et al., 1997).
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The expression of the ovine SLPI cDNA in 293 cells by the use of the plasmid pIRES-GFP#3-ovine
SLPI-FLAG demonstrates that the ovine SLPI protein is secreted. Demonstration of the protein in the
293 cell supernatant was achieved by Western blot analysis. The predicted size for ovine SLPI after
putative signal cleavage is 11.6 kDa. However, after expression of the o-SLPI cDNA in 293 cells, a
different pattern of migration was apparent with two bands visible, a major one of approximately 20
kDa and a minor band of approximately 12 kDa (with the recombinant human SLPI positive control at
approximately 14 kDa).
Since SLPI is, like elafin, heavily cationic (o-SLPI has an overall charge after putative signal cleavage
of +9), and since cationic proteins are known to sometimes appear larger than their actual size, when
analysed by SDS-PAGE, the higher 20 kDa form may reflect an artifact of migration, and the 12 kDa
be a minor degradation product.
Alternatively, the native o-SLPI may form aggregates or be bound to an unknown culture-medium-
derived protein, through SDS and p-mercaptoethanol-resistant bonds. This has indeed already been
observed for both SLPI and elafin, when these proteins were derived from complex biological fluids
(Nara et al., 1994; Tremblay et al., 1996; Sallenave et ah, 1999).
When the biological activity of supernatant from 293 cells transfected with o-SLPI was assessed it
was shown to have an elastase inhibitory capacity (EIC) of 44nM, well in excess of that of
untransfected cells (2.6nM). This value (44nM = 510ng/ml of 'active o-SLPT) is in agreement with
the antigenic levels measured by dot blot analysis (results not shown).
The mainly mucosal tissue distribution of o-SLPI is consistent with it being, like its human ortholog,
an antimicrobial 'defensin-like' molecule (Hiemstra et ah, 1996). Indeed, evidence is forthcoming
that, like elafin (Simpson et ah, 1999) SLPI may have important functions in innate immune responses
(Hiemstra et ah, 1996).
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4.5. CONCLUSIONS
The data presented in this chapter has demonstrated the successful identification and cloning of the
gene encoding for the ovine ortholog of SLPI and the determination of its tissue expression at the
RNA level. In addition, by over-expressing the o-SLPI cDNA, I have demonstrated that the protein is
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The previous chapters have identified the ovine forms of the proteins elafin and SLPI and confirmed
that they share certain characteristics with these proteins in other species. These characteristics, at the
level of the gene, cDNA and protein, along with the respective tissue distributions, have led to the
supposition that these anti-proteases may play important roles in the inflammatory response,
specifically in the innate immune response in a similar fashion to the human orthologs (Sallenave,
2000).
Additionally, the identification of the ovine orthologs of these proteins will add to the currently
available information with regards the trappin family (Schalkwijk et ah, 1999) and the whey acidic
protein family (Drenth et ah, 1980; Seemuller et ah, 1986) to which elafin and SLPI members belong
respectively. Many members of these families have also been characterised in other species and this
has enabled the identification of a shared evolutionary development between these two families of
proteins (Furutani et ah, 1998; Schalkwijk et ah, 1999).
The specific characteristics of the elafin and SLPI family members with regards their suitability for
use as potentially modulatory proteins in the field of pulmonary inflammation is of great interest and




1. This chapter will demonstrate how ovine elafin and SLPI relate to other members of the trappin and
whey acidic protein (WAP) families both in terms of distribution and also at a phylogenetic level.
2. Data will be presented which show how both proteins are influenced by inflammation in the ovine
lung.
3. The ovine elafin and SLPI orthologs, and their specific characteristics, will then be considered with






5.3.1. Phylogenetic Tree analysis of elafin and SLPI family members.
The whey acidic protein domains of the two ovine elafin proteins and ovine SLPI (with elafin
containing one and SLPI two) are aligned with all currently known members of the WAP and trappin
families in addition to the murine elafin-like proteins 1 and 2 and also human vasopressin in fig. 1A.
The alignment is 'controlled' around the highly conserved cysteine residues shown by asterisks. The
boxed region signifies the region conveying anti-elastase activity in those family members with this
property.
The phylogenetic tree analysis performed on the WAP/trappin domain alignment is shown in fig. IB.
This shows that the two forms of ovine elafin are closely related to the bovine form of elafin and all of
which appear to be evolutionarily older than the bovine trappins 4 and 5. Bovine trappin 6, however,
seems to be more closely related to the larger group of porcine trappins included in which are trappins
isolated from the peccary and warthog.
The tree also demonstrates the obvious divergence between the WAP domains one and two of the
SLPI family members. Also we can see the close relationship between the second WAP domain in the
SLPI members and the trappin WAP domains. Indeed as mentioned above it is this second domain in
the SLPI family and the WAP domain in trappin members which confer the anti-elastase activity in
those members which act in this way.
5.3.2. Comparison of tissue distribution between trappin family members.
Table 1 shows the distributions of the currently known elafin orthologs. There are wide differences
between the mammals for which the elafin orthologs have been described i.e. man, pig, cow and now,
















human SLPI WAP 1
ovine SLPI WAP 1
rat SLPI WAP 1
murine SLPI WAP 1
porcine SLPI WAP 1
human SLPI WAP 2
ovine SLPI WAP 2
rat SLPI WAP 2
murine SLPI WAP 2








porcine trappin 1 WAP
warthog trappin 3 WAP
bovine trappin 4 WAP
bovine trappin 5 WAP
bovine trappin 6 WAP
porcine trappin 7 WAP
porcine trappin 8 WAP
porcine trappin 9 WAP
peccary trappin 10 WAP
hippopotamus trappin 11 WAP
elafin-like protein 1 WAP
elafin-like protein 2 WAP 1
elafin-like protein 2 WAP 2
human vasopressin
CPPK-KS-AQ C—LRYKKPE -CQSDWQCPG KKR-CCPD-T CG--IKC
CPPR-KS-AQ C—FGNEKPR -CSSDWQCPH KKK-CCLD-T CG—TEC
CPAR-KP-AQ C—LKREKPE -CSTDWGCPG KQR-CCQD-T CG—FKC
CPAK-KP-AQ C—LKLEKPQ -CRTDWECPG KQR-CCQD-A CG—SKC




























































































CP-E-YR-VP CPFVLI—PK -CRRDKGCKD ALK-CCFF-Y CQM-R-C
CP-E-FL-LD CPFVLL—PV -CSRDKGCKG TKK-CCFY-Y CQM-RIL
-P-D-YV-R- C--IRQDDPQ -CYSDNDC-G DQEICCFW-Q CGF-K-C
CQEENYLPSP C QSGQKA -CGSGGRCAA FGV-CCNDES CVTEPEC
B
86j bovine trappin 5 WAP




| porcine trappin 8 WAP
H porcine elafin WAP
warthog elafin WAP
" porcine trappin 9 WAP
"
peccary trappin 10 WAP
bovine trappin 6 WAP
- porcine trappin 1 WAP
j warthog trappin 3 WAP
— porcine trappin 7 WAP
Vfrappin family WAP domains
68 L
i— simian elafin WAP
9fp— human elatin WAP
— hippopotamus trappin 11 WAP
- rat SLPI WAP 2
- murine SLPI WAP 2
porcine SLPI WAP 2
ovine SLPI WAP 2
human SLPI WAP 2
rat SLPI WAP 1
murine SLPI WAP 1
- ovine SLPI WAP 1
human SLPI WAP 1
J
' SLPI second WAP domain
SLPI first WAP domain
Fig.
elafin-like protein 2 WAP 2
~ human vasopressin
porcine SLPI WAP 1
- elafin-like protein 2 WAP 1




Fig. 1. Comparison of the Whey acid protein (WAP) domains for the
proteins of the trappin family, SLPI family and the recently
discovered elafin-life proteins in the mouse, and the WAP motif of
the human vasopressin molecule.
A. Alignment of the 1st and 2nd WAP domains of the currently known SLPI
proteins, along with the WAP domains for a variety of trappins including the
ovine forms of elafin derived from the alleles TOM-1 and TOM-2, and including
the WAP domains of the murine elafin-like proteins 1 and 2 (Hagiwara et al.,
2003) and human vasopressin. The WAP motifs for all the proteins were aligned
by using ClustalW software available online. Conserved cysteine residues are
indicated by asterisks. The boxed region indicates the putative active anti-
protease active site in the second WAP domains of the SLPI family and in the
WAP domain of the trappin family. B. Phylogenetic tree constructed using a
neighbour-joining technique with Poisson corrected data from the above
alignment. Bootstrap values above 40 are indicated. Branch length is





elafin Tongue, trachea, small intestine, large intestine, skin - present study
Human
elafin
Sputum (Hochstrasser etal., 1981; Kramps and Klasen, 1985; Sallenave et al., 1991
and 1992)
Skin (Schalkwijk et al., 1990; Wiedow et al., 1990; Molhuizen et al., 1993)
Ocular secretions (Sathe et al., 1998)
Endometrium (King et al., 2003)
Oral cavity (Pfundt et al., 1996)
Porcine
elafin Trachea, large intestine (Tamechika et al., 1996; Suzuki et al., 2000)
Bovine
elafin
Snout epidermis, tongue (Zeeuwen et al., 1997)
Table 1. The distribution of the members of the elafin family to date.
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species. Hagiwara et al. (2003) have described two murine elafin-like proteins, SWAM-1 and 2. These
have a whey acidic protein (WAP) domain with a conserved core containing 8 cysteine residues which
are involved in 4 disulphide bonds. However, neither SWAM-1 nor 2 contain a discernible anti-
elastase site (as shown by the boxed region in the alignment of the WAP motifs of all the known
trappins (fig. 1 A)) and so cannot be regarded as murine elafin equivalents. The mammalian elafin
orthologs investigated to date have been found either at the RNA level by RT-PCR or Northern blot
analysis, or by direct demonstration of protein by ELISA, immuno-histochemistry or Western
Blotting. These methods demonstrate a general distribution of elafin orthologs at mucosal surfaces
like the buccal cavity, upper respiratory tract and intestinal tract. In addition, in the present study
ovine elafin was found in the skin. This has also been shown in humans (Schalkwijk et al., 1990;
Wiedow et al., 1990). Also human elafin has been shown to be upregulated in skin disease involving
neutrophil infiltration (Pfundt et al., 1996). Overall a distribution of elafin orthologs where the body is
exposed to the external environment is seen.
The distributions (where known) of other members of the trappin family as described in members of
the suidae, tayassuidae, bovidae and hippopotamidae (Tamechika et al., 1996; Furutani et al., 1998)
show similarities to that for elafin. For example, the bovine trappins 4 and 5 are expressed in trachea,
ileum and tongue, and trachea respectively (Zeeuwen et al., 1997).
5.3.3. Comparison of tissue distribution between SLPI family members.
The present work using RT-PCR analysis showed the presence of o-SLPl RNA in tongue, trachea,
kidney, bladder, liver and skin. Work in other species, namely the mouse, rat, pig and man, has shown
a variation in tissue distribution as shown in table 2. Again we can see commonalities in the general
distribution but with some specific differences. SLPI is thought to be secreted at sites exposed to the
external environment in the same way as elafin. Hence we see ovine SLPI in the tongue, trachea,





SLPI Tongue, trachea, kidney, bladder, liver, skin - present study
Human
SLPI
Uterus (Casslen et al., 1981)
Serous glands maxillary sinus and trachea (Fryksmark et al., 1982)
Middle ear mucosa (Carlsson et al., 1983)
Synovial fluid (Ekerot et al., 1983)
Salivary glands (Ohlsson et al., 1984)
Nasal secretions/mucosa (Fryksmark et al., 1989; Westin et al., 1994)
Male reproductive tract (Ohlsson et al., 1995)
Cervical mucus and foetal membranes (Helmig et al., 1995)
Intestinal mucosa (Bergenfeldt et al., 1996; Nystrom et al., 2001)
Articular cartilage/lntervertebral disc (Bohm et al., 1991; Jacoby et al., 1993;
Ohlsson et al., 1997)
Mast cells (Westin et al., 1999)
Neutrophils (Bohm et al., 1992)
Pancreatic beta cells (Nystrom et al., 1999)
Kidney (Ohlsson et al., 2001)
Squamous cell carcinoma (Westin et al., 2002)
Lacrimal secretions (Sathe et al., 1998)
Alveolar macrophages (Mihaila et al., 2001)
Clara/Type II alveolar cells (Sallenave et al., 1993)
Endometriosis Endometrium (Suzumori et al., 1999)
Psoriatic epidermis (Wiedow et al., 1993)
Porcine
SLPI
Endometrium (Farmer et al., 1990)
Myometrium (Simmen et al., 1991)
Placenta/allantoic fluid/foetal cord blood/foetal liver (Simmen et al., 1992)
Murine
SLPI
Spleen/lung/liver/skeletal muscle/testis (Zitnik et al., 1997)
Tumour cell lines (Morita et al., 1999)
Skin tumours (Schlingemann et al., 2003)
Macrophages, Neutrophils, spleen (Jin et al., 1997;Odaka et al., 2003)
Rat SLPI Lung (Gipson et al., 1999)
Articular cartilage (Song et al., 1999)
Table 2. The distribution of the members of the SLPI family to date.
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with their distributions. For example human SLPI is seen in lung, nasal secretions, salivary glands,
intestinal mucosa and inflamed skin (table 2).
5.3.5 Up-regulation of ovine elafin and SLPI protein in bronchoalveolar lavage fluid after
lipopolysaccharide administration in vivo.
Fig. 2. shows the dot blot analysis of ovine bronchoalveolar lavage fluid (BALF) after segmental
administration of Mannheimia haemolytica LPS. The densitometry analysis demonstrates that both
elafin and SLPI are upregulated in the lung after LPS administration. Ovine elafin levels increase
slightly at 6 hours, are significantly raised by 24 hours (P<0.005) and then return to baseline levels by
1 week. SLPI, on the other hand, is significantly increased at both 6 hours and 24 hours (P0.0005
and P<0.005 respectively).
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Fig. 2. Secretion of SLPI and elafin in bronchoalveolar lavage
collected from sheep lung segments exposed to lipopolysaccharide.
450pg Mannheimia haemolytica LPS was administered to discrete lung
segments of twelve sheep. Bronchoalveolar lavage was collected a week prior to
and 6, 24 and 168 hours after administration of the LPS. 200pl of
broncholaveolar lavage from each animal at each time point was used in a dot
blot and probed with either (A) human anti-SLPI polyclonal antibody, or (B)
Trab 2-0 monoclonal antibody detecting ovine elafin. Results are shown as
median arbitrary densitometry units against time after dosage of LPS with error
bars showing inter-quartile ranges. Also shown are representative dot blot results
for each protein. ** signifies a P value of <0.005 and *** signifies a P value of




Over the last several decades there has been considerable interest in developing and refining
laboratory animal models of inflammatory lung disease and in parallel with this work, interest has
focused on modulating the inflammatory response through targeting a variety of cellular and secreted
proteins, either by up-regulation or by down-regulation. This approach forms the basis of many lung-
directed gene therapy applications and the possible targets which can be modulated in vivo by the use
of viral and non-viral vectors have been discussed in depth elsewhere.
The orthologs of elafin and SLP1 have multiple potential anti-inflammatory functions as discussed in
chapter 1 but briefly these functions are summarised here with additional information derived from the
newly described ovine orthologs of these proteins. Firstly the proteins' main function has been
thought to be as locally produced anti-proteases with a slight difference of spectrum of inhibition for
elafin compared to SLPI (Sallenave, 2000). Thus both proteins are of importance in maintaining the
integrity of mucosal surfaces against the deleterious effects of neutrophil derived proteolytic enzymes.
The kinetics of inhibition imply that neutrophil derived elastase is the major target for inhibition
particularly with regards SLPI (Vogelmeier et al., 1996). Observations in relation to the distributions
of elafin and SLPI orthologs have fuelled predictions of a protective role for these proteins in the
innate immune system. Indeed, both human elafin and SLPI have been shown to have potent anti¬
microbial functions in vitro (against bacteria, fungi and a potential anti-HIV activity (McNeely et al.,
1995 and 1997; Hiemstra et al., 1996; Schalkwijk et al., 1999; Simpson et al., 1999)). Interestingly,
the trappin family members show a high degree of variation at the active anti-elastase site (Zeeuwen et
al., 1997) which raises the possibility that these proteins have a role in inhibiting exogenous bacterial
proteases in the same way that elafin (Trappin-2) has a primary role against endogenous neutrophil
derived proteases. In addition to a direct protective function against enzymatic damage to mucosal
surfaces, the inhibition of human neutrophil elastase (HNE) can have indirect anti-inflammatory
effects due to the inhibition of HNE-stimulated up-regulation of the release of chemo-attractant
cytokines such as 11-8 and MCP-1 from both epithelial and non-epithelial cells (Van Wetering et al.,
1997; Ishihara et al., 1999; Devaney et al., 2003; Uehara et al., 2003). This function of HNE (and
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other serine proteases such as proteinase 3 and cathepsin G) is due in part to activation of protease
activated receptors.
The anti-proteases considered here have also been shown to have direct effects on the stimulation of
macrophages by LPS and analogous substances. Jin at al. (1997) showed that murine SLPI was a
major factor influencing the responsiveness of macrophages to LPS stimulation and that the stable
transfection with mSLPI of cells normally responsive to LPS attenuated the LPS-stimulated release of
nitric oxide and TNFa. This was due to mSLPI suppressing the LPS-induced activation of NF-kB.
Indeed mice deficient in SLPI have been shown to have significantly greater susceptibility to LPS-
induced shock than normal mice (Nakamura et al., 2003) which is at least in part due to an increase in
the secretion of 11-6 and HMG-1, and NF-kB activation in the SLPI -/- animals' macrophages
compared to SLPI +/+. Additionally this group found that SLPI attenuated B cell proliferation and
IgM production after LPS stimulation. Further work (Jin et al., 1998) has shown a similar effect for
SLPI in down-regulating macrophage responses to lipotechoic acid, a Gram +ve bacterial wall product
analogous to LPS. In addition, Zhu et al. (1999) confirmed that this inhibitory activity can be repeated
by the transfection of a non-secreted form of mSLPI into a murine macrophage cell line. Interestingly,
recombinant human SLPI inhibits human monocyte production of cyclooxygenase 2 (and hence
decreased PgE2 and matrix metallo-proteases) after LPS stimulation (Zhang et al., 1997). This
function of SLPI was shown to be largely independent of anti-protease activity.
There is evidence that SLPI has a role in controlling inflammation in the lung by influencing the
nuclear localization of the transcription factor NF-kB. Lentsch et al. (1999) showed that blocking
endogenous SLPI in a rat model of immune complex mediated lung disease led to a significantly
raised activation of NF-kB compared to immune complexes (ICs) alone. Administration of
recombinant human SLPI intra-tracheally in addition to ICs led to significant decreases in lung
vascular ICAM-1 expression, lung myeloperoxidase content and whole lung NF-kB activation
compared to ICs alone. There was no effect of exogenous SLPI on the IC mediated activation ofNF-
kB in alveolar macrophages harvested from the rats post IC administration and also there were no
changes in bronchoalveolar lavage levels of TNFa, MIP-2, CINC and C5a in SLPI treated rats
compared to controls. Overall, the authors show that the down regulation of NF-kB activation by
exogenous SLPI is due to an increase in IkBP but not IxBa. Elafin has been shown to inhibit NF-kB
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activation after adenoviral delivery to human umbilical vein endothelial cells in response to LPS and
low density lipoprotein and also in peripheral blood derived macrophages in response to LPS
(Henriksen et al., 2004B).
Evidence therefore exists to the effect that the elafin and SLPI orthologs both inhibit locally secreted
proteolytic enzymes in addition to modulating the response of epithelial and non-epithelial cells to
LPS type substances. The potential significance of the latter modulation is appreciated in the
observation that manipulation of SLPI levels in the whole organism influences mortality following
exposure to LPS (Nakamura et al., 1993). Considerable work has focused on the administration of
these proteins in laboratory animal models of disease.
Simpson et al. (2001A) have shown the beneficial use of adenovirus delivery of the human elafin
ortholog in a murine model of lung infection. This work has demonstrated the delivery of the human
elafin protein improving the clearance of bacteria from the lungs of mice compared to that seen in
virus control and uninfected mice. Human elafin has also been used as a recombinant protein
administered directly to the lungs of hamsters that have received human neutrophil elastase or LPS
endotracheally (Tremblay et al., 2002; Vachon et al., 2002). The administration of elafin led to a dose-
dependent inhibition of HNE induced lung haemorrhage. Interestingly pre-elafin (complete with
trappin-like repeats - see below) proved more effective than elafin at reducing HNE-induced
haemoglobin release into the BALF. The importance of the trappin-like repeats is discussed in more
depth below.
Wang et al. (2003) showed that in a rat model of ischemic stroke, the administration of Ad-rat SLPI
attenuated ischemic damage 24 hours after middle cerebral artery occlusion as measured by lesion size
and also by examining neurological deficits. The precise mechanism of action of SLPI in this model
was not investigated.
Recombinant human SLPI has been used both by inhalation and by intravenous use in many models
of lung disease as well as in human clinical trials (Mulligan et al., 1993; Wright et al., 1999). However
the focus of this work has been on supplementing the anti-elastase activity as measured in
bronchoalveolar lavage. As discussed above, such an approach may potentially ignore other possibly
important functions which may be independent of anti-protease activity.
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Multiple transglutaminase substrate repeats of consensus sequence PVKGQD (Schalkwijk et al.,
1999) are present in the first domain of the trappins. This hexapeptide has been shown to take part in
the transglutaminase-mediated cross-linking of elafin to matrix proteins (Molhuizen et al., 1993; Nara
et al., 1994; Steinert and Marekov, 1995). An interesting consequence of this is that proteins
containing these repeats can potentially competitively inhibit the transglutaminase itself. This enzyme
is considered important in the direct formation of fibrosis in the lung (Griffin et al., 1979; Richards et
al., 1991; Toida et al., 1991) as well as the activation of TGFP (Kojima et al., 1993).
Transglutaminase also has stimulatory effects on phospholipase A2 (Sohn et al., 2003), an enzyme
which is also directly inhibited by proteins containing the PVKGQD repeats which serve as
transglutaminase substrates. Indeed, peptides based upon the trappin PVKGQD repeat sequence have
been shown direct clinical benefit in a guinea pig model of conjunctival hypersensitivity. In this
model inhibition of these enzymes (Sohn et al., 2003), led to a decrease in both lipoxygenase and
cyclooxygenase activities and hence controlled the arachidonate cascade. Another secreted protein
which is a known substrate for transglutaminase is uteroglobin/Clara cell lOkDa protein (Manjunath et
al., 1984) and this has also been shown to have immunomodulatory effects (Singh and Katyal, 2000)
due, at least in part, to inhibition of phospholipase A2. The improved efficacy of pre-elafin compared
to elafin in modulating HNE-induced lung damage (Tremblay et al., 2002) is possibly due to anti¬
inflammatory effects of the trappin-type region in the pre-elafin protein.
Ovine elafin is predicted to be a very good substrate for, and hence a competitive inhibitor of,
transglutaminase and hence phospholipase A2. If the availability of the PVKGQD repeats has an
influence on the competitive inhibition of transglutaminase (and hence phospholipase A2) then ovine
elafin may have a significant advantage over human elafin in this regard due to the presence of 19
repeats compared to 5 in the human form.
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5.5. CONCLUSIONS
Overall, both ovine SLPI and ovine elafin have characteristics (in common with other SLPI and elafin
orthologs) that make them attractive for use as anti-inflammatory proteins in the field of inflammatory
models. However, ovine elafin may have various advantages over ovine SLPI as a potential
therapeutic, most significantly due to the presence of the large transglutaminase substrate domain. As
discussed this may serve several useful functions in the inhibition of transglutaminase and hence
phospholipase and so lead to a down-regulation of the arachidonic acid cascade locally which may
convey an improved phenotype in an inflammatory model of lung disease.
It is this background which led to the construction of a replication-deficient adenoviral vector
encoding for ovine elafin. This work is detailed in the next chapter.
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CHAPTER 6
CONSTRUCTION AND OPTIMISATION OF A REPLICATION-
DEFICIENT ADENOVIRAL VECTOR ENCODING OVINE ELAFIN
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Introduction
Chapter 5 highlighted the potential benefits that ovine elafin may have as a modulatory protein in the
field of pulmonary inflammation. These can be summarised as shown below:
• Ovine elafin has intrinsic anti-protease activity
• Ovine elafin shows characteristic properties of other members of the elafin family and this
has prompted speculation that the elafin members have 'defensin-like' functions
(Sallenave, 2000)
• The presence of a large 'transglutaminase substrate domain' may confer additional
beneficial characteristics to the secreted protein (Sohn et al., 2003)
These characteristics prompted the construction of a vector encoding for ovine elafin which would
subsequently allow the investigation of the local up-regulation of this anti-protease in an ovine model
of pulmonary inflammation. The data presented within this chapter requires as a background a brief
review of the principles of gene therapy as a tool and therapeutic technique, and also the vectors
available for this work with emphasis on the use of the recombinant adenoviruses.
The principles of gene therapy.
Gene therapy can broadly be defined as the use of genes to cure disease. This may involve the
permanent correction of an incorrect gene for example in the treatment of severe combined immuno¬
deficiency (Cavazzana-Calvo et al., 2000), or the temporary up-regulation of a potentially therapeutic
transgene as in the work in this laboratory using adenoviral vectors encoding for the human elafin
protein (Simpson et al., 2001 A). Each method of utilising a gene therapy or gene transfer technique
may exploit different features of the chosen vector. The vectors in common usage today are discussed
below along with a brief analysis of their advantages and disadvantages.
Vectors available for gene transfer to the respiratory tract.
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These can be categorised as either non-viral or viral vectors. Non-viral methods of delivery have
focused predominantly on the use of cationic liposomes which can be readily conjugated to anionic
DNA in either plasmid or linear form. These complexes are generally cationic and interact with the
negatively charged cell surface allowing the DNA to migrate into the cytoplasm of the 'transfected'
cell (Schofield and Caskey, 1995). Other non-charged liposomes can also be used (neutral liposomes)
and all liposomes can be made up of single or multiple lipid bilayers (unilamellar or multilamellar
respectively) (Feigner et al., 1994). The DNA-liposome complexes are simple to produce and the
liposomes can bind large amounts ofDNA.
Other non-viral vectors include polycationic polymers such as polylysine and polyethylenimine (PEI)
(Wagner et al., 1991; Boussif et al., 1995; Ferrari et al., 1997; Densmore et al., 2000; Wiseman et al.,
2003). These have also been used conjugated to ligands to allow cellular targeting. Advantages of this
system include ease of production, improved DNA packaging and the ability to target specific cells.
However, the transfection efficiency remains lower than that seen with viral vectors.
Viral vectors for gene transfer to the respiratory tract include retroviruses, adeno-associated viruses
(AAV), Sendai virus (SV) and adenoviruses. Adenoviruses will be discussed in more detail below. All
the virus vectors have a limited capacity for 'foreign' DNA i.e. transgene. This varies from 4.7kb in
AAV, through 7-8kb in retroviruses, to 37kb in adenoviruses.
Retroviruses can infect a broad range of cells, providing the cells are replicating, and integrate into the
host cell's genome. This has been used to achieve stable infection of cells ex vivo followed by re¬
implantation of these cells. This has been widely reported recently in the treatment of severe
combined immuno-deficiency in children (Cavazzana-Calvo et al., 2000). As illustrated by the
potential sequelae to this type of intervention, the integration of the virus into the host genome can
cause specific problems with regards activation of previously silent oncogenes with subsequent
neoplastic potential (Marshall, 2003; McCormack and Rabbitts, 2004). Equally, the cells lining the
respiratory tract are relatively differentiated and as such are not readily amenable to retroviral
infection and hence this vector has limited applicability in the field of pulmonary gene therapy for
inflammatory diseases.
Adeno-associated viruses (AAV), which typically remain epichromosomal but may integrate with
high MOI, are members of the parvovirus family which as yet has not been shown to be pathogenic in
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humans. This implies a good safety index for this virus as a possible vector. The main disadvantage of
AAV as a vector is the limit on the size of inserted transgene (Tal, 2000). The clear advantage of
AAV is a markedly reduced inflammatory response post -infection, which in turn allows the repeated
administration of vector. Interestingly, Beck at al. (1999) showed that serum anti-AAV titres do not
predict the neutralisation of AAV in the airways after instillation and indeed preliminary trials using
repeated administration of aerosolised AAV type 2 vectors to deliver the CFTR cDNA to human
patients have led to encouraging results (Moss et ah, 2004).
Sendai virus, a relatively new viral vector, has been used to infect respiratory tissue in vivo. Its
efficiency is several log orders higher than that seen with any other viral or non-viral vector
(Yonemitsu et al., 2000).
The recombinant adenovirus as a vector for lung directed gene transfer.
Recombinant adenoviruses were chosen as the vector for gene delivery in this thesis. As such a more
detailed appraisal of this vector is appropriate.
'Wild type' adenovirus has developed an exquisitely efficient biology related to the infection (in the
mammalian context) of cells lining the respiratory tract. Such viruses have been subject to genetic
modification to allow the insertion of foreign genes and hence these recombinant viruses allow the
efficient delivery of these transgenes to the nuclei of infected cells. The genetic manipulation also
removes the ability of the virus to replicate itself thereby serving as a control on infection.
Recombinant adenoviruses have the additional advantages that they can infect both replicating and
non-replicating cells equally efficiently, and also, unlike retroviruses, they do not integrate into the
host cell genome and thereby avoid problematic up-regulation of oncogenes (Kremer and Perricaudet,
1995).
It is appropriate to examine the wild type virus structure as it has an important bearing on the
mechanism of cell interaction and infection.
The wild type virus (and indeed recombinant adenovirus) is, grossly, icosahedral with a diameter of
approximately 80nm. At the points where 5 of the faces meet are penton subunits to which are
attached the fibres. These fibres terminate in a knob protein and it is this knob portion of the fibre
Chapter 6 125
The construction and optimisation of Ad-o-elafin
which interacts with the adenovirus receptor (the Coxsackie-adenovirus receptor or CAR) on the
surface of permissive cells (Bergelson et al., 1997; Mayr et al., 1997). Following this interaction,
internalisation of the virus depends upon an interaction between the penton base unit itself and a-P
integrins on the cell surface (Wickham et al., 1993). The adenovirus particles are subsequently
transported to the nucleus before disassembly occurs with release of the genetic material, allowing
initiation of transcription and translation to begin. The genetic material is double stranded DNA and
the wild type genome is approximately 36kb in size. The genome contains both early genes and late
genes. The important genes with regards the manufacture of recombinant replication deficient
adenoviruses are the El and E3 regions. The El region initiates viral transcription and does this
without the need for trans-activating factors. El genes are transcribed rapidly after cell infection;
indeed E1A mRNA/protein is detectable within 1 hour. The removal of the El region removes the
possibility of virus replication.
The E3 region is not necessary for viral replication and has been deleted, either entirely or partially,
from many of the currently used adenoviral vectors to allow larger transgenes to be inserted (Bett et
al., 1994; Ng and Graham, 2003).The E3 region is potentially of interest as it contains genes which
may decrease the immune response to the virus in the infected animal. For example, proteins encoded
by this region interfere with the translocation of major histocompatability complex proteins to the
surface of the cell, and also interfere with the TNF mediated cytolysis of infected cells (Feuerbach and
Burgert, 1993; Wold, 1993; Beier et al., 1994; Lee et al., 1995; Wold et al., 1995). Indeed the co-
expression of E3 proteins along with a transgene of choice has been shown to markedly reduce both
the appearance of neutralising antibodies in sera and also the cyto-toxic lymphocyte (CTL) response
of treated animals, when compared to expression of transgene alone (Ilan et al., 1997). The result of
this attenuation of the immune response is that the repeated administration of the same virus led to a
second wave of transgene-derived protein production whereas a second administration of the same
virus minus the E3 genes was neutralised completely with no transgene product detected.
A significant disadvantage of adenoviruses relates to the fact that wild type adenoviruses are
pathogenic and hence genetically modified viruses may still retain pathogenic features. Wild type
virus can be associated with a fulminant pneumonia in man especially in immuno-compromised adults
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(Klinger et al., 1998) although it can also act alongside other pathogens in respiratory disease with
multiple aetiology. In the field of human gene therapy trials, two patients have been recorded as
having respiratory pathology after receiving high doses of recombinant adenovirus and indeed one
patient subsequently died (Crystal et al., 1995; Hollon et al., 2000). It is therefore of the utmost
importance to carefully consider the dosage regime when any adenoviral vector is to be used and to
take into account the route of administration in the particular situation under review. The pathology
induced by the adenovirus, whether wild type or recombinant, is in part due to the host response
towards a known foreign organism. This immune response is also of interest in that it is a major
influence in the duration of transgene expression and also has an important influence in the possibility
of repeated administration of the same vector.
The lung's immune response to adenovirus can be simplified if one considers as an example a single
instillation of a recombinant virus into the air spaces of the lung. The majority of the instilled
adenovirus is rapidly taken up by the resident alveolar macrophages present in large numbers in the air
spaces themselves (Kuzmin et al., 1997; Worgall et al 1997). Additionally, infected cells are
eliminated by a vigorous cytotoxic T cell response (Yang et al., 1994 and 1996; Wilson, 1996). Both
these components make up the initial cell mediated response to the presence of virus. The humoral
response comprises the formation of neutralising antibodies both locally within the bronchoalveolar
fluid (BALF) and in the systemic circulation. It is this component of the immune response which is
responsible for the difficulty in repeating administration of the same or a very similar vector. Both this
humoral response and the cell mediated response may be directed not only towards the adenoviral
components themselves (such as capsid proteins, proteins involved in replication and the genetic
material) but also towards exogenous protein encoded by the inserted transgene. For example many
marker genes used in gene transfer studies are derived from bacteria (beta galactosidase), jelly-fish
(green fluorescent protein) or other organisms. In addition work involving rodent models of in vivo
gene transfer may use viral (viral 11-10 - Lechman et ah, 1999 and 2003; Whalen et ah, 2001) or
human (human elafin - Simpson et ah, 2001A) cDNAs and hence human exogenous proteins will be
produced following administration of virus. These proteins will be presented by antigen presenting
cells in combination with MHC proteins and will elicit a further response. The obvious conclusion to
draw from this data is that it is preferable to study gene transfer using a gene already present within
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the organism of interest, such as up-regulation of a murine gene by adenoviral transfer in a mouse
model and a human gene in human volunteers. In must be borne in mind, however, that adenoviral
vector-induced inflammation can act as a 'danger signal' and as such play an important role in the
breaking of tolerance to an endogenous protein (Camargo et al., 2000).
The incorporation of the ovine elafin cDNA into a replication deficient adenoviral vector would
potentially be of great interest in the investigation of the roles of this anti-protease in the control of
local pulmonary inflammation. Preliminary experimental work would also be of use in the
optimisation of infection protocols using adenoviral vectors both in vitro and in vivo.
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6.2. AIMS
As summarised in chapter 5 ovine eiafin has potential interest in the modulation of the inflammatory
response in the lung. To investigate the up-regulation of ovine eiafin an efficient vector expressing
this protein was constructed and its usage in vitro and in vivo investigated as summarised below:
1. This chapter details the construction of an adenoviral vector which codes for the shorter form of the
ovine eiafin allele (TOM-1).
2. Standard methods involving homologous recombination in human embryonic kidney (HEK-293)
(Graham et al., 1977; Graham and Prevec, 1995) cells were employed.
3. Correct transgene insertion was confirmed by Southern blot analysis and restriction analysis, and
functional activity assessed by infection of A549 cells and Western blot of the supernatants for
secreted eiafin.
4. Positive plaques were expanded to obtain a concentrated stock solution of active Ad-o-elafin and
the concentration confirmed by titration on HELA cells.
5. The use of transfection reagents to up-regulate expression in vitro was explored.
6. Preliminary studies aimed at dose-finding in vivo were conducted.
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6.3. RESULTS
6.3.1. Insertion of the ovine elafin cDNA into the shuttle vector pDC516.
Full length ovine elafin cDNA in pCRR4-TOPOR (see chapter 3) was used as a template for two
consecutive PCRs with firstly Bgl-f-el and FLAG-r-el, followed by Bgl-f-el and Sac-r-FLAG-el (to
yield Bglll-elafin-FLAG-SacI). This product was ligated into shuttle vector pDC516 (which contains
the murine cytomegalovirus (MCMV) promoter). Product from this reaction was used to transform
XL 1-Blue subcloning grade E. coli. A positive colony was identified by restriction analysis and
plasmid isolated with the Qiagen Maxi-Prep kit. This plasmid will henceforth be known as pDC516-o-
elafin.
6.3.2. Homologous recombination in 293 cells.
The techniques used in this chapter to produce a replication-deficient Ad have been developed by
Professor Frank Graham's research group at McMaster University and the particular protocol used
here utilising FLP/frt recombinase technology is discussed in one of his group's publications (Ng at al
2001). This protocol relies on the protein FLP catalysing a site-specific recombination event between
the shuttle plasmid (here pDC516) and the adenoviral vector plasmid (pBHGfrt(del)El,3FLP) so that
a viral genome is produced lacking only the El and part of the E2 regions. The result is an Ad that can
only replicate in the presence of El delivered in trans (in this case the human embryonic kidney cell
line, HEK 293, are stably transfected with El).
293 cells were co-transfected with pDC516-o-elafin and pBHGfrt(del)El,3FLP (a kind gift from Dr.
M. Hitt, McMaster University) at various ratios or with the single control plasmids pFG140 (as a
positive control) and pDC516-o-elafin or pBHGfrt(del)El,3FLP (as negative controls). This process is
shown diagrammatically in fig. 1.
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Fig. 1. Insertion of ovine elafin cDNA into shuttle vector followed by
site-specific recombination in 293 cells to yield Ad-o-elafin.
The ovine elafin cDNA isolated in chapter 3 was used as a template in PCR
reactions to produce Bglll-ovine elafin-FLAG-SacI as described in chapter 2.
This was ligated into the shuttle vector pDC516 as described. 293 cells were then
co-transfected with this shuttle vector and also the adenovirus genome plasmid
pBHGfrt(del)El,3FLP and site-specific recombination events yielded the
adenovirus genome as shown (Ad-o-elafin). This genome contains the ovine
elafin cDNA driven by the MCMV promoter and the vp packaging sequences
derived from the shuttle vector. This genome is packaged in the 293 cells which
deliver in trans the El proteins necessary for the initiation and continuation of
viral replication.
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Five dishes (referred to as 'a' to 'e') demonstrated complete cytopathic effect (CPE).
6.3.3. Southern blot analysis of CPE-positive cells for ovine elafin cDNA insert.
The cell pellets from dishes 'a' to 'e' were extracted for DNA. A 1% agarose gel of the products of
Hind III digestion is shown in fig. 2A. Southern blot analysis, confirming two wells ('b' and 'e') as
positive, is shown in fig. 2B. Positive bands were identified at approximately 3.5kbps and 4.5kbps.
6.3.4. Restriction digestion and Western blot analysis of six positive plaques.
Cell supernatant from dish 'b' was used to re-infect adherent 293 cells under agarose to isolate pure
plaques. This led to the isolation of six positive plaques referred to as 1-6. These plaques were subject
to freeze-thaw lysis and the resultant supernatant used on fresh 293 cells until 100% CPE to re-check
the efficiency of infection, functional activity, and the DNA banding pattern after Hind III digestion.
The results of Hind III digestion are shown in fig. 3. The putative o-elafin positive band seen at
3.5kbps (see fig. 2B) was present in cell pellets from dishes 4, 5 and 6. All six dishes demonstrated a
band at 4.5kbps which is the weight of the heavier band seen by Southern blot analysis (see above and
fig. 2B).
The origin of the banding patterns seen in the Southern blot analysis and Hind III digestion (figs. 2
and 3) are discussed in section 6.4.1.
Western blot analysis on supernatants from these dishes is shown in fig. 4. Dishes 4, 5 and 6 were
positive for secreted ovine elafin (detected by both the Trab-20 antibody and also the anti-FLAG
antibody). Supernatant from dish 5 was used in further experiments to amplify the adenovirus stock
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Fig. 2. Restriction digestion and Southern blot analysis of DNA post
homologous recombination.
DNA from dishes positive for cytopathic effect after the homologous
recombination stage of adenovirus production was digested with Hind III and
run out on an agarose gel (A) before being transferred to PVDF membrane and
used in Southern blot analysis (B) probed with the ovine elafin cDNA. The
positive lane refers to DNA from the positive control dish transfected with
pFGMO plasmid. a-e refer to the 5 dishes that showed full cytopathic effect.
Dishes b and e are positive for the ovine elafin cDNA at approximately 3.5 and
4.5kb.
C shows the resultant map of the first portion of the resultant recombinant
adenovirus genome after FLIP mediated recombination between pDC516 and
pBHGfrt(del)El,3FLP. The Hind III sites are indicated below. Figures denote
the base pair number from the start of the Adenoviral genome.
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Fig. 3. Hind III digestion of DNA from 6 plaques isolated after 293
infection under agarose.
DNA isolated from the positive plaques isolated during adenovirus preparation
was digested with Hind III as described in Chapter 2. The resultant digested
DNA was run on an agarose gel and the photograph reproduced here. The lanes
corresponding to plaques 1-3 have the same band pattern as each other and are
different to the bands seen in the lanes corresponding to plaques 4-6 which again
are the same as each other. Plaques 4-6 contain a band at the 3.5kb (A) seen by
Southern blot in fig. 2B. A band is seen at approximately 4.5kb (B) which
corresponds to the heavier band seen in Southern blot analysis but this band
seems to be present in all 6 plaques.
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by recognised methods (Graham and Prevec, 1995). This adenovirus will now be referred to as Ad-o-
elafin.
6.3.5. The assessment of polyethylenimine, calcium phosphate, EGTA and LPS as transfection
reagents for up-regulating adenoviral infection ofA549 cells.
In order to investigate possible methods of improving the infection efficiency of adenoviral vectors in
vitro (with potential subsequent use in vivo), a variety of infection protocols was used as described in
chapter 2 (section 2.2.6). Fig, 5 shows representative photomicrographs taken 24 hours after infection
of A549 cells with Ad-GFP under the following conditions. Virus was used either alone (multiplicity
of infection (MOI) of either 1 or 10), or after co-precipitation with calcium phosphate (CaP), or pre¬
incubation with polyethylenimine (PEI, 500 molecules per virus particles) or in combination with
hypotonic EGTA (lOOmM EGTA in 37.5mosm/l PBS). As seen in fig. 5 all three treatments caused an
up-regulation in both the number ofGFP +ve cells and their fluorescent intensity. The increase in GFP
seen with the calcium phosphate co-precipitation was more marked than that seen with either the PEI
complex or the pre-treatment with hypotonic EGTA.
Cell counts confirmed the visual impression (fig. 6) with calcium phosphate, PEI and EGTA
significantly increasing the number of A549 cells infected (P<0.005, P<0.05 and P<0.05 respectively
compared to virus alone).
A second experiment assessed the effect, relative to the above conditions, of incubating the cells with
bacterial lipopolysaccharide (LPS). This experiment was conducted in order to investigate the
potential up-regulation of the activity of the MCMV promoter by bacterial LPS (Loser et al., 1998;
Sallenave et al., 1998; Simpson et al., 2001B). After 1 hour incubation with the virus (MOI 10),
virus+CaP, virus+PEI, or virus+EGTA the cell culture medium was changed. LPS (lOpg/ml) was
added to some of the virus alone wells on day 3. Supernatants were collected after 4 days and
analysed by the use of a direct ELISA as described in Chapter 2 (Section 2.2.7).
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Fig. 4. Western blot analysis of supernatants from adenovirus
positive plaques.
Supernatant from A549 cells infected with freeze/thaw lysate from the positive
plaques (plaques 1 to 6) yielded after the 're-plaquing' stage of adenovirus
production were used in Western blot analysis using either Trab-20 antibody
(A) or anti-FLAG monoclonal antibody (B). Plaques 4-6 are positive for
adenovirus producing elafin-FLAG protein.
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Fig. 5. The up-reguiation of adenoviral infection of A549 cells by the
use of polyethylenimine, calcium phosphate and EGTA.
A549 cells were plated out at 80,000 per well in 48 well format and infected with
Ad-GFP MOI l (upper group ofmicrographs) or 10 (lower group) for 1 hour
either alone or after pre-incubation with PEI or calcium phosphate, or with the
addition of EGTA to the cells along with the virus as described in chapter 2
(section 2.2.6). GFP +ve cells were visualised by UV microscopy after 24 hours.
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Virus alone Virus plus Virus plus Virus plus
PEI CaP EGTA
Fig. 6. The up-regulation of the number of A549 cells infected by
adenovirus by the use of polyethylenamine, calcium phosphate and
EGTA.
A549 cells were plated out at 80,000 per well in 48 well format and infected with
Ad-GFP MOI 1 for 1 hour either alone or after pre-incubation with PEI or
calcium phosphate, or with the addition of EGTA to the cells along with the
virus. GFP +ve cells per high power field were counted after 24 hours. Results
are displayed as the mean of 3 wells and error bars represent standard deviation.
* Indicates P<0.05 compared to virus alone and ** indicated P<0.005 compared
to virus alone when data analysed by T Test.
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Both LPS and calcium phosphate co-precipitates significantly up-regulated the secretion of ovine
elafin compared to that due to Ad-ovine elafin alone (P<0.05 and P<0.005 respectively) (fig. 7). and
calcium phosphate was significantly more effective than LPS in this regard (P<0.005).
6.3.6. Optimisation of calcium phosphate as a transfection reagent.
6.3.6.1. Time of contact.
A549 cells were incubated with virus or virus+CaP (MOI 10) for 1 minute, 5 minutes, 20 minutes or 1
hour before washing and further incubation in fresh medium. Photomicrograph images were captured
24 hours post-infection and analysed by the use of Image J software to count GFP +ve pixels.
Calcium phosphate significantly increased the number of GFP+ve pixels relative to virus alone
following all incubation times (P<0.05 for 1 minute, P<0.0005 for 5 minutes, 20 minutes and 1 hour)
(fig. 8). The pixel count declined significantly between 20 minutes and 1 hour with virus+CaP
(P<0.05).
6.3.6.2. Toxicity.
A549 cells were infected virus alone or virus+CaP (MOI 10) for 1 hour before washing and further
incubation in fresh medium. After 24 hours cell viability was assessed by trypan blue exclusion.
The use of CaP led to a significant and marked increase in cell death relative to virus alone (P<0.05)
(fig- 9).
6.3.6.3. Verification on primary cells.
Ovine alveolar macrophages, plated at 250,000 per well, were infected with Ad-GFP alone or Ad-
GFP+CaP (MOI 100) for twenty minutes after which the medium was replaced and culture continued
for 24 hours.
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Virus Virus plus Virus plus Virus plus Virus plus
alone LPS EGTA PEI CaP
Fig. 7. The increase in the efficiency of Ad-o-elafin infection by the
use of polyethylenimine, calcium phosphate, EGTA and LPS.
A549 cells were plated out at 80,000 per well in 48 well format and infected with
Ad-o-elafin MOI 10 for 1 hour either alone or after pre-incubation with PEI or
calcium phosphate, or with the addition ofEGTA or LPS to the cells along with
the virus. Secreted ovine elafin was assessed by direct ELISA after 4 days (See
chapter 2 sections 2.2.6 and 2.2.7). Results are displayed as the mean of 3 wells
and error bars represent standard deviation.
* Indicates P<0.05 and ** indicated P<0.005 when data analysed by T Test.
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1 minute 5 minutes 20 minutes 1 hour
Fig. 8. The effect of contact time between vector and cells on the up-
regulation of adenoviral infection of A549 cells with and without the
use of calcium phosphate.
A549 cells were plated out at 80,000 per well in 48 well format and infected with
Ad-GFP MOI 10 after pre-incubation with either calcium phosphate or control
medium alone for 20 minutes. After 24 hours photomicrographs were taken and
analysed by the use of Image J software. Pixel counts are shown as the means of
3 wells and error bars represent standard deviation.
* indicates P<0.05 and *** indicates P<0.0005 when CaP treatment is compared
with no CaP for each contact time.
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Virus alone Virus plus CaP
Fig. 9. The effect of adenovirus/CaP incubation on A549 viability.
A549 cells were plated out at 80,000 per well in 48 well format and infected with
Ad-GFP MOI 10 for 1 hour after pre-incubation with either calcium phosphate
or control medium alone for 20 minutes. After 24 hours cells were assessed for
viability by trypan blue exclusion. Results are shown as mean of 3 wells and
error bars indicate standard deviation.
* indicates P<0.05 when CaP treatment is compared with no CaP.
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Twenty-four hours after infection, approximately 5% of the cells infected with Ad-GFP alone were
GFP+ve (fig. 10A) whereas approximately 80% of the cells infected with Ad-GFP+CaP were GFP+ve
(fig. 10B). The latter cells were more intensely fluorescent.
In a separate experiment, ovine alveolar macrophages, plated at 250,000 per well, were infected with
Ad-o-elafin alone or Ad-o-elafin+CaP (MOI 100 and 200) for twenty minutes after which the medium
was replaced and culture continued for 4 days. Western blot analysis of the supernatants 4 days after
infection with o-elafin at both MOIs demonstrated an obvious up-regulation of secreted elafin with
Ad-o-elafin+CaP relative to Ad-o-elafin alone (fig. 10C)
Cell viability at 24 hours was assessed by propidium iodide staining. The use of CaP led to a
significant and marked increase in cell death relative to virus alone (P<0.05) (fig. 11).
6.3.6.4. Verification in vivo.
As discussed above the use of co-precipitation with calcium phosphate led to the most marked up-
regulation of Ad infection efficiency and verification of this principle was sought in vivo. A one year
old Suffolk cross sheep was instilled endo-bronchially in separate segments with lxlO7, 5xl07 and
1x10s plaque forming units (pfu) of Ad-GFP either in PBS alone or after pre-incubation with CaP for
20 minutes (chapter 2 (section 2.3.6)). Other segments received PBS alone or PBS with CaP, or were
not treated (nai've). The doses of Ad instilled in this experiment will be referred to as low, medium and
high (relating to lxlO7, 5xl07 and 1x10s plaque forming units (pfu) respectively) from this point. 48
hours after the instillation the sheep was killed and bronchoalveolar lavage (BALF) collected from
each segment. The cellular content of the BALF samples was assessed for total and differential cell
counts. The BALF supernatant was assayed for total protein content. Tissue sections were examined
under UV microscopy for quantification ofGFP +ve cells.
Ad-GFP alone (medium and high dose) and Ad-GFP+CaP (low, medium and high dose) increased the
number of neutrophils in the BALF (Fig. 12A and B) relative to the nai've segment.
Treatment did not appear to influence the total protein content ofBALF (fig. 13).
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Fig. 10. Calcium phosphate increases the efficiency of adenoviral
infection of ovine alveolar macrophages.
Ovine alveolar macrophages were plated out 250,000 per well in 24 well plates
and were infected with Ad-GFP and Ad-ovine elafin at MOI 100 and 200 either
pre-complexed with calcium phosphate or as virus alone.
A. Ovine alveolar macrophages 24 hours after infection with Ad-GFP MOI
100 alone.
B. Ovine alveolar macrophages 24 hours after infection with Ad-GFP MOI
100/calcium phosphate co-precipitate.
C. Western blot analysis of ovine alveolar macrophage supernatant using
Trab-20 antibody 4 days after infection with Ad-ovine elafin at MOI 100
and 200 either with or without co-precipitation with calcium phosphate.
Uninfected alveolar macrophage supernatant is included as a control.
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Virus alone Virus plus CaP
Fig. 11. The effect of adenovirus/CaP incubation on alveolar
macrophage viability.
Alveolar macrophages were plated out at 250,000 per well in 24 well format and
infected with Ad-GFP MOI 100 for 20 minutes after pre-incubation with either
calcium phosphate or control medium alone for 20 minutes. After 24 hours cells
were assessed for viability by propidium iodide staining. Results are shown as
mean of 3 animals macrophages and error bars indicate standard deviation.
* indicates P<0.05 when CaP treatment is compared with no CaP.
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Fig. 12. The effects of adenovirus/CaP instillation on cell number
and percentage neutrophils in bronchoalveolar lavage (BALF).
BALF was collected 48 hours after instillation into different segments of vehicle
(PBS), vehicle and CaP, lxlO7, 5xl07 and 1x10s pfu Ad-GFP either in PBS or
after pre-incubation with calcium phosphate. Differential cell counts (A) and the
percentage of neutrophils in the BALF (B) are shown.
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Fig. 13. The effects of adenovirus/CaP instillation on the total
protein content of bronchoalveolar lavage (BALF).
BALF was collected 48 hours after instillation of vehicle (PBS), vehicle and
CaP, lxlO7, 5xl07 and 1x10s pfu Ad-GFP either in PBS or after pre-incubation
with calcium phosphate, and the total protein content of the BALF shown.
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High power fields in tissue sections from segments exposed to Ad-GFP alone (medium dose) and Ad-
GFP+CaP (medium and high dose) had significantly more GFP+ve cells than fields in sections from
the naive segment. Co-precipitation with CaP significantly increased the number of GFP+ve cells in
the segments exposed to medium and high dose Ad (fig. 14A).
Fig. 14B shows representative high power views from the high dose Ad-GFP+CaP treated segment.
These photomicrographs show efficient infection of individual cells, mainly what appear to be Type II
epithelial cells in the alveolar sacs (closed arrows) and alveolar macrophages (open arrow). Evidence
of infection of type I epithelial cells was apparent although these cells were more difficult to visualise
due to their physical shape and size.
6.3.7. Utility of CaP in optimising protocols for Ad-o-elafin administration in vivo.
The data from the last experiment prompted the investigation of the instillation of Ad-o-elafin into the
ovine lung in order to subsequently examine the potential for elafin to modulate the lung's
inflammatory response.
3 sheep were instilled endo-bronchially, in separate lung segments with 1x10 , 5xl07 and 1x10s
plaque forming units (pfu) of Ad-o-elafin after incubation with CaP for 20 minutes (chapter 2 section
2.3.6). Other segments received PBS alone or PBS+CaP, or were not treated (naive). 48 hours after
virus administration the sheep were killed and bronchoalveolar lavage (BALF) collected from each
segment. The cellular and protein content of the BALF samples was assessed and compared to pre-
experimental samples taken 1 week prior to virus administration.
Neutrophil numbers in BALF increased significantly in the high dose Ad-o-elafin+CaP segment when
compared to the naive segment (P<0.05). No significant change occurred in relation to the pre-
experimental BALF samples (figs. 15A and B). No other cell type was affected as a consequence of
treatment.
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Fig. 14. The in vivo infection of ovine lung with Ad-GFP/CaP co-
precipitates.
Cryo-sections were prepared from lung tissue 48 hours after instillation of
vehicle (PBS), vehicle and CaP, IxlO7, 5xl07 and lxlO8 pfu Ad-GFP either in
PBS or after pre-incubation with calcium phosphate. 24 random fields were
counted under high power using UV light and the number of GFP+ve cells
recorded.
A. The number ofGFP+ve cells per high power field is presented here as the
mean with error bars indicating standard deviation. ** and *** indicate
P<0.005 and P<0.0005 respectively compared to naive; ## and ### indicate
P<0.005 and P<0.0005 respectively when compared to the same dose of
virus minus CaP co-precipitates using a T Test.
B. Representative fields from the high dose/CaP segment showing infection of
Type 11 epithelial cells (filled arrow) and an alveolar macrophage in an
airway (open arrow). Counterstaining of nuclei is with DAPI.
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Fig. 15. The effects of Ad-o-elafin/CaP instillation on cell number
and percentage neutrophils in bronchoalveolar lavage (BALF).
BALF was collected 48 hours after instillation of vehicle (PBS) and CaP, lxlO7,
5xl07 and 1x10s pfu Ad-ovine elafin after pre-incubation with calcium
phosphate, and the differential cell counts (A) and the percentage neutrophils in
the BALF (B) shown. Data is shown as mean (n=3) and error bars represent the
standard deviation. * represents P<0.05 when compared to naive segment counts
when analysed by T test.
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BALF total protein increased significantly in the high dose Ad-o-elafin+CaP segment when compared
to the nai've segment (P<0.05). No significant change occurred in relation to the pre-experimental
BALF samples (figs. 16A and B).
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Pre Naive Vehicle Low dose Medium High dose
alone virus dose virus
virus
Fig. 16. The effects of Ad-o-elafin/CaP instillation on total protein
content of broncho-alveolar lavage (BALF).
BALF was collected 48 hours after instillation of vehicle (PBS and CaP), or
lxl07, 5x107 and lxl08 pfu Ad-o-elafin after pre-incubation with calcium
phosphate, and the total protein content of the BALF shown. Data is presented as
means (n=3) and error bars represent standard deviation. * indicates P<0.05
compared to naive segment when data analysed by T test.
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6.4. DISCUSSION
6.4.1. The construction of Ad-o-elafin.
As discussed in depth in chapter 5 ovine elafin was chosen in this study from the two newly
characterised ovine anti-proteases detailed in chapters 3 and 4, as the more likely to have beneficial
modulatory activity in models of inflammation. This chapter detailed the use of the ovine elafin cDNA
to produce a replication deficient Ad vector in order to further study the effects of elafin delivery in
vivo.
The ligation of the ovine elafin cDNA into the shuttle vector pDC516 as discussed above was
relatively undemanding and as such warrants little in the way of discussion. However the site-specific
recombination between genomic plasmid and shuttle plasmid in 293 cells was more complex and
carried the potential for error introduced by the recombination process. Hence the reason for assessing
the 'banding' pattern of the potentially positive cultures either at the stage of CPE in 293 cells in
normal culture conditions, or at the latter stage of plaque formation under agarose. Analysis of the
same digested DNA at the CPE stage by Southern Blot confirmed the presence of the ovine elafin
cDNA.
Positive samples showed positive bands at approximately 3.5 and 4.5kbps. Fig. 2C shows the map of
the resultant Ad Ad-o-elafin. The predicted size of the portion of DNA after Hind III digestion which
contains the ovine elafin cDNA is 3617bps. This band is likely to correspond to the band seen at
approximately 3.5kbps on the Southern blot (fig. 2) and the Hind III digested DNA post re-plaquing
(fig. 3). The source of the band seen at approximately 4.5kbps is likely to be due to partial digestion of
the Hind III site at the extreme 5' end of the ovine elafin cDNA (see chapter 3, fig. 10 base pair 607).
The partial digestion at this site would lead to a Hind III product of 4645bps (fig. 2).
Western blot analysis demonstrated that only the supernatants from A549 cells 'infected' with the
lysate from the plaques which were positive for the band at approximately 3.5kbps by Hind III
Chapter 6 155
The construction and optimisation of Ad-o-elafin
digestion (plaques 4 to 6) showed production of secreted ovine elafin-FLAG (fig. 4). A 40kDa
secreted protein was detectable by Trab-20 (detecting the repeat PVKGQD motifs) and the anti-
FLAG monoclonal antibody. This, taken together the Western blot analysis, restriction analysis and
Southern blot analysis, suggested that plaques 4, 5 and 6 contained adenovirus which could
successfully infect A549 cells leading to the correct transcription, translation and processing of ovine
elafin-FLAG.
Large amounts of adenovirus were produced by further infection of 293N3S cells in a spinner culture
system using a cell lysate from the positive plaque. The infected cells in the spinner culture were then
subject to further purification involving ultra-centrifugation in a caesium chloride gradient to allow
the isolation of a concentrated solution of adenoviral particles. This solution was then de-salted in an
ion exchange column before the final elution of 'banded' Ad for use in subsequent studies. This final
eluent was aliquoted to avoid freeze-thawing virus stocks, and stored at -70°C. All the stages in the
purification of Ad subsequent to the identification of a positive plaque were performed in the Rayne
Laboratory Adenovirus Facility by Alison Flarris using techniques developed in McMaster University,
Ontario (Graham and Prevec, 1995).
The final outcome of the bulking up of the Ad constructed within this chapter was a virus stock of
1.26x10" plaque forming units (pfu) per ml (1.25xl013 particles per ml) of Ad-o-elafin for use in the
latter part of this chapter looking at the adenoviral infection of respiratory epithelium and alveolar
macrophages both in vitro and in vivo.
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6.4.2. The Investigation ofmethods to up-regulate adenoviral infection efficiency in vitro and in vivo.
The first experiments focused on investigating the possibility of up-regulation of transgene expression
after a defined, and low, number of adenoviral particles were used to infect epithelial cells in culture.
To this end, we used both an Ad expressing GFP (Ad-GFP) and also the potentially therapeutic Ad (as
described earlier in this chapter) coding for ovine elafin (Ad-o-elafin). The main goal of the
experimental work presented within this part of this chapter was to develop a protocol for the efficient
infection of the ovine lung with an adenovirus encoding ovine elafin (Ad-o-elafin) in order that
subsequent work could investigate the potential benefits elafin may have (as discussed in chapter 5) in
the inflamed lung (see chapter 7).
Efforts were directed at maximising the protein output from recombinant Ad infected cells in vitro. It
is pertinent to review the scientific literature which prompted this work.
Adenovirus particles normally enter cells in culture by the interaction of the Ad fiber with cellular
receptors (Bergelson at al., 1997; Mayr at al., 1997) and the binding of the penton base with a-p
integrins (Wickham et al., 1993). Further work by Walters et al. (1999) showed that the adenoviral
receptors CAR and MHC class I were located baso-laterally in the differentiated human airway
epithelial cultures used in their work. Both the prevalence of these receptors, and also their
accessibility, are crucial to the efficacy of this process. Indeed, Zabner et al. (1997) showed that
ciliated airway epithelium was resistant to Ad infection (unless a long incubation period was used -
Zabner et al., 1996) due to the lack of such receptors on the apical surface of differentiated respiratory
epithelium. Fasbender et al. (1997) and Arcasoy et al. (1997) both used complexes of Ad and cationic
compounds to try to circumvent this receptor-based viral entry pathway with good success. Both
groups found that complexing the Ad with either poly-L-lysine (PLL) or cationic lipids increased the
efficiency of Ad infection due to the cationic compound forming non-covalent bonds with the virus
and these positively charged moieties interacting with the negatively charged cell surface membrane.
However, the use of cationic lipids can cause significant cyto-toxicity in vitro (Fasbender et al., 1995;
Cortesi et al., 1996) and also can cause inflammation in vivo as shown by Scheule et al. (1997).
Fasbender et al. (1998) postulated that the incorporation of Ad with a cationic lipid may result in an
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exaggerated immune response to the virus with the lipid acting as an adjuvant. Hunter et a!. (1981)
showed an adjuvant activity in surface active non-ionic surfactants potentially due to their lipophilic
nature allowing close contact between surfactant coated antigens and the hydrophobic cell wall. In
contrast, however, subsequent work has shown that coating ofAd particles shields them from the host
immune system. Chillon et al. (1998) demonstrated that coating of Ad with polyethylene glycol and
lipid necessitates a 50x increase in amount of neutralizing serum in order to abrogate infection. In
another example, Dodds et al. (1999) showed a similar phenomenon when infecting mouse
myotubules with Ad-lacZ complexed with polycations.
Ad access to the specific cellular receptors (CAR and MHC class I) is of fundamental importance in
allowing primary attachment of the virus to the cell surface before integrin modulated internalisation
can begin. Specifically the number and localisation of these receptors are important predictors of the
'sensitivity' of a tissue or epithelial layer to adenoviral infection. In the respiratory tract, with the Ad-
specific receptors found baso-laterally on the columnar cells making up the airway wall, virus access
to the receptors is limited, hence there is a low level of infectability (Zabner et al., 1997). One way
that has been used to increase access to these receptors is to simply damage the intercellular
attachments, the 'junctional complex' made up of tight junctions, adherens junctions and
desmosomes. This has been investigated primarily by the use of chelators of bivalent cations
exploiting the fact that all 3 components of the junctional complex depend on Ca2+ for their correct
functioning. Specifically, the Ca2+ chelator ethylene-glycol-bis-(beta-aminoethyl ether)-A(A(A',A'-
tetra-acetic acid (EGTA) has been the focus of much work both in vitro and in vivo. Wang et al.
(2000) demonstrated that EGTA in a hypotonic buffer caused an effective and rapid disruption of the
epithelial junction complex in human differentiated epithelial cells in culture allowing viral access to
the intercellular spaces. This group also showed that in vivo the same formulation could markedly
increase the magnitude of transgene-driven protein production in the rabbit trachea. A similar
approach albeit this time using an isotonic formulation of EGTA was used by Chu et al. (2001) where
up to a 50 fold increase in transgene derived protein was seen both in vitro and in vivo (murine trachea
using both standard instillation and aerosolisation). Of note is the more recent use of sodium caprate
(another epithelial junction disruptor) both in vitro and in vivo where this compound's efficacy in up-
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regulating adenoviral infection was associated with fewer side effects (Gregory et al., 2003; Johnson
et al., 2003). Of significant importance to projected in vivo use is the time required for the chelator to
be in contact with the target tissue prior to vector administration. For example, Wang et al. (2000)
instilled hypotonic EGTA solution into rabbit tracheas for 45 minutes before removing this solution
and applying the virus vector. In contrast, cationic substances can be instilled as a complex with Ad
i.e. no pre-treatment of the tissue is required.
Prior literature indicated the potential of using inorganic salt complexes in vivo in the same way that
calcium phosphate had long been used to increase the transfection efficiency of plasmid DNA into
cells in culture (Chen et al., 1987 and 1988). Fasbender et al. (1998) were the first to show that the
incorporation of Ad into a calcium phosphate precipitate markedly enhanced the efficiency of
infection into cells that were low in fiber receptors. In addition, however, cells with sufficient fiber
receptors were also infected more efficiently with the use of the calcium phosphate co-precipitate
technique. This methodology was therefore permitting infection of the cells by a non-fiber/fiber
receptor mediated route. Furthermore the success of this method indicated that ot-P integrins were not
necessary due to their paucity on the apical surface of airway epithelial cells (Zabner et al., 1997;
Goldman and Wilson, 1995). Fasbender et al. (1998) also investigated the in vivo infection of the
murine lung and found a similar up-regulation of transgene expression. Interestingly the increase in
efficiency seemed to be localized to the murine airway with no real change in infection efficiency in
the parenchyma. Subsequent work (Walters and Welsh, 1999) has shed light on the mechanism by
which calcium phosphate co-precipitate enhances gene delivery and has demonstrated that this
mechanism is independent of fiber receptors and integrins.
The above work concentrated on the modification of the interaction between Ad and host cell either
by facilitating access to viral receptors or allowing viral infection to bypass the usual mechanisms of
cell entry. Once the virus has entered the cell the protein output of that cell depends primarily on the
activity of the transgene within the recombinant virus. This, in turn, relies on the activity of the
promoter which in the case of the Ad constructed in this chapter contains a promoter derived from the
murine cytomegalovirus (MCMV). This promoter was used after previous work showed a higher
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transgene activity from constructs using this promoter when used in human alveolar epithelial cells
(A549 cells as used here) and human and rat primary fibroblasts (Sallenave et al., 1998) when
compared to the human cytomegalovirus (HCMV) promoter and the Ad major late promoter.
Similarly to the HCMV promoter, the MCMV promoter also contains regulatory elements sensitive to
NF-kB. This leads to the promoter being sensitive to LPS stimulation via the activation of NF-kB
(Loser et al., 1998; Sallenave et al., 1998; Simpson et al., 2001B), hence the possibility of up-
regulating transgene expression by exogenous LPS. Loser et al. (1998) showed the re-activation by
LPS ofHCMV promoter driven transgene expression in murine hepatocytes, which was dependent on
NF-kB activation. In addition, the same group showed activation of the HCMV promoter in HCMV-
lacZ transgenic mice after the administration of a recombinant Ad, hence the Ad itself up-regulates
factors which have a positive feedback on the expression of transgene contained in that virus. Simpson
et al. (200IB) showed marked up-regulation of MCMV driven transgene production after in vivo
administration of recombinant Ad and bacterial LPS. These data indicate the usefulness of a highly
active promoter in a recombinant Ad which is up-regulated by the very inflammation (here
exemplified by LPS) which the Ad induces. Because of this a low dose of virus can be used with the
addition of LPS to up-regulate transgene expression.
This background inspired the investigation of these techniques to up-regulate the transgene activity for
a given, low dosage of administered recombinant adenovirus. The data indicated that the incorporation
of Ad into a calcium phosphate precipitate was highly effective in increasing the infection efficiency
of the virus. Further, the data indicated that the 20 minute incubation time was optimal.
With the physiological goal of achieving efficient transgene expression in vivo, a delivery and assay
system modeled on endo-bronchial administration (Emerson et al., 2003) of Ad was selected. With
such a system the target cell populations consist of those cells lining the bronchioles, alveolar ducts
and sacs, and the mobile cell population therein. This last population is made up in the quiescent ovine
lung almost entirely of alveolar macrophages (Collie et al., 1999). As alveolar macrophages are easily
sampled by bronchoalveolar lavage and play a pivotal role in the initiation and progression of the
innate immune response they were considered suitable candidates to follow the progression of events
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ex vivo following exposure to Ad. Alveolar macrophages are believed to be relatively resistant to Ad
infection due primarily to a low level of expression of the CAR receptor (Kaner et al., 1999). This
group, however, showed that human alveolar macrophages (AMs) could be infected by recombinant
Ad at high MOIs by a fiber dependent (and hence CAR independent) mechanism. Conron et al. (2001)
showed that alveolar macrophages from human sarcoid sufferers were permissive for Ad infection and
that this was due to an increase in surface expression of both CAR and the internalisation integrins
avp3 and avp5. The change in the surface expression of the receptors and integrins was attributed to
the alveolar macrophages being in contact with an inflamed milieu. It was hypothesised that the use of
Ad in conjunction with calcium phosphate may potentially bypass this 'requirement' for inflammation
by allowing infection of the alveolar macrophages by the endocytosis based pathway previously
referred to.
Initial experiments with Ad-GFP demonstrated the beneficial effect of co-precipitation on the
infection efficiency and further experiments with Ad-o-elafin confirmed those benefits in relation to
elafin secretion.
The issue of calcium phosphate induced cyto-toxicity was addressed for both alveolar macrophages
and an alveolar epithelial cell line (A549 cells). A significant and marked increase in cell death due to
the use of Ad+CaP relative to Ad alone was apparent in A549 cells (as measured by trypan blue
exclusion) (fig. 9) and a similar situation was seen in alveolar macrophages (with cytotoxicity assayed
by propidium iodide staining) (fig. 11). Although different methods render accurate comparisons
impossible some information can be gained from this work. Data from the scientific literature
examining calcium phosphate mediated cell death is limited currently but it can be fairly assumed that
at least some of the cytotoxicity observed here is due to an increase in the viral burden seen by the
cells infected due to the fact that the co-precipitation with calcium phosphate is increasing the
infection efficiency of the cells. Additionally, some workers have reported a cytotoxic effect attributed
directly to GFP itself (Liu et al., 1999). Obviously the level of cytotoxicity seen in these experiments
(medians of 40% and 50% for A549s and alveolar macrophages respectively) cannot be described as
negligible in itself. However, this experiment was designed to investigate primarily the effect of
calcium phosphate co-precipitation on the infection efficiency of Ad-GFP and as such has showed that
there is a great benefit over Ad-GFP alone with respect to the number of cells infected and to the GFP
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contained within each cell. Additionally the alveolar macrophages infected by such a protocol using
Ad-o-elafin secrete much increased amounts of ovine elafin into the culture supernatant compared to
Ad-o-elafin alone (fig. IOC). It is this beneficial effect on transgene mediated protein production that
proved persuasive and prompted the decision to use adenovirus co-precipitated with calcium
phosphate for the subsequent in vivo work detailed below.
6.4.3. Preliminary investigation of the instillation of recombinant adenoviruses segmentally to the
ovine lung.
With the benefits of calcium phosphate co-precipitation established in vitro using A549 cells and ex
vivo using primary cultures of alveolar macrophages, the foundation for progressing towards in vivo
studies was established. Initial experiments examined the expression of Ad-GFP as a 'reporter
construct' in the lung. As described, one sheep was used to look at the local effects of 3 different
dosages of instilled Ad-GFP (lxlO7, 5xl07 and 1x10s pfu) with or without pre-incubation with
calcium phosphate to form a co-precipitate. These dosages of Ad are referred to as low, medium and
high respectively. Flowever, it must be stressed that these terms are meant only as comparisons to each
other. In other words, a dosage of 1x10s pfu of adenovirus is not very high when used in an in vivo
context. Dosages of adenovirus used in animal models of lung-directed gene therapy vary from 3x107
pfu (Simpson et al., 2001A and B - murine model) to 4.6xl010 pfu (Weiss et al., 2002 - macaque
model) and although in the experiments described here the total pfu instilled per animal was 1.6x10s
there was little evidence locally in the BALF of any major inflammatory response to the vector at 48
hours post-instillation. In the highest dose of Ad with the calcium phosphate co-precipitate the
percentage of neutrophils increased from zero to approximately 9% neutrophils at 48 hours. Although
the practical relevance of an inflammatory response of this magnitude is difficult to predict it should
be considered in the context of inflammatory responses to other non-viral vectors in sheep where
neutrophilic inflammation predominates (Emerson et al., 2003). Indeed the lack of change in the
protein content of the BALF (fig. 13) is indicative of an intact alveolar epithelial barrier.
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The information collected from this preliminary experiment informed the design of a further
progression whereby the dose-response relationship of Ad-o-elafin precipitated with calcium
phosphate was assessed in the segmental model. Here the only significant difference between any of
the cell counts was noted when the neutrophil counts in the high dose (108 pfu) segment were
compared with those in the naive segment. However, this difference was not seen when neutrophil
counts in the high dose (108 pfu) segment were compared to the pre-experimental values in this
segment. The absolute neutrophil counts for this experiment are shown in Appendix 1 and they serve
to indicate that values for one animal were unexpectedly high in the pre-experimental analysis. It is
likely that this data is the source of this anomaly.
It is clear that the significant, but mild, inflammatory response that develops 48 hours following
instillation of 108 pfu (high dose) of Ad co-precipitated with calcium phosphate does not occur when
107 or 5x107 pfu (low and medium doses) are instilled.
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6.5. CONCLUSIONS
This work prompted the selection of a dosage of lxlO8 pfu of Ad co-precipitated with calcium
phosphate, as an appropriate dose for future in vivo instillations. This dosage causes a small amount of
inflammation in the segment as assessed by BALF neutrophil counts and total protein but of equal
interest is the fact that there is no evidence that the calcium phosphate alone has any pro-inflammatory
effect itself on the lung. Other workers using Ad/calcium phosphate co-precipitates in the lung have
reported minimal 'toxicity' after intra-pulmonary deposition (Fasbender et al., 1998). Further,
Fasbender states the potential usefulness of Ad co-precipitated with calcium phosphate, in murine
models, in that the Ad now 'targets' the airways rather than the parenchyma (Fasbender et al., 1998).
This is seen to be an advantage in the pursuit of therapeutic strategies for airway related diseases such
as cystic fibrosis. The data presented here does not support this 'targeting' in the ovine lung -
relatively few airway cells were infected, but multiple sections demonstrated infection of alveolar
epithelial cells and macrophages (fig. 14). This is a potential major difference between the two models
(murine and ovine) in looking at adenoviral gene therapy in the lung and potentially reflects a
difference in the physical access of instilled vector to the alveolar structures between the two species.
Equally, comparisons between the results seen by Fasbender at al. and those seen in this chapter must
be approached with caution as the promoter in the adenoviral vectors used in the two pieces of work
are different. In the murine model (Fasbender et al., 1998) the human cytomegalovirus promoter
(HCMV) was used whereas in this work the murine cytomegalovirus (MCMV) promoter was used
due to the latter showing higher activity in the murine lung (Sallenave et al., 1998).
The potential use of adenoviral gene transfer to the ovine lung in the modulation of inflammation is
investigated in the next chapter in addition to studies examining the effects of repeated instillations of
recombinant adenovirus.
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CHAPTER 7
THE IN VIVO EFFECTS OF REPEATED INSTILLATION OF
RECOMBINANT ADENOVIRUS AND CALCIUM PHOSPHATE
CO-PRECIPITATES AND THE MODULATION OF THE LUNG'S
RESPONSE TO LPS
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7.1. INTRODUCTION
Chapter 6 detailed the construction of a replication-deficient adenovirus coding for ovine elafin (Ad-
o-elafin) and its optimisation both in vitro and in vivo.
There exists good background data to suggest the therapeutic potential for manipulating the lung's
innate immune response through the up-regulation of ovine elafin (Simpson et al., 2001A and B). To
investigate, and expand upon this, experiments were performed to examine the effect that Ad-o-
elafin/CaP delivery would have on the lung's response to endo-bronchial instillation of
lipopolysaccharide. The ovine model used allows the further investigation not only of the LPS
response in the segment treated with Ad-o-elafin but also in a distant non-Ad treated segment.
Additionally, the circulating response to LPS can be examined in this model.
Below is a review of the current scientific knowledge detailing the response of the lung to bacterial
lipopolysaccharide.
The recognition and effects of LPS in the lung.
This thesis examines the modulation of the lung's response to lipopolysaccharide (LPS) derived from
Mannheimia haemolytica. Mannheimia haemolytica (previously known as Pasteurella haemolytica) is
a weakly haemolytic, gram-negative coccobacillus that is an opportunistic pathogen of cattle, sheep
and other ruminants. Pneumonic pasteurellosis is a common disease of sheep, where outbreaks are
associated with management practices such as overcrowding and transport. The ovine lung
demonstrates a characteristic cellular inflammatory response to LPS derived from this pathogen
(Brogden et al., 1984). The response which is neutrophil-dominated conforms to that seen in other
species, including man in response to LPS (Michel et al., 1997; Nightingale et al., 1998).
LPS itself is the archetypal Gram negative bacterial 'alarm signal' and comprehensive literature
surrounds the recognition and effects of LPS in the lung. LPS interacts with specific pattern-
recognition receptors leading to a tightly regulated sequence of events. LPS itself is made up of a lipid
A core attached to a chain of oligosaccharides which gives the LPS its antigenic properties and also
varies between bacterial species. LPS naturally forms micelles which do not favour interaction with
the cell surface. However, these micelles are disrupted by the presence of LPS-binding protein (LBP)
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which binds to LPS molecules with a 1:1 stoichiometry and transfers the LPS to cell surfaces and to
high density lipoproteins (HDL). LPS bound to HDL is inactive and this appears to be one mechanism
by which LPS is rendered non-toxic in vivo (Wurfel et al., 1994; Ulevitch et al., 1981; Baumberger et
al., 1991). The receptor for LPS/LBP was originally identified as CD14 (Wright et al., 1990). CD14,
which is membrane bound on macrophages, also exists as a soluble form in the plasma and interaction
of LPS/LBP with soluble CD14 allows activation of some CD14 negative cells (Pugin et al., 1993).
The LPS-induced stimulation of CD14 positive cells is not a direct activity of the CD14 itself and in
man the Toll-like receptor family of proteins (TLRs) play an essential role in this regard. More than
10 members of this family have been characterised now conferring the ability to respond to a whole
range of bacterial products. The member of importance with respect to LPS-stimulation is TLR-4
(Lien et al., 2000). TLR-4 was originally thought to be present only on myeloid cells (Muzio et al.,
2000) but has since been shown to be present intra-cellularly in intestinal epithelial cells (Hornef et
al., 2002) and in human alveolar epithelial cells and bronchial epithelial cells (Guillot et al., 2004).
In the lung, LPS first encounters the epithelial lining fluid which lines the air-spaces. This is a lipid
rich fluid containing surfactant proteins as well as soluble CD14 and LBP. The two main constituents
in BALF that can interact with LPS are surfactant protein A (SP-A) and LBP. In the absence of
inflammation, the concentration of SP-A is far in excess of that of LBP (250-500pg/ml compared to
50-100ng/ml respectively - Greene et al., 1999; Martin et al., 1997). SP-A, which is produced by type
11 alveolar epithelial cells and non-ciliated bronchial cells (McCormack and Whitsett, 2002), may
serve a purpose in binding LPS and rendering it less active - a hypothesis supported by in vitro
evidence (Kalina et al., 1995). In the inflamed lung, however, the ratio of SP-A to LBP is reversed
with the SP-A decreasing to approximately 25pg/ml and the LB-P rising to approximately 5-10pg/ml
(Gregory et al., 1991; Greene et al., 1999). The potential for LPS to interact with LBP is increased
with anticipated effects on macrophage activation via CD 14. Originally LBP was thought to be solely
produced in the liver however several lines of evidence point to the lungs as an additional source of
this protein. LBP RNA is increased in rat lungs undergoing acute inflammation and this increase in
gene expression is associated with increased levels of this protein in BALF (Su et al., 1994). Human
LBP has been shown to be produced at the level ofRNA and protein by A549 cells, a cell line derived
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from a pulmonary adenocarcinoma (Dentener et al., 2000). This group also showed production of
murine LBP by a murine alveolar epithelial cell line and also that human LBP RNA was found in
primary isolates of human type II epithelial cells. Crucially, the A549 production of LBP was shown
to be up-regulated by IL-ip, IL-6 and TNF, these cytokines being part of the acute inflammatory
process in the lung.
The major source of the soluble CD14 seen in BALF is likely to be the circulation itself and the
increase seen in inflammatory conditions in the lung probably relates to a change in the permeability
of the lung vasculature and alveolar epithelium. Alveolar macrophages release soluble CD 14 in vitro
(Flasday et al., 1997) and extra-myeloid sources of CD14 have also been shown in vivo (Fearns et al.,
1995; Fearns and Ulevitch 1998).
The interaction between LPS and other proteins already present in the lung lining fluid likely depends
upon the relative concentrations of LBP and SP-A which themselves depend on the inflammatory
status of the lung. As previously noted, IL-ip and TNF also promote the up-regulation of the anti-
proteinase elafin which acts as an 'alarm antiprotease' in the lung (Sallenave, 2000). The intriguing
possibility of elafin acting as a 'surrogate' LBP-type molecule has arisen from prior work in this
laboratory (J. McMichael et al., submitted manuscript) in which the incubation of synthetic elafin
peptides with bacterial LPS up-regulates the production of TNF by murine macrophages. The balance
between activation of target cells by LPS and the detoxifying effects of other BALF components is
complicated by the distinction between the epithelial cells' response to LPS compared to that of the
alveolar macrophages. Hamann et al. (2002) have shown that moderately increasing the concentration
of LBP in culture conditions stimulates rat alveolar macrophages to increase LPS uptake and show a
greater activation in response to the LPS. In contrast, highly elevated concentrations of LBP in the
same situation inhibit both the response and the LPS uptake by the alveolar macrophages. The same
group also looked at an A549 alveolar epithelial cell line under the same conditions. Interestingly, the
very high LBP concentrations enhance LPS uptake into these cells but without any signs of activation.
A549 cells themselves have very low levels of TLR-4 expression (Monick et al., 2003) which may
have a bearing on their response to LPS and LBP.
Chapter 7 168
The in vivo response to recombinant adenovirus and the modulation of the LPS response in
the lung
However, dissecting alveolar macrophage and epithelial cell responses in vitro is of questionable
relevance to the in vivo situation where these cells are in very close contact. Indeed, recent work has
shown that the epithelial cells may have a 'memory' of LPS activation and may activate the alveolar
macrophages in contact with them via epithelial surface ICAM-1 expression (Lee et al., 2004). The
authors postulate that this inter-dependence may be one reason why strategies aimed at neutralising
LPS have led to disappointing results in the clinic.
The modulation of the lung's response to LPS by the localised up-regulation of the anti-protease ovine
elafin prompted the experimental work presented within this chapter.
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7.2. AIMS
1. The data presented in this chapter concerns an analysis of the effects of repeated administration of
adenoviruses (either Ad-o-elafin or Ad-GFP) on both transgene activity and local and systemic
responses to administration.
2. Additionally, the potential role of ovine elafin as a 'defensin-like' molecule (see chapter 5) is
explored in relation to the innate immune response to bacterial lipopolysaccharide.
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7.3. RESULTS
7.3.1. The effects of repeated administration of Adenovirus/calcium phosphate co-precipitates on
bronchoalveolar lavage cytology.
A flow diagram outlining the experimental protocols employed is shown in fig. 1 and a more detailed
representation is shown in fig. 2. Bronchoalveolar lavage fluid (BALF) was collected from 8 animals
pre-experimentally (d-7) and 3 days (d3), 7 days (d7) and 10 days (dlO) after the administration of 10s
pfu of either Ad-GFP (n=4) or Ad-o-elafin (n=4) (CaP co-precipitated) to each of three selected lung
segments. A second dose of the same adenovirus was administered to those segments on day 14 and
again BALF collected after a further 3, 7 and 10 days (left hand branch fig. 1). In a further eight
animals, the initial process of delivery and assessment was as described (n=5 for Ad-o-elafin and n=3
for Ad-GFP), however 10 days after the initial administration of Ad, LPS was delivered to both a
nai've segment and a segment pre-treated with Ad and the innate immune response assessed in those
segments and a further naive segment at day 14 (right hand branch fig. 1).
The total cell counts per ml BALF in naive segments are shown in fig. 3A. There are no significant
differences in total cell count per ml BALF for the Ad-o-elafin group of animals. Flowever, in the Ad-
GFP group there is a significant increase in total cell count per ml BALF at both day 21 and day 24
compared to pre-experimental cell counts (P<0.05). There are no significant differences between the
groups treated with the different viruses at any time point.
When the absolute cell counts are converted to percentage of pre-experimental values (fig. 3B) there
are no significant differences between the two Ad groups.
Fig. 4A shows the total cell counts per ml BALF for the Ad treated segments. The Ad-o-elafin group
show a significant increase in total cells per ml BALF at days 17, 21 and 24 compared to pre-
experimental values (P<0.005, P0.005 and P<0.05 respectively). The Ad-GFP group show a
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Fig. 2. Protocol for the repeated administration of adenovirus and
also the modulation of the LPS response in the ovine lung.
The diagram shows the times of the administration of either Ad-o-elafin or Ad-
GFP to the ovine lung and subsequent sampling by broncho-alveolar lavage and
airway brushing. A represents the protocol for animals 188-192; B the protocol
for animals 193-196; C the protocol for animals 453, 468, 809, 897 and 909; D
the protocol for animals 472, 478, and 920.
(In protocols C and D, examining the effects ofAd-o-elafin and Ad-GFP on the
response to bacterial LPS within the lung and also systemically, segment a
represents Ad-/LPS+ segments, segment b represents Ad+/LPS+ segments and
segment h represents Ad-/LPS- segments as discussed in section 7.3.5).
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Fig. 3. The effect of repeated adenovirus administration on the total
cell count per ml of BALF in naive segments.
A. Graph showing the total cell count in the BALF of naive segments (i.e.
segments which did not receive recombinant adenovirus) pre-experimentally and
also after adenovirus administration at day 0 and day 14 in separate treated
segments (either Ad-o-elafin or Ad-GFP).
B. Graph showing the above data presented as percent change in total cell count
compared to pre-experimental values.
All data is shown as median and inter-quartile range. Statistical significance
calculated by Mann-Whitney analysis.* represents PO.05 comparing values at
the points indicated with the pre-experimental values.
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Fig. 4. The effect of repeated adenovirus administration on the total
cell count per ml of BALF in treated segments.
A. Graph showing the total cell count in the BALF pre-experimentally and also
after adenovirus administration at day 0 and day 14 in treated segments (either
Ad-o-elafin or Ad-GFP).
B. Graph showing the above data presented as percent change in total cell count
compared to pre-experimental values.
All data is shown as median and inter-quartile range. Statistical significance
calculated by Mann-Whitney analysis.* and ** represent P<0.05 and P<0.005
respectively when comparing values at the points indicated with the pre-
experimental values.
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significant increase in total cells per ml BALF at 3, 7, 21 and 24 days compared to pre-experimental
values (P<0.05). There are no significant differences between the 2 groups at any time point.
Again when the counts are converted to percentage of the pre-experimental values, there are no
significant differences between the groups (fig. 4B).
Fig. 5A shows the absolute neutrophil counts per ml BALF n the nai've segments at each time point.
As shown, there are no significant differences at any time point when naive segment counts are
compared to pre-experimental values. When the absolute numbers are converted to percentage of pre-
experimental values (Fig. 5B), the only significant difference when comparing the two adenovirus
groups is at day 3 with the elafin group showing a higher percentage change compared to the GFP
group (P<0.05).
In fig. 6A the absolute neutrophil counts per ml BALF are compared with pre-experimental values in
the virus treated segments. Here there are significant increases in BALF neutrophils per ml at day 3
and 17 for Ad-o-elafin (P<0.05) and at day 17 alone for Ad-GFP (P<0.05). There are no significant
differences between the two adenovirus groups at any time point. When the numbers are converted to
percentage of pre-experimental values (fig. 6B) there are no significant differences between the two
adenovirus groups at any time point.
Fig. 7A shows the absolute lymphocyte counts per ml BALF in the nai've segments for each time
point. There are significantly fewer lymphocytes per ml BALF in the elafin treated animals at day 3
and 24 compared with pre-experimental values (P<0.005) and significantly fewer than the GFP treated
animals at day 24 (P<0.05). When the values are converted to percentages of pre-experimental values
there are significant differences between the two Ad treated groups at days 3, 17 and 24 with the
elafin treated group showing a lower percentage change compared to the GFP treated group at days 3
and 24 and a higher percentage change at day 17 (P<0.05) (fig. 7B).
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Fig. 5. The effect of repeated adenovirus administration on the PMN
count per ml of BALF in naive segments.
A. Graph showing the PMN count in the BALF of naive segments pre-
experimentally and also after adenovirus administration at day 0 and day 14 in
separate treated segments (either Ad-o-elafin or Ad-GFP).
B. Graph showing the above data presented as percent change in PMN count
compared to pre-experimental values.
All data is shown as median and inter-quartile range. Statistical significance
calculated by Mann-Whitney analysis. # indicates P<0.05 when the 2 virus
treatments are compared at the time point indicated.
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Fig. 6. The effect of repeated adenovirus administration on the PMN
count per ml of BALF in treated segments.
A. Graph showing the PMN count in the BALF of treated segments pre-
experimentally and also after adenovirus administration at day 0 and day 14
(either Ad-o-elafin or Ad-GFP).
B. Graph showing the above data presented as percent change in PMN count
compared to pre-experimental values.
All data is shown as median and inter-quartile range. Statistical significance
calculated by Mann-Whitney analysis.* represents P<0.05 comparing values at
the points indicated with the pre-experimental values.
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Fig. 7. The effect of repeated adenovirus administration on the
Lymphocyte count per ml of BALF in naive segments.
A. Graph showing the lymphocyte count in the BALF of naive segments pre-
experimentally and also after adenovirus administration at day 0 and day 14 in
separate treated segments (either Ad-o-elafin or Ad-GFP).
B. Graph showing the above data presented as percent change in lymphocyte
count compared to pre-experimental values.
All data is shown as median and inter-quartile range. Statistical significance
calculated by Mann-Whitney analysis. * and ** indicate P<0.05 and P<0.005
respectively comparing data to pre-experimental values at the time-point
indicated or between treatment groups. # indicates P<0.05 when the 2 virus
treatments are compared at the time point indicated.
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Fig. 8A shows the absolute lymphocyte counts per ml BALF in the Ad treated segments. The GFP
treated group showed a significant increase in BALF lymphocyte concentration at day 24 (P<0.05)
and the elafin treated group showed a significant increase at days 17 and 21 (P<0.005). The GFP
treated group had significantly higher lymphocyte counts per ml BALF than the elafin treated group at
day 24 (P<0.05).
When converted to percentage change over baseline (fig. 8B) then the only significant difference
between the two Ad treatment groups is at day 24 with the GFP treated animals showing a higher
percentage change compared to the elafin treated animals (P<0.05).
7.3.2. The effects of repeated administration of Adenovirus/calcium phosphate co-precipitates on the
circulating leukocyte profile.
Fig. 9A shows the total cell counts per ml of blood up to 24 days after the start of the experiment
when the first Ad instillation was performed. There are no significant changes in the circulating white
cell number per ml when any of the time points are compared to the pre-experimental values. There
are also no significant differences between the two adenovirus groups at any time point.
There are also no significant differences between the two adenovirus groups when the total cell counts
are converted to percentage of pre-experimental values as shown in fig. 9B.
Circulating lymphocyte counts are shown in fig. 10A. There are no significant differences between the
pre-experimental values and the values at any of the time-points shown for the Ad-GFP group. There
is, however, a significant decrease at day seven compared to pre-experimental values in the Ad-o-
elafin group.
When the values are converted to percentage of pre-experimental values as shown in fig. 10B, there
are significantly lower values at both days 7 and 14 in the Ad-o-elafin group when compared to the
Ad-GFP group.
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Fig. 8. The effect of repeated adenovirus administration on the
Lymphocyte count per ml of BALF in treated segments.
A. Graph showing the lymphocyte count in the BALF of treated segments pre-
experimentally and also after adenovirus administration at day 0 and day 14 in
separate treated segments (either Ad-o-elafin or Ad-GFP).
B. Graph showing the above data presented as percent change in lymphocyte
count compared to pre-experimental values.
All data is shown as median and inter-quartile range. Statistical significance
calculated by Mann-Whitney analysis. * and ** indicate P<0.05 and P<0.005
respectively comparing data to pre-experimental values at the time-point
indicated or between treatment groups. # indicates P<0.05 when the 2 virus
treatments are compared at the time point indicated.
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Fig. 9. Total circulating white cell count over 24 days with 2
administrations of Adenovirus.
A. Graph showing the total circulating white cell count over 24 days with the
administration of adenovirus (either Ad-GFP or Ad-o-elafin) at days 0 and 14.
B. Graph showing the total circulating white cell count as a percentage of the
pre-experimental cell count.
All data is shown as median and inter-quartile range. Statistical significance was
calculated by Mann-Whitney analysis. No significant differences between pre-
experimental values and the other values in A or between the 2 Adenovirus
groups in B
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Fig. 10. Total circulating lymphocyte count over 24 days with 2
administrations of Adenovirus.
A. Graph showing the total circulating lymphocyte count over 24 days with the
administration of adenovirus (either Ad-GFP or Ad-o-elafin) at days 0 and 14.
B. Graph showing the total circulating lymphocyte count as a percentage of the
pre-experimental lymphocyte count.
All data is shown as median and inter-quartile range. Statistical significance was
calculated by Mann-Whitney analysis. * indicates P<0.05 comparing the data at
points indicated. # indicates P<0.05 between the 2 Adenovirus groups at the
time-point indicated.
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Finally, in fig. 11A are shown the absolute circulating neutrophil counts over the 24 days for the two
virus groups. There are no significant changes in PMN counts compared to pre-experimental values in
the Ad-GFP group, but there is a significant increase in absolute PMN counts compared to pre-
experimental values at day 7 in the Ad-o-elafin group (P<0.05).
When the values are converted to percentage of pre-experimental values there are no significant
differences between the two virus groups (fig. 1 IB).
7.3.3. The duration of transgene expression after the repeated administration of adenovirus to the
ovine lung.
Fig. 12 shows the percentage of GFP+ve alveolar macrophages (AMs) in the Ad-GFP administered
animals after the cellular content of the BALF sampled at each time point was cultured for 24 hours.
There is a rapid decrease from the day 3 median of 6.061% to 0.472% at day 7 and to 0.002% at day
10. After day 10 no GFP+ve cells were isolated even after a second dose of Ad-GFP at day 14.
Fig. 13 shows the Western blots obtained from culture supernatants of AMs collected at 3, 7 and 10
days after the instillation of Ad-o-elafin or Ad-GFP. There is increased secretion of ovine elafin by
AMs collected from the animals that were instilled with Ad-o-elafin compared to Ad-GFP. The
secretion is most marked 7 days after the instillation of virus and continues for up to at least 10 days.
AM supernatants were not examined for secretion of ovine elafin after the second virus instillation.
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Fig. 11. Circulating neutrophil counts over 24 days with 2
administrations of Adenovirus.
A. Graph showing the circulating neutrophil count over 24 days with the
administration of adenovirus (either Ad-GFP or Ad-o-elafin) at days 0 and 14.
B. Graph showing the circulating neutrophil count as a percentage of the pre-
experimental cell count.
All data is shown as median and inter-quartile range. Statistical significance was
calculated by Mann-Whitney analysis. * represents P<0.05 when comparing the
values at the indicated time point with the pre-experimental values.
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day 3 day 7 day 10
Fig. 12. Decrease in GFP+ve alveolar macrophages in BALF after
administration of Ad-GFP.
Graph showing the percentage of alveolar macrophages in BALF after
administration ofAd-GFP at day 0. Lines represent the median. NB. Zero values
are not shown due to the use of a log scale.
After day 10 no GFP+ve cells were lavaged from any of the Ad-GFP animals
even after the second dose of Ad-GFP at day 14. None of the Ad-o-elafin
administered animals yielded any GFP+ve cells at any time-point.
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Fig. 13. Western blot analysis of alveolar macrophage supernatant
after collection by broncho-alveolar lavage 3, 7 and 10 days after
recombinant adenovirus instillation.
This figure shows Western blots of the alveolar macrophage supernatants after l
weeks culture following harvesting by broncho-alveolar lavage of virus treated
segments. The blots show macrophage supcrnatants from 5 Ad-ovinc elafin-
FLAG treated animals and 3 Ad-GFP treated animals.
The blots were probed with Trab-20 monoclonal antibody which detects the
endogenous ovine elafin and also ovine elafin-FLAG.
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7.3.4. The effects of the repeated instillation of adenovirus on circulating anti-adenovirus antibody
activity.
Fig. 14 shows the percentage change in serum anti-adenovirus activity, after complement inactivation,
in the serum of the animals that received two instillations of either Ad-o-elafin or Ad-GFP. The elafin
treated animals show a higher relative activity at each time point compared to the GFP animals and
this difference is significant at days 10, 17, 21 and 24 (P<0.05).
7.3.5. The effects of Ad-o-elafin and Ad-GFP on the local lung response to bacterial
lipopolysaccharide.
After a single administration of each Ad as shown in fig. 2, bacterial lipopolysaccharide (LPS) was
instilled topically into previously nai've segments (fig. 2, protocol C and D, segment 'a') and also into
segments previously instilled with the Ad/CaP (fig. 2, protocol C and D, segment 'b') (n=5 for Ad-o-
elafin, n=3 Ad-GFP). 4 days after the LPS instillation BALF was collected and analysed for total cell
counts per ml and also neutrophil concentration. These values are graphed alongside pre-experimental
values and the values for a nai've segment at day 14 (fig. 2, protocol C and D, segment 'h').
In order to simplify the discussion of the results from this experiment segment 'a' will be referred to
as Ad-/LPS+, segment 'b' as Ad+/LPS+ and segment 'h' as Ad-/LPS-.
Fig. 15A shows the absolute total cell counts at day 14 (4 days post-LPS administration) for the two
Ad groups. In the Ad-o-elafin treated animals there was a significant increase in total cell count in
both the Ad-/LPS+ segments and the Ad+/LPS+ segments when compared to both pre-experimental
values (P<0.005) and also compared to Ad-/LPS- segments at day 14 (P<0.05). In the Ad-GFP treated
animals there is a small but significant increase in total cell count at day 14 in the Ad-/LPS+ segments
compared to the pre-experimental values (P<0.05) but also in the Ad-/LPS- segments at day 14
(P<0.05). However, in these animals the total cell counts in the Ad+/LPS+ segments are not
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Fig. 14. Circulating Anti-Adenovirus antibody activity after 2 doses
of adenovirus.
Graph showing the neutralising antibody titre of the serum after 2 doses of either
Ad-GFP or Ad-ovine elafin FLAG at day 0 and day 14. Data is shown as
percentage of titre at day 0.
All data is shown as median and inter-quartile range. Statistical significance
calculated by Mann-Whitney analysis.* represents P<0.05 comparing the 2 virus








































Fig. 15. The effect of local LPS administration on the total cell count per ml
BALF after adenovirus administration.
A. Graph showing the total cell count in the BALF pre-experimentally and also post-LPS
administration. Post-LPS BALF was collected on day 14 from naive segments (Ad-/LPS-
), LPS treated segments (Ad-/LPS+), and also LPS treated segments that had also been
treated at day 0 with adenovirus (either Ad-o-elafin or Ad-GFP) (Ad+/LPS+).
B. Graph showing the above data presented as percent change in total cell count
compared to pre-experimental values.
All data is shown as median and inter-quartile range. Statistical significance calculated by
Mann-Whitney analysis.* and ** represent P<0.05 and P<0.005 respectively comparing
values at the points indicated.
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significantly different to the pre-experimental values or from the Ad-/LPS- segments at day 14.
Additionally, in the Ad+/LPS+ segments the Ad-o-elafin treated animals have a significantly
increased total cell count compared to the Ad-GFP treated animals.
Fig. 15B shows the percentage change over pre-experimental values for the total cell count and the
effects of local LPS instillation. Again we see a significant increase in the Ad-o-elafin animals in the
Ad-/LPS+ and Ad+/LPS+ segments compared to Ad-/LPS- segments at day 14 (P<0.05). This
increase is not seen in the Ad-GFP animals. Equally, there is a significant increase in the Ad-o-elafin
group in the Ad+/LPS+ segments compared to the Ad-GFP group (P<0.05).
Fig. 16A shows the absolute BALF neutrophil concentration at day 14 (post LPS) along with the pre-
experimental values. There is a significant increase in the BALF neutrophil concentration in the Ad-o-
elafin animals in the Ad-/LPS+ and Ad+/LPS+ treated segments compared to both pre-experimental
values and the Ad-/LPS- segments at day 14 (P<0.05). In the Ad-GFP group there is a significant
decrease in neutrophils per ml BALF in the Ad-/LPS- segments at day 14 compared to pre-
experimental values (P<0.05) and also a small but significant increase in neutrophils per ml in the
Ad+/LPS+ segments compared to pre-experimental values (P<0.05).
Fig. 16B shows that there is a significant increase in the neutrophil percentages in the Ad-/LPS+ and
Ad+/LPS+ segments compared to the Ad-/LPS- segments at day 14 in the Ad-o-elafin treated animals.
This difference is not seen in the Ad-GFP treated animals.
Fig. 17A shows the absolute lymphocyte counts per ml BALF at day 14 (4 days post LPS) compared
with pre-experimental values. There is a significant increase in BALF lymphocyte concentration at
day 14 in the Ad-/LPS+ segments (P<0.005) and a significant decrease in the Ad-/LPS- segments
(P<0.05) compared to pre-experimental values. There is also a non-significant increase in the
Ad+/LPS+ segments compared to pre-experimental values. There is also a significant increase in
lymphocyte concentration in the Ad-/LPS+ segments compared to the Ad-/LPS- segment s (P<0.05)
and an increase in the Ad+/LPS+ segments compared to the Ad-/LPS- segments which approaches
Chapter 7 191





























Fig. 16. The effect of local LPS administration on the BALF PMN
concentration after adenovirus administration.
A. Graph showing the PMN count per ml ofBALF pre-experimentally and also post-
LPS administration. Post-LPS BALF was collected in naive segments (Ad-/LPS-), LPS
treated segments (Ad-/LPS+), and also LPS treated segments that had also been treated
at day 0 with adenovirus (either Ad-o-elafin or Ad-GFP) (Ad+/LPS+).
B. Graph showing the above data presented as percent change in PMN count compared
to pre-experimental values.
All data is shown as median and inter-quartile range. Statistical significance calculated
by Mann-Whitney analysis.* and ** represent P<0.05 and P<0.005 respectively
comparing values at the points indicated.
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Fig. 17. The effect of local LPS administration on the BALF lymphocyte
concentration after adenovirus administration.
A. Graph showing the lymphocyte count per ml of BALF pre-experimentally and also
post-LPS administration. Post-LPS BALF was collected in naive segments (Ad-/LPS-),
LPS treated segments (Ad-/LPS+), and also LPS treated segments that had also been
treated at day 0 with adenovirus (either Ad-o-elafin or Ad-GFP) (Ad+/LPS+).
B. Graph showing the above data presented as percent change in lymphocyte count
compared to pre-experimental values.
All data is shown as median and inter-quartile range. Statistical significance calculated
by Mann-Whitney analysis.* and ** represent P<0.05 and P<0.005 respectively
comparing values at the points indicated.
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significance (P=0.056). In the Ad-GFP treated group there were no significant changes from the pre-
experimental values or from the Ad-/LPS- segments at day 14.
When these results are converted to percentage change over pre-experimental values (fig. 17B) then
the only result of note is that the elafin treated animals showed a non-significantly higher percentage
change than the GFP treated animals in the Ad+/LPS+ segments (P=0.071).
The myeloperoxidase (MPO) activity in the BALF is shown in fig. 18. Fig. 18A shows the absolute
MPO activity at day 14 in the segments instilled with LPS (both Ad-/LPS+ and Ad+/LPS+ segments).
There is no significant difference in any of the segments though there seems to be trend towards
higher MPO levels in the Ad+/LPS+ segments in the o-elafin treated animals compared to the GFP
treated animals.
The MPO activity per cell present in the BALF is shown in fig. 18B. There is no significant difference
between any of the segments.
7.3.6. The effects ofAd-o-elafin and Ad-GFP on the systemic response to bacterial
lipopolysaccharide.
Fig. 19A shows the total circulating white cell counts per ml for the two Ad treatment groups from
pre-experimental samples through to day 14 after receiving LPS at day 10. In the Ad-GFP treated
group there is a significant increase in the total circulating white cell counts at day 14 compared to
pre-experimental values (P<0.05). There is a significant difference between the Ad-o-elafin and the
Ad-GFP group at day 14 (P<0.05). When the values are converted to percentages of the pre-
experimental values as shown in fig. 19B, there are no significant differences between the two virus
treatment groups at any of the time points although post-LPS at day 14 the difference approaches
significance (P=0.071).
Chapter 7 194










































Elafin Ad-/LPS+ Elafin Ad+/LPS+ GFP Ad-/LPS+ GFP Ad+/LPS+
Fig. 18. Myeloperoxidase activity in broncho-alveolar lavage does
not correlate with BALF cellularity.
A. Graph showing the total myeloperoxidase (MPO) levels in the BALF
collected at day 14 after LPS was instilled at day 10 into both a naive segment
(Ad-/LPS+) and a segment previously exposed to adenovirus (Ad+/LPS+). The
figures above each segments data indicate the total cell counts in the BALF
(median and IQ range).
B. Graph showing the MPO activity divided by the total cell count in the BALF.
No statistical significance was seen.
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Fig. 19. Total circulating white cell count after one administration of
adenovirus and one administration of LPS.
A. Graph showing the total circulating white cell count over 14 days with the
administration of adenovirus (either Ad-GFP or Ad-o-elafin) at days 0 and intra-
pulmonary LPS administration at day 10.
B. Graph showing the total circulating white cell count as a percentage of the
pre-experimental cell count.
All data is shown as median and inter-quartile range. Statistical significance
calculated by Mann-Whitney analysis.* represents P<0.05 comparing values at
the points indicated. # indicates P<0.05 comparing the Ad-GFP and Ad-o-elafin
groups.
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The circulating lymphocyte counts after the first administration of either Ad at day 0 followed by
intra-pulmonary instillation of LPS at day 10 are shown in fig. 20A. In the Ad-o-elafin group there is
a significant decrease in circulating lymphocytes at day 7 compared to pre-experimentally (P<0.05).
In the Ad-GFP group there is a significant increase in the lymphocyte count after administration of
LPS (P<0.05). When the figures are converted to percentages of pre-experimental values (fig. 20B)
there are no significant differences between the two adenovirus groups except at day 7 with the elafin
group having lower counts compared to the GFP group (P<0.05).
The circulating neutrophil counts are shown in fig. 21A over 14 days with either Ad-o-elafin or Ad-
GFP given at day 0 and LPS given at day 10. There is a significant increase in the circulating
neutrophils per ml at day 7 compared to pre-experimentally in the Ad-o-elafin animals (P<0.005).
There are no significant changes in the Ad-GFP group. When the numbers are converted to
percentages of the pre-experimental values there are no significant differences between the two virus
groups at any time point (fig. 2IB).
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Fig. 20. Circulating lymphocyte counts after one administration of
adenovirus and one administration of LPS.
A. Graph showing the total lymphocyte count over 14 days with the
administration of adenovirus (either Ad-GFP or Ad-o-elafin) at day 0 and intra-
pulmonary LPS administration at day 10.
B. Graph showing the lymphocyte count as a percentage of the pre-
experimental lymphocyte count.
All data is shown as median and inter-quartile range. Statistical significance
calculated by Mann-Whitney analysis.* represents P<0.05 comparing values at
the points indicated.
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Fig. 21. Total circulating neutrophil count after one administration of
adenovirus and one administration of LPS.
A. Graph showing the total circulating neutrophil count over 14 days with the
administration of adenovirus (either Ad-GFP or Ad-o-elafin) at days 0 and intra-
pulmonary LPS administration at day 10.
B. Graph showing the total circulating neutrophil count as a percentage of the
pre-experimental count.
All data is shown as median and inter-quartile range. Statistical significance
calculated by Mann-Whitney analysis.** represents P<0.005 comparing values
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7.4. DISCUSSION
7.4.1. Controls used in the in vivo experiments.
Selection of Ad-GFP as a control virus was governed by practical issues rather than an idealised
concept of what properties the control virus should possess. Indeed selection of a transgene encoding
for a small, secreted protein or even a genetically modified form of the ovine elafin gene would
potentially have offered particular advantages in interpreting effects of this antiprotease. However,
time constraints and the perceived need to visualise the target cell population largely dictated the
selection of Ad-GFP as a 'reporter' construct.
Despite the widespread use of this reporter it should be borne in mind that GFP itself may induce
toxicity (Liu et al., 1999).
7.4.2. The time-course of the response both locally and systemically to the instillation of one or two
doses of recombinant adenoviruses.
The experiments performed in the previous chapter provided the background information necessary to
investigate the time-course of the inflammatory response both locally in the lung and also
systemically. In this experiment the instillation of Ad-o-elafin was compared directly to the
instillation of Ad-GFP (this time acting as a virus control). Figs. 1 and 2 show a flow diagram of the
experiment performed and a more detailed outline of the animal groups used (more details are found
in chapter 2).
There was no change in the total cell count per ml BALF in the untreated naive segments after the
initial Ad instillation (day 0) in either Ad-o-elafin or Ad-GFP treated animals. After the second
instillation, there is an increase in cellularity which becomes significant in the Ad-GFP treated group
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at days 21 and 24 (fig. 3A). Hence there is a need for caution in the interpretation of results at these
time-points and the assumption of segmental interdependence, at the phenotypic level (a requirement
if one is to use the naive segments as internal controls), is seen to be invalid. The neutrophil counts in
the BALF of the naive segments do not change significantly through the whole experiment (fig. 5).
Examination of the BALF cell counts from the Ad instilled segments indicates that Ad-o-elafin
treatment limits the total cellular influx at days 3 and 7 (fig. 4) but promotes a more marked neutrophil
influx (fig. 6). The lymphocyte data from Ad treated segments (fig. 8) is difficult to assess due to the
wide variation and low absolute counts within the BALF.
Human elafin has been shown to act as a chemo-attractant for neutrophils on its own in vitro and
increases the influx of neutrophils into the lung in response to LPS in vivo (Simpson et al., 2001B;
Sallenave et al., 2003).
Ad-o-elafin instillation at day 0 causes both a significant lymphopenia (fig. 10) and a significant
neutrophilia (fig. 11) at day 7 which is not seen in the Ad-GFP treated animals.
7.4.3. The duration of transgene expression after the segmental instillation of recombinant adenovirus
in the sheep.
The lack of any evidence ofGFP expression after the second administration likely indicates the onset
of a rapid anti-viral response presumably comprising cell-mediated and humoral components. No
macrophages from the nai've segments were seen to be GFP+ve. Whilst not conclusive, this latter
observation adds weight to the assumption that there is negligible transfer of material between
segments either at the point of instillation or subsequently.
Western blot analysis of the supernatant collected after culture of alveolar macrophages (AMs)
collected from virus treated segments after the 1st dose of either Ad-o-elafin or Ad-GFP confirmed
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the infection of these cells in the Ad-o-elafin treated segments and the subsequent secretion of ovine
elafin (fig. 13). The secretion of elafin appeared to extend beyond the time course suggested by GFP
expression profiles. Whether this reflects the sensitivity of the respective assays or other factors
including potential cytotoxicity ofGFP must remain speculative.
7.4.4. Serum neutralising anti-adenovirus antibody activity after one and two instillations of
adenovirus.
The BALF cytology and circulating white cell counts examined above (section 7.3.2) demonstrated an
inflammatory response to the local instillation of Ad vectors. This prompted the investigation of the
serum anti-Ad neutralising capacity. To examine the circulating anti-adenovirus immunoglobulin
levels the neutralising activity of the serum from each animal at each time-point through the repeated
virus administrations for the two virus groups was assayed. The elafin treated animals show higher
anti-adenovirus antibody activities compared to the GFP group when the titers at each point are
compared to pre-experimental titers (P<0.05 at days 10, 17, 21 and 24) indicating that the elafin
treated animals mounted an increased anti-adenovirus immune response (fig. 14). Ifwe accept the fact
that the increase in titer in the GFP group is indicative of the animals mounting an anti-adenovirus
response sufficient to inhibit infection of at least the alveolar macrophages in the instilled segment
then we can expect that the far more marked response in the elafin group will mean that the AMs in
these animals will not be infected either after a repeated instillation. This, however, is perhaps an
over-simplification as we have so far examined the percentage change over baseline and not absolute
titers. For example the absolute titers for the GFP group and the elafin group at day 10 are 1:18.27 and
1:18.40 respectively. Harvey et al. (1999) showed that there was no transgene activity observed after
infection of sub-segmental bronchi of cystic fibrosis patients with an adenovirus expressing human
cystic fibrosis trans-membrane conductance regulator (CFTR) if their circulating anti-adenovirus titer
was greater than 1:80. Obviously methodology has a major effect on calculation of titer and in the
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work presented here the titer is a measure of the maximum dilution of serum which will still inhibit
100% of virus activity. On the other hand Harvey et al. (1999) use a measure of dilution until 50%
inhibition of adenovirus infection is achieved. In fact it is entirely plausible that individual titers are
only usefully compared to titers in the same animal at a different time point. If this is the case,
however, it is useful to observe that the absolute titers in the two Ad groups here were similar at day
10 and so again if there were no GFP+ve AMs seen after the second instillation then it is highly
unlikely that there will be elafin secreting AMs after a second instillation.
Of note is the fact that although not examined directly in this work, there is a possibility that the
incorporation of adenovirus into calcium phosphate precipitates may have an effect on the antigenicity
of the virus itself. Others with an interest in the repeated administration of adenovirus have used
techniques to covalently modify the capsid proteins by conjugation of polyethylene glycol (PEG) to
free lysine groups on the adenovirus (Croyle et al., 2001). This group showed a diminution of the
humoral antibody response of instilled animals directed towards these 'PEGylated' adenoviruses.
However if the same PEGylated virus was administered twice then the usual antibody and cell
mediated immunity was seen to neutralise the second instillation markedly. The authors postulated
that the PEGylated virus was directed away from antigen presenting cells (APCs) and hence there was
a decrease in antigen presentation. Due to the co-precipitation of adenovirus with calcium phosphate
the infection of alveolar macrophages is facilitated as shown in chapter 6. As the protocol used in this
chapter is directed at infecting the APCs preferentially there is the possibility that an increased
antigenicity will be seen.
7.4.5. Ad-o-elafin and its role in modulating the innate immune response to local lung instillation of
bacterial LPS.
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The instillation of bacterial LPS into a segment of ovine lung which had 10 days previously been
instilled with Ad-o-elafin, caused an exaggerated cellular response relative to that seen following a
similar challenge in a segment with a prior history of exposure to a control adenovirus (figs. 15 to 17).
This observation warrants a consideration of the potential influence of ovine elafin on the response of
the lung to bacterial LPS:
What is the mechanism whereby elafin up-regulates the lung's cellular response to LPS?
When bacterial LPS is instilled locally into the lung it acts predominantly on the mobile cell
population contained therein specifically the alveolar macrophages (Koay et al., 2002). LPS
responsive cells express a variety of 'pattern-recognition molecules' which are involved in the
recognition of micro-organisms. Predominantly with regards the LPS response are the Toll-like
receptors (specifically TLR-4) and CD-14. The currently accepted mechanism for LPS stimulation of
macrophages is shown in fig. 22. Briefly, LPS derived from Gram negative bacterial cell walls is
present in micelles until these make contact with LPS-binding protein (LBP). LBP catalyses the
transfer of individual LPS moieties to the 'membrane receptor complex' made up of CD 14, Toll-like
receptor 4 (TLR4) and the myeloid differentiation protein 2 (MD-2). Downstream signalling then
occurs via MyD88, TRAF6, NIK and IKK ending in the nuclear translocation ofNFkB and hence the
up-regulation of pro-inflammatory cytokines such as TNFa, IL-1J3, IL-6 and IL-8 (Martin, 2000;
Fujihara et al., 2003). In the lung instilled or inhaled LPS first comes into contact with the fluid lining
the respiratory tract (the epithelial lining fluid or ELF). This fluid is rich in lipids and also contains
soluble CD14 and LBP. Acute lung injury leads to a marked increase in the concentrations of these
two proteins in the ELF as assessed by bronchoalveolar lavage (BALF) (Martin et al., 1997). ELF also
contains large amounts of surfactant protein A (SP-A). This protein binds LPS via its lipid A portion
(Kalina et al., 1995) reducing its biological activity. In acutely inflamed lungs the concentration of SP-
A is markedly reduced leaving more LPS to associate with LBP contained within the epithelial lining
fluid and increasing the potential for macrophage activation.
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It is quite plausible that secreted elafin acts as a 'surrogate' lipopolysaccharide binding protein. In the
normal lung the bronchoalveolar fluid contains low levels of lipopolysaccharide binding protein
(LBP) (0.05-0. lpg/ml - Martin, 2000). In this situation the majority of inhaled or instilled LPS binds
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Fig. 22. Schematic representation of the stimulation of
macrophages by LPS in the presence of LBP.
This figure shows the currently accepted pathway by which LPS stimulates
macrophages. Firstly, LPS micelles are transferred as monomers to the complex
of proteins in the macrophage membrane made up ofCD 14, TLR-4 and MD-2.
The binding of LPS to this complex sets in motion a series of downstream
reactions ending in the nuclear translocation ofNFkB and the activation of genes
encoding for IL-1P, IL-6, IL-8 and TNFa.
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to surfactant protein A (SP-A) and is inactivated. If secreted proteins can act as a 'surrogate' LBP then
there is the possibility of increasing the activation of the macrophage population contained in the air¬
spaces. There is little in the scientific literature to confirm the presence of LBP-type substances in
vivo but human elafin does interact with certain LPS types. Synthetic human elafin peptides bind to E.
coli LPS and significantly increase TNFa secretion from murine RAW cells in culture conditions
deplete in LBP (i.e. serum-free conditions) (McMichael et al., submitted manuscript). If secreted
ovine elafin functions in this manner in the LPS-induced inflammation model used in this chapter then
the BALF would indeed contain more activated macrophages which would in turn attract more
macrophages and neutrophils into the airspaces. A subsequent increase in LBP concentration due to
leakage from the serum would propagate the LPS induced inflammation. The cell counts in the BALF
would tend to substantiate this hypothesis and indeed the total protein content of the BALF in the Ad-
o-elafin treated segments after LPS had a median of 602pg/ml (range 435-1198) compared to the Ad-
GFP segments post LPS of 282 pg/ml (range 281-596) (see Appendix I) although this difference is not
statistically significant. Simpson et al. (200IB) showed an increase in BALF MIP-2 in LPS treated
mice that had previously received Ad-human elafin, when compared to LPS treatment of mice that
had received vehicle alone or Ad-lac Z. There were also non-significant increases in TNF-a and MIP-
la in the Ad-elafin animals. This situation reflects that expected by the up-regulation of the LPS
response in the elafin-rich lung. The MIP-2 increase could explain the increase in BALF neutrophil
counts due to its chemo-attractant properties. MlP-la is released by LPS stimulated macrophages and
is a known chemo-attractant for neutrophils and macrophages (VanOtteren et al., 1994; Standiford et
al., 1995).
Further, although data exists to suggest that intra-cellular elafin down-regulates NFkB activation and
hence the inflammatory response to LPS (Henriksen et al., 2004), the converse of the observed
situation in the ovine model, there is some evidence for a link between the down-regulation of the
nuclear translocation of NFkB and an increase in lung cellularity seen after in vivo LPS
administration. Aoki et al. (2002) showed that dexamethasone prior to intraperitoneal LPS suppressed
NFkB activation but enhanced MIP-2 and neutrophil counts in the lung. The authors speculate that
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this enhancement of neutrophil influx by dexamethasone is one of this steroid's important anti¬
inflammatory properties.
It is of particular note that LPS instillation into a nai've segment in an animal which had received Ad-
o-elafin in the contra-lateral lung (ten days prior to LPS) caused a significant increase in BALF total
cell counts and neutrophil counts compared to a totally naive (i.e. un-touched) segment at day 14 (figs.
15 and 16). This situation was not seen in the animals instilled with Ad-GFP. Elafin appears therefore
to up-regulate the inflammatory response at sites distant to the site of instillation. This situation has
been reported in other gene transfer experiments, most notably in models of arthritis and kidney
inflammation, and has led to the term 'contra-lateral effect' implying an effect being manifest at a site
distant to the primary site of gene transfer. It is pertinent to briefly review the work in this area that
has led to this term.
Ghivizzani et al. (1998) were the first to report a contra-lateral effect after adenoviral transfer of IL-1
and TNF-a soluble receptors to the stifle joint of rabbits conferred a beneficial effect to the opposite
'control' stifle in an antigen-induced arthritis model. In this model transgene expressing cells were
found in the instilled joint and also in the drainage lymph node and the opposite joint synovium,
although not in the contra-lateral lymph node, and no transgene product could be detected out-with the
injected joint. Further work by the same group (Lechman et al., 1999) showed a similar effect in the
same model using an adenovirus expressing viral IL-10. This paper also demonstrates the migration of
a specific morphologically discrete population of adenovirus infected cells to the contra-lateral joint.
The authors postulate that these cells may be immature dendritic cells and macrophages (Lechman
unpublished data). Kim et al. (2002) also demonstrated a contra-lateral effect after intra-articular
injection of ex vivo modified synovial fibroblasts expressing soluble IL-1 and TNF-a receptors.
However, as these cells don't migrate from their site of injection the contra-lateral effect is considered
to be less likely related to the migration of the transfected cell population. Whalen et al. (2001)
showed that Ad-viral IL-10 injection in mice could lead to the generation of antigen-presenting cells
(APCs) capable of inhibiting both local and distant delayed type hypersensitivity (DTH) reactions
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following adoptive transfer. However, this transfer was only effective when the donor mice were
sensitised to the same antigen used to illicit the DTH response in the recipients indicating an antigen
dependence. Subsequent elegant work by Lechman et al. (2003) demonstrated that Ad-viral IL-10 will
only ameliorate arthritis in the contra-lateral limb to the joint instilled if the same antigen is used in
both joints as the causative factor. Kluth et al. (2001) demonstrated a contra-lateral effect in rat
kidneys using macrophages infected ex vivo with Ad-IL-4. The localised expression of IL-4 led to a
marked reduction in proteinuria and a decrease in macrophage infiltration both in the injected kidney
and the contra-lateral kidney. Although systemic IL-4 was not detected a small number of infected
macrophages did arrive in the contra-lateral kidney and cannot be ruled out as the source of the
contra-lateral effect.
The current body of evidence, therefore, suggests that exposure of APCs to a milieu rich in a specific
mediator may modify the future biological activity of that APC leading to a contra-lateral, or perhaps
more precisely a 'distant' effect.
In considering possible mechanisms underlying the contra-lateral effect in this model a working
hypothesis emerges in relation to possible events following local lung instillation of Ad-o-elafin. Fig.
23 depicts the instillation of adenovirus to one segment in our model system. The open arrows signify
the presence of 'free' (i.e. not cell associated or phagocytosed) adenovirus/calcium phosphate co-
precipitates. This precipitate can infect both type I and type II alveolar epithelial cells, airway cells
and alveolar macrophages. Infection of these cells with Ad-o-elafin will result in the secretion of
ovine elafin into the epithelial lining fluid. Infected alveolar macrophages will then migrate to local
drainage lymph nodes via the tissue and local lymphatics (Harmsen et al., 1985). Kato et al. (2003)
demonstrated that alveolar epithelial cells could phagocytose latex beads and transfer them by a
process of transcytosis to monocytes in local capillaries. This may be a further route by which the
adenovirus may reach a draining lymph node. Finally, Harmsen at al. (1987) showed that pulmonary
neutrophils may also translocate particulate matter from the airspaces to draining lymph nodes. Thus
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Fig. 23. Diagrammatic representation of the infection of the lung
with adenovirus.
The diagram shows a schematic of the lungs anatomy in relation to instilled
adenovirus. Free adenovirus/calcium phosphate is represented by open blue
arrows. This has been shown in the sheep to infect type I and type II alveolar
epithelial cells (TIAEC and TIIAEC) and also alveolar macrophages (AM). Free
adenovirus may also be able to migrate to lymphatics in the lung and to blood
vessels, and by either route arrive at local drainage lymph nodes. In addition, the
infection of the alveolar epithelial cells may enable transcytosis of adenovirus to
local blood vessels. Finally, adenovirus may arrive at local lymph nodes via
mobile cells specifically the alveolar macrophages, but also possibly by air-space
neutrophils (closed blue arrows).
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there are a variety of routes through which locally administered adenovirus could reach the lymph
node, either in a free form whereby it can infect permissive cells present there, or in infected cells
which may continue to secrete elafin. Either would potentially result in a lymph node environment
with a higher than normal concentration of elafin. As was discussed in the introduction and chapter 5
human elafin has been shown to be a substrate for transglutaminase and as such is cross linked to
various proteins (Molhuizen et al., 1993; Nara et al., 1994; Steinert and Marekov, 1995) and in an in
vivo setting elafin has been shown to be cross-linked to heavier and as yet unidentified proteins
present in human BALF (Tremblay et al., 1996; Nara et al., 1994; Sallenave et al., 1999). The lack of
data in this model in relation to elafin concentrations, whether in serum or BALF, is disappointing.
Much effort was directed towards identifying secreted elafin in the BALF samples collected during
this work but this task proved unrewarding as a consequence of limitations wth respect to the
available antibodies and possible cross-linking of the secreted elafin with BALF or tissue components.
However, given the likely initial sequence of events following Ad-o-elafin administration further
consideration can be given to the mechanism of the contra-lateral effect in this model.
It is possible that elafin-rich epithelial lining fluid may have moved from the instilled segment to the
naive segment or that such fluid raised systemic levels of elafin by leakage. However, although
unpublished data from intra-nasal Ad-human elafin administration to mice at up to 109 pfu elicited no
detectable elafin in the serum of instilled animals both at five and nine days after administration
(Simpson, 2002), intra-tracheal administration of 5x1010 pfu of an adenovirus encoding for human
LL-37 in mice led to detection of LL-37 in the serum after 5 days which decreased to background
again at 14 days whereas lung levels remained elevated until at least 21 days (Bals et al., 1999).
Although dosage of virus in these respective models is of critical importance the notion that elafin
protein may have translocated to other segments via the epithelial lining fluid or systemically, cannot
be discounted.
It is potentially more plausible however that the modulation of the response is taking place either in
the draining lymph nodes common to the experimental lung segments used or at the level of the
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nervous system. Background data involving the modulation of dendritic cell function and lymphocyte
phenotypic modulation are detailed in Appendix II but an examination of the specific mechanisms at
play in this model system are naturally beyond the scope of this thesis.
7.4.6. The effect of local instillation of Ad-o-elafin on the neutrophil activation within the lung and on
the systemic response to bacterial LPS.
The inflammatory profile seen in the cell counts was not reflected by the changes in myeloperoxidase
(MPO) activity. The major source ofMPO in the lung is the neutrophil (Schmekel, 1990). In the study
presented here the MPO activity was not expressed per neutrophil in the BALF as some of the
segments contained no neutrophils. When expressed in relation to the total cell count there was the
suggestion that the cellular infiltrate in the elafin treated animals was less activated than that seen in
the GFP animals.
The local stimulation of the LPS response (as assessed by BALF cellularity) in segments in animals
that were treated with Ad-o-elafin (Ad+/LPS+ and Ad-/LPS+ segments) was not, however, reflected
in the circulating leukocyte counts (figs. 19 and 20) which show a more marked response post-LPS in
the GFP animals compared to the elafin animals.
The instillation of Ad-o-elafin into the ovine lung has a dual effect on the response to the segmental
administration of bacterial LPS, an up-regulation of the local response to LPS and a dampening down
of the circulating leukocytosis caused by the administration of LPS. Conversely, the systemic anti-
adenovirus antibody levels are increased in the elafin group compared to the GFP group.
The reason for the dampening down of the systemic response to intra-pulmonary LPS in the sheep
which were instilled with Ad-o-elafin compared to those which received Ad-GFP (see figs. 19-21)
remains at this point unresolved. The only other model system in which this scenario has been
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replicated is in mice transgenic for human elafin (Sallenave et al., 2003). These animals showed an
increase in LPS-induced white cell influx into the lung but also showed reduced serum TNF-a levels
after intra-peritoneal LPS. The authors suggest that these results are due to elafin having an effect on
the cytokine gradient between systemic circulation and the lung itself. Again, it is an attractive
mechanism to explain the ovine model results but since cytokine data are lacking this must remain
purely speculation.
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7.5. CONCLUSIONS
The work presented in this chapter utilised the advantages inherent in the ovine segmental lung model
in order to expand our current knowledge with regards adenoviral gene therapy in the lung.
Specifically this work demonstrated a systemic response to adenoviral vectors which limits repeated
administration. The low doses administered in this chapter caused relatively mild inflammation within
the lung itself but the up-regulation of ovine elafin does have a significant effect on the response to
bacterial LPS both within the lung itself and in the systemic white cell counts. This result adds to our
knowledge of the functions of elafin from rodent model systems (both models of inflammation and
transgenic animals) and is important for the future development of adenoviral delivery of elafin to
regulate the inflammatory response with benefits to the recipient animal.
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CONCLUDING REMARKS AND FUTURE DIRECTIONS
The data presented within this thesis can readily be sub-divided into three sections.
In the first, data is presented in relation to the identification and characterization of the ovine
orthologs of the anti-proteases elafin and secretory leukoprotease inhibitor (SLPI) at the gene, cDNA
and protein levels. While both ovine elafin and SLPI have features characteristic of their respective
families, the ovine form of elafin has been shown to exist in allelic forms, a situation not previously
demonstrated within the trappin family. Both ovine elafin and SLPI are shown to display
characteristics of potential value in the context ofmodulating inflammation in the lung.
The second section details the construction of an adenoviral vector encoding one of the ovine elafin
alleles (Ad-o-elafin) and the preliminary in vitro investigation of methods to maximise the infection
efficiency of adenoviral vectors. The section culminates in the demonstration of local up-regulation of
ovine elafin following lung instillation in the sheep. The efficiency of this system was augmented by
co-precipitating the vector with calcium phosphate. The target cell population consisted primarily of
alveolar macrophages.
The final section examines the influence that local administration of Ad-o-elafin has on the local and
systemic innate immune response to LPS. The data suggests a role whereby this anti-protease
mediates effects specific to tissue and systemic compartments, namely an up-regulation of the LPS
response within the Ad-o-elafin treated lung concurrent with a down-regulation of the LPS response
systemically. Additionally, the in vivo experimentation identified a 'contra-lateral' effect not
previously documented within the field of pulmonary gene therapy whereby the up-regulation of
ovine elafin within one lung segment influences the innate response within a separate, discrete
segment. This observation is potentially of major interest with regards the modulation of inflammation
at sites distant to that exposed to gene transfer agent. Fig. 1 shows a summary of the results of this
work whereby segmental administration of Ad-o-elafin enhances the LPS-induced leukocyte influx
within the same segment (segment B) and also to a distant segment within the opposite lung (segment
C), in addition to decreasing the systemic response to intra-pulmonary LPS. The potential mechanisms
for this action have been discussed in chapter 7 and indeed further in Appendix 2. Briefly, it is





LPS response in the
circulation
Fig. 1.
Concluding remarks and future directions 216
Fig. 1. Diagrammatic summary of the modulation of the LPS
response by local administration of Ad-o-elafin.
The administration ofAd-o-elafin to segment B augments the LPS-induced
leukocyte infiltration in both the virus instilled segment (segment B) and a
distant segment which received LPS alone (segment C), but has no effect on the
BALF cellularity in a naive segment which receives neither Ad-o-elafin nor LPS
(segment A).
Additionally, the administration of Ad-o-elafin to segment B causes a down-
regulation of the LPS induced circulating leukocytosis.
The most likely mechanism for this response (as discussed within the text) is a
migration of a distinct cellular population from the treated region to other sites of
inflammation (signified by the line arrows i and ii).
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considered that the most probable explanation involves the movement of a specific cell population
away from the site of adenoviral instillation to directly or indirectly influence responses elsewhere
within the same animal. Although this could involve infected cells (dendritic cells, alveolar
macrophages) it is equally possible that the high local concentrations of elafin might influence
migration and/or differentiation of an alternative cell population. As discussed previously the lymph
system within the lung is a potential 'bridge' between adenoviral treated and non-treated segments
either via the lymphatic network in the lung or via the blood stream. Work within this thesis has
demonstrated the efficient infection of alveolar macrophages within the treated segments with no
apparent migration of this cell type to naive segments. However, it is possible that lymphatic
migration might indeed occur and lead to immune modulation at the level of the draining lymph node
itself.
A natural progression of the work presented in this thesis would be aimed at defining the anatomical
and immunological mechanisms behind the actions of elafin. A preliminary experiment of great
interest would be the ex vivo infection of alveolar macrophages with recombinant adenovirus (again
comparing Ad-o-elafin with Ad-GFP) followed by adoptive transfer to recipient animals and
subsequent analysis of the response to intra-pulmonary LPS. This would yield information as to
whether the alveolar macrophages are the pivotal cell population underlying the observed local and
systemic effects and indeed whether the infection of these cells with Ad-o-elafin is the reason behind
the marked increase in circulating neutralising antibody levels.
Equally important would be tracing any presumed migration of these cells to facilitate investigation of
the mechanisms underlying both the systemic and 'contra-lateral' effect within the lung. Labelling of
alveolar macrophages infected with Ad-o-elafin ex vivo would potentially add to our knowledge
regarding the interactions of this cell type with other cell populations after leaving the bronchoalveolar
milieu. Knowledge of local lung cytokine regulation as a consequence of elafin expression would be
of value in relation to both defining the specific nature of the innate immune response in this model
and relating such amongst the comparative species where such data exists. In parallel to the work
within this thesis, other investigators in Edinburgh have demonstrated the utility of real time PCR on
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RNA samples isolated from ovine bronchial wall brushings and also from the BALF cell pellet and
have developed repeatable assays for a panel of cytokines which were previously unavailable.
The identification of cellular migration is obviously time dependant and as such an analysis of the
time-course of transgene activity would be of benefit both with regards the localised secretion into the
BALF (by the development of an o-elafin specific ELISA) and the sensitive detection of o-elafin
containing cells which have left the bronchoalveolar compartment (by immunohistochemistry). The
presence of detectable o-elafin within the bronchoalveolar lavage fluid (BALF) itself would prompt
analysis of transglutaminase activity (in addition to metabolites of this important enzyme) within the
BALF as this may have an influence on the inflammatory milieu as discussed within Appendix II.
Several avenues of investigation would benefit from the identification of the ovine cytokines
mentioned previously, Indeed, the consequence of intra-pulmonary elafin secretion on remote organ
responses would be of direct relevance to the pathogenesis of ARDS as a consequence of sepsis. In
this regard, tracking LPS responses in the skin as well as in the lung after elafin up-regulation would
offer further insight into the wider potential benefits of local gene therapy protocols.
Additionally, the segmental up-regulation of ovine elafin by the use of Ad-o-elafin may have
beneficial effects with regards the lung injury seen after systemic LPS administration. Indeed the
systemic administration of bacterial LPS to sheep is a well characterised model of the acute
respiratory distress syndrome (ARDS) and has been used to examine the effects of potential therapies.
As discussed in Chapter 1, interest has focused on the compartmental effects of 11-10 on the lung's
immune response, (see 1.3.2) The ovine model used within this thesis presents an ideal opportunity to
examine the situation with regards the localised expression of elafin in similar situations. Equally, the
converse situation is of potential interest whereby the effects of systemic administration of Ad-o-
elafin on the pulmonary response to LPS could be examined (see 1.3.3).
These different strategies aimed at examining the local and systemic modulation of inflammatory
processes by the application of compartmentalised adenoviral gene transfer will be of major benefit
with regards the future development of relevant therapies and the implications in terms of safety and
delivery strategies in compromised patients are obvious.
Finally, the presence of o-elafin at sites of continuous bacterial contamination as discussed in chapters
3 and 5 of this thesis acts as a reminder of the potential for this protein, and indeed o-SLPI, as a local
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modulator of inflammation with a broad range of actions. So far there has been limited progress in
relation to examining the potential interactions between these anti-proteases and other areas of the
immunological response. Indeed, it would be of particular interest to examine the relationship of these
anti-proteases to the y5 subset of T lymphocytes which have been recognised as important both in the
primary immunological defense of the body and also in the pathogenesis of acute lung injury and its
sequelae. Given that local expertise exists with regards the identification of ovine lymphocyte subsets
and the identification of these in the ovine models utilised here, further investigation is warranted.
In summary, the experimental data presented has expanded upon our current knowledge of the use of
adenoviral vectors in the lung, the sheep as a model for respiratory gene transfer, and the functions of
elafin in localised inflammatory responses. As anticipated the work poses new questions of direct




BALF Neutrophil counts in animals receiving three instillations ofAd-o-elafin (see 6.4.3).
Animal Animal Animal TT cf TT cf
1 2 3 pre naive
Pre-experimental 500 16830 3363 1 0.54
Naive 1554 6573 2056 0.54 1
Vehicle alone 6006 4874 1390 0.62 0.76
lxlOA7 pfu Ad-o-elafin 2445 11606 1801 0.80 0.62
5xlOA7 pfu Ad-o-elafin 3651 3212 1946 0.48 0.80
lx!0A8 pfu Ad-o-elafin 19791 22576 9190 0.19 0.03
The table shows the absolute neutrophil counts per ml BALF pre-experimentally (day -7) and 48
hours after the instillation of PBS+CaP, 107 pfu Ad-o-elafin/CaP, 5xl07pfu Ad-o-elafin/CaP, and 108
pfu Ad-o-ealfin/CaP. An additional naive segment was lavaged after 48 hours. Student's T Test
probability values are shown comparing the data from the treated segments either with the pre-
experimental results or the naive results at 48 hours.
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Total protein levels in segments post-LPS treatment.
A
Elafin
P re- Naive day LPS day LPSA/day
experimental 14 14 14
586.1 448.7 616.3 673.4
370.1 359.8 432.9 435.2
517.0 309.0 332.8 1198.3
725.9 725.1 617.9 602.8




median 581.7 448.7 616.3 602.8
Q1 481.1 359.8 432.9 579.0






P re- Naive day LPS day LPSA/ day
experimental 14 14 14
586.1 351.9 220.8 282.0
370.1 679.8 367.0 596.4






581.7 364.6 367.0 282.0
481.1 358.2 293.9 281.6
665.7 522.2 578.6 439.2
Tables A and B show the total protein content of the BALF pre-experimentally (day -7) and at day 14
for nai've segments, segments which received LPS at day 10 and segments which were instilled with
adenovirus at day 0 and then LPS day 10. Table A shows the total protein for the animals which were
instilled with Ad-o-elafin and table B the animals which were instilled with Ad-GFP. All data shows
individual animal results along with the median, upper quartile (Ql), and lower quartile (Q3).
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Possible mechanisms for ovine elafin mediated modulation of dendritic cell function.
The effects that the potentially defensin-like molecule ovine elafin may have on dendritic cell function
could possibly have functional relevance with respect the 'pro-inflammatory' effects seen within the
lung after instillation with Ad-o-elafin and then bacterial LPS (see Results section chapter 7). There
are many possible mechanisms to explain this up-regulation which is seen not only in the virus
instilled segments but also in 'nai've' segments in the contra-lateral lung and these were discussed
briefly in the Discussion section of chapter 7. It is of interest to discuss potential dendritic cell
modulation here as the effects of human elafin on murine dendritic cell functions are being
investigated within this laboratory currently. Unfortunately the mechanism in the sheep remains pure
conjecture at this moment.
The basis behind the hypothesis presented here is that the development of dendritic cells in a specific
milieu alters the subsequent phenotype of the dendritic cells. This is the fundamental principle behind
the work of Davidson et al. (2004) who has shown that the ex -vivo culture of murine monocytes in the
presence of the human cationic peptide LL-37 along with factors to direct them towards a dendritic
cell phenotype has important effects on the functioning of the resultant immature dendritic cells
(iDCs). For example, LL-37 derived iDCs show an altered degree of interaction with antigen as
predicted by an alteration in surface receptor expression. Additionally, LL-37 derived iDCs showed a
characteristic Th-1 inducing cytokine response after maturation with LPS and stimulated increased
proliferation of T cells secreting IFN-y. This work is of fundamental interest with regards the data
presented in this chapter as LL-37 shows many similarities to elafin. LL-37 is the cleavage product of
the human cathelicidin hCAP-18 (Lehrer and Ganz, 2002) and as such is a cationic secreted protein
produced by many inflammatory white cells and epithelial cells. Of particular interest is its presence
in BALF and indeed its up-regulation in states of inflammation (Schaller-Bals et al., 2002). Ovine
elafin is up-regulated during acute pulmonary inflammation induced by bacterial LPS (chapter 5) and
other work in this laboratory supports this finding (Sallenave, 2000). Therefore, in an inflamed lung
there are potentially high elafin levels in the epithelial lining fluid. Following up-regulation using an
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adenoviral vector, we can expect even higher local concentrations compared to a viral control. Such
elevated concentrations of elafin could potentially have modulatory effects on tissue dendritic cells in
the lung in a similar way to LL-37, and have an influence on the subsequent response after migration
of the mature dendritic cell to the local drainage lymph node.
In addition, the secreted protein murine P-defensin-2 has been shown to have a direct maturing effect
on DCs via a TLR-4 dependant mechanism (Biragyn et al., 2002) which is not seen in the LL-37 work
discussed above. The P-defensins are also cationic proteins (Lehrer and Ganz, 2002) and so this
maturation may also be a possible consequence of increased elafin levels locally. Interestingly, the
prostaglandin PGE2 has been shown to increase iDC maturation and promotes a Th-2 response
(Kalinski et al., 1998) while PGE2 blockade induces IL-12 release from DCs (Harizi et al., 2001).
PGE2 is a product of phospholipase A2 (PLA2) activity on membrane phospholipids and as such may
be influenced by transglutaminase inhibition as seen in a guinea pig model of conjunctivitis (Sohn et
al., 2003). In guinea pig models of LPS induced acute lung injury alveolar macrophages are one of the
major contributors of secretory PLA2 in the BALF (Arbibe et al., 1997). The secretion of PLA2 ex
vivo induced by LPS was shown to be TNFa dependant and so the alveolar macrophages may be
regulating secretion in an autocrine fashion. This increase in secretory PLA2 has also been shown to
increase the levels of fatty acid and lyso-phosphatidylcholine levels in the BALF post LPS, substances
which are injurious to the lung cellular membranes in acute lung injury (Arbibe et al., 1998). So the
PGE2 may have direct effects on DC function but also the enzymatic cascade results in direct lung
injury.
A diagrammatic representation of the possible interactions between elafin and dendritic cell
functioning along with inhibition of transglutaminase mediated phospholipase A2 stimulation are





















Fig. 1 (App.). Diagrammatic representation of the possible effects of
elafin as an inhibitor of PLA2 in the lung.
The diagram shows a schematic of the lungs anatomy in relation to instilled LPS
and the modulation of the subsequent actions of the secreted PLA2 by the
presence of increased amounts of ovine elafin.
A. This part of the diagram is the sequence of events with regards PLA2 activity
in the normal lung. LPS activates alveolar macrophages (AM) to secrete TNFa
which in turn stimulates the AMs to secrete PLA2 which then leads to the
production of harmful lyso-phosphatidyl choline (LPC) and also PGE2. PGEo
stimulates the maturation of local dendritic cells (DC) and favours the clonal
expansion of Th-1 lymphocytes which secrete IL-4, IL-5, IL-10 and TGF-p.
B. In the presence of up-regulated amounts of ovine elafin, the PLA2 activity of
the lining fluid will be inhibited and so harmful products such as LPC will not be
formed. In addition the DCs will mature normally and a Th-1 phenotype
favoured with the lymphocytes producing IL-2, IFN-y and TNF-p. These Th-1
lymphocytes can then further activate the macrophages to produce increased
levels ofTNFa, IL-8 and MCF, the latter of which may lead to increased chemo-
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Brown, Thomas I., Rohit Mlstry, D. David Collie, Sleven Tate,
and Jean-Michel Salienavc. Trappin ovine molecule (TOM), (he
ovine ortholog ofelatin, is an acute phase reaetant in the lung. Physiol
Genomics 19: 11-21, 2004. First published August 3, 2004; doi:
10.1152/physiolgcnomics.OO 113.2004.—As large animal models con¬
tinue to play an important role in translating lung-directed therapeutic
strategies from laboratory animals to humans, there is an increasing
interest in the analysis of endogenous regulators of inflammation al
both a genomic and a therapeutic level. To this end, we have sought
to cliaracterize the ovine crtholog of elafin, an important regulator of
inflammation in humans. We have isolated both flic claftn cDNA and
gene, which have a similar structure to other species" orthologs.
Interestingly, we have isolated two alleles for ovme elatm, which
contain a veiy high number of tianagluiamination repeats, thought to
be important in binding elafin to the interstitium. The mainly mucosal
inRNA distribution for ovine elafui suggests that ovine elafin may,
like its human ortholog, have functions ui innate immunity. This is
supported by analysis of claim and the related protein secretory
leukocyte protease inhibitor (SLPI) in ovine bronchoalveolar fluid in
response to locally administered lipopolysnecharide and confirmation
of them acting as "alarm" antiproteases. We have also cloned the
ovme elafin cDNA into an adenoviral vector and have demonstrated
correct processuig of the secreted proteui as well as biological activ¬
ity. Ovcrexpression of ovine clafin ui a lung-derived epithelial cell
line has a protective effect against the enzymes human neutrophil and
porcine pancreulic elasldsc. The identification of the ovine dafin gene
and its translated protein are important in developing practical strat¬
egies aimed at regulating inflammation in the large mammalian lung.
antiprotease; elastase; sheep
the trafwns [acronym for "transglutaminase substrate and
WAP (whey acidic protein) domain containing protein"; Ref.
27] arc a group of proteins characterized by the presence of a
NH.-.-terminal transglutaminase substrate ("ccmcntoin") do¬
main ;uid a C-disulfide core domain, also called WAP domain,
which contains, in some members, an antiprotease active site.
Current knowledge suggests that the two domains may have
evolved from exon shutiling and gene duplication between
rapidly evolving seminal vesicle transcribed (REST) genes ;uid
the WAP domains of ancestral genes (3), Indeed, in humans,
Article published online before print. See web site for dale of publication
(h«p://pbysiolgenomics .phvstolojry org).
Addicsft for reprint requests and other correspondence: J.-M. Sallenave,
Rayric Laboratory, Respiratory Medicine Unit, MRC Centre for Inflammation
Research, Univ. of Edinburgh, Edinburgh, BH8 9AG, Scotland, UK (E-mail:
jsallena@staiTmail.ed.ac.uk).
coloca fixation of the human trappin-2 gene (also known as
elaliri/elastase-spccific-inliibitor/SKALP) and die secretory
leukocyte protease inhibitor (SLPI) gene (which contains two
WAP domains) in die same region of cliromosome 20 is in
agreement with this hypothesis (8, 12). Our group is particu¬
larly interested in the study ofelafin, which was identified as an
antielastase inhibitor in the early 1990s (19, 21, 26, 35). The
closely related protein SLPI also lias important functions as an
inhibitor ofneutrophil clasta.se (Rcf. 20 and references therein),
and both molecules have been found to be present in humans
at mucosal sites and also have been shown to be synthesized by
epithelial cells and alveolar macrophages. In addition, it has
recently been demonstrated that both elafin and SLPI have
antimicrobial functions and may be able to prime the innate
immune system (20).
More than 15 trappins and many more WAP-containing
proteins have been identified to date, throughout the animal
kingdom. Although the sequence in the WAP domain predicts
that a number of trappin species orthologs arc anticlastasc
molecules, this has only formally been demonstrated for hu¬
man and porcine clafin (19, 21, 26, 32, 35).
Because of our interest in the modulation of lung inflamma¬
tion in ovine models (2) and the known modulatory activity of
an!iproteases (20), we set out to isolate the ovine elatin cDNA
and gene ortholog and to study its properties.
Wc identihed in this study two allelic forms of the ovine
elafin gene (named TOM-1 and TOM-2, for "trappin ovine
molecule" 1 and 2) and analyzed their mRNA distribution in a
variety of tissues. Furthermore, we have demonstrated that
secreted ovine elafin can protect a lung-derived epithelial cell
line from proteolytic damage due to both human neutrophil
elastase (HNE) and porcine pancreatic elastase (PPE). The
distribution, antielastase activities, and kinetics of expression
in vivo of ovine elafin predict that it may also have mucosal
protective functions in inflammation. This should prove a
valuable tool in developing therapeutic strategies in a large
animal model of lung inflammation, currently being developed
in our laboratories.
F.XPF.RIMENTAI. PROCEDURES
Molecular biology reagents Primers were synthesized and sup¬
plied by MWG-Biotech (Milton Keynes. UK). Primer design for
5'-rapid amplification of cDNA ends (RACE) (GSPl) was based on
preliminary ovine elalin sequence (R. Mistry, unpublished data).
Subsequent pruncrs were based on the newly determined ovine elaftn
109445341/04 S5.00 Copyright O 2004 the American Physiological Society 11
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sequence: elafin gene-specific reverse priiner (GSP1) 5 '-CAT GGC
GCA CCG GAT CA-3'; elafin gene-specific forward primer (GSP2)
5-ATG AAG ALL' AGA AUL TTC TTG GTC C-3\ full-length
reverse primer (r-el) 5 -CTG GGG ATC CAT ACA GGT CTT-3';
Bgll\ forward clafiu primer (Bgl-f-el) 5-GCC GGAGATCTG ACA
ACA TGA AGA CCA GAA GCT TCT TGG TC-3' (^/II site is
shown with underscore; Kozak sequence in bold); 5VjcI elafin reveise
pruner (Sac-r-el) 5 - TAC GTG AGO TCT CAT CAC TGG GGA
TCC ATA CAG GTC TT-3' (Sircl site is shown with underscore);
forward bacterial artificial chromosome (BAC) primer (IBAC) 5'-
TGA AAA GGG TCC AAT CAA CG-3'; reverse BAC primer
(rBAC) 5'-GAG CCA CGC TTA GTG AGG AG-3'.
Tag DNA polymerase, 25 mM uiagnesiiun cliloride, DNA poly¬
merase buffer, dNTPs, oligo (dT) primer, EcoRl, Buffer H for EcoR I,
BglU, Buffer D for BglU, Sad, Buffer J for Sad, MM.LV reverse
transcriptase (MMLV RT), and 5x MMLV RT buffer were supplied
by Piomega UK (Southampton, UK).
Shuttle vector pDC5!6 was obtained from Microbix Biosystems
(Toronto, Ontario, Canada). Shuttle vector pIRES-GFP3 was kindly
donated by Dr. Mary Hitt (Dept. of Pathology and Molecular Medi¬
cine, McMastcr University, Hamilton, Ontario, Canada).
RNA preparation and RACE. Ovine tissues were obtained locally
from a selection of 5-mo-old crossbred lambs (Moredun Research
Institute, Edinburgh, Scotland, UK). The tissue samples obtained from
sheep organs were treated as follows. Samples of each tissue were
removed at autopsy and frozen at 80°C. Approximately I g of each
of these was then homogenized, and the RNA was extracted using
TRIzol (Invitrogcn, Paisley, UK). RNA quality was assessed by
running 10 jlI on a 1 % agarose gel. Quantification of RNA m samples
was by dual-wavelength spectrophotometry.
RACE-PCR for ovine elafin was performed using ovine tracheal
mucosal RN'A. Fust, to obtaui 5' information, we used a primer
specific for ovine elafin, GSP1 (derived from partial sequence already
obtained from preliminary experiments, not shown), and the 5' for¬
ward GeneRace Primer. Thie was followed by a nested PGR using
GSP1 and nested 5' forward GeneRace Primer. Cycling parameters
were as follows: initial incubation of 92°C lor 5 min, followed by
92r*C for 1 min, 55°C for I min, and 72°C for I mm (30 cycles
followed by a final amplification step of 72,;'C for 5 min). Products
were run out on a 1 % agarose gel. These conditions were used for both
the original and nested PCRs.
To perform the 3'-RACE, a slightly different strategy was used.
Reverse transcription of the original RNA sample was performed
using the GencRace oligo-dT supplied in the GeneRacer kit and
MMLV RT (Promega). PCR was then performed using the forward
primer GSP2 and llie reverse GeneRace primer to obtain the full-
length cDNA sequence. GSP2 was designed from the sequence
derived from the 5 '-RACE procedure. PCR conditions were similar to
those above except for a magnesium chloride concentration of 2.2
mM. Tins was followed by a nested PCR using GSP2 and nested
reverse GeneRacc primer,
DNA preparation and sequence analysis. Genomic DNA was
extracted from lung and liver samples of the above animals by
proteinase K digestion in NTES (50 mM Tris, 50 mM EDTA, 100
mM NaCl, 1% SDS, pH 8), followed by phenol-'chloroform extraction
and washing with 100% isopropanol followed by 70% ethanol. The
DNA was resuspended in water and kept at ~20°C.
DNA sequence analysis was done both in house and by MWG-
Biotech, and the sequence data were analyzed with the online com¬
puter software packages NCBI Open Reading frame finder I National
Center for Biotechnology Information (NCBI)], NCBI Blast (NCBI),
and BCM Multiple Sequence Alignment tools (BCM).
Extraction ofPCR products and cloning reactions. All PCR prod¬
ucts were run on 1% agarose gels, and bands of interest were cut out
and purified using the QIAQuick gel extraction kit (Qiagen, Crawley,
W. Sussex).
Cloning of the extracted RACE cDNA fragments was achieved by
using the TOPO TA cloning kit for sequencing included with the
GeneRacer kit. The cDNAs wore hgated into pCR 4-TOPO plasm id
followed by transformation into TOP 10 Escherichia colt cells (In-
vitrogen). Plasnud DNA was purified with the Promega SV Miniprep
system.
BAC library screening and subdoning. An ovine BAC library was
screened using primers specific for elafin by Dr. P. Piumi at Institut
National de la Recherche Agronomique (1NRA), Laboratoire mixte
INRA-CRA dc Radiobiologic ct d'Etude du Genome (I.RF.G), Jouy-
en-Josas, France. One positive clone was isolated ami DNA was
prepared with Qiagen Plasrnid Maxi kit (Qiagen, Crawley, UK). One
microgram of the BAC-positive clone was digested with £"coR 1, run
out on a 1% agarose gel, and blotted onto GeneScrcen membranes
[PerkinElmer Life .Sciences (UK), Cambridge, UK]. This was probed
for I h with [a-32PJdCTP-labeled full-length cDNA coding for ovine
elafin, using ExpressHyb (Clontceh, Palo Alto, CA) following the
manufacturer's protocol. Positive bands were identified with a Storm
Phospliorhnager system(Amersham Biosciences UK, Little Chalfont,
UK) and further subcloned into plasmid PDC516 for sequencing using
various internal primers.
Tissue screening of ovine elafin by Northern blot and RT-PCR
analysis. Twenty micrograms of each tissue RNA sample was dena¬
tured m 50% formainide, 16% formaldehyde, 20 mM MOPS, pH 7.0,
5 mM sodium acetate, and I mM EDTA, for 15 min ar 65°C,
elcctrophorcscd in a 1 % agarose gel containing 2.2 M formaldehyde,
and transferred to a GeneScreen membrane. The membrane was
hybridized with [ot-32P]dCTP-labeled lull-length cDNA coding for
ovine elafin in ExpressHyb following the manufacturer's recommen¬
dations. The membrane was then visualized on a Storm Phosphorlm-
ager system.
One microgram of each tissue RNA sample was used in a reverse
transcriptase reaction using MMLV RT (Promega). Product from this
reaction was split into two PCRs, using either forward and reverse
{3-act in primers or the full-length elafin primers GSP2 and r-el.
Conditions weit as for the RACE o la fin PCR except for there being 35
cycles for elafin and 28 cycles for the p-actin.
Comparison of ovi/ie elafin products synthesized by PCR from
positive BAC done, genomic DNA, and RT-PCR synthesized cDNA
To compare the elafin cDNA, identified by the RACE procedure, with
die gene sequences, PCR was performed using as template purified
elafin BAC DNA and ovine liver DNA alongside cDNA synthesized
from ovine skin and pIRES-GFP-ovine elafin, using the non-intron-
spanning primers fBAC and rBAC. PCR parameters were as for the
RACE elafin PCR. Products from the genomic DNA PCR were
lighted into pCR 4-TOPO plasmid, which waa transformed into
TOP 10 E coli celts. Plasmid was extracted with Promega SV Mini¬
prep system, and elafin sequences were sequenced.
An additional PCR was performed on ovine genomic DNA using
the primers GSP2 and r-el. Products from this PCR were also cloned
into pCR 4-TOPO as above and sequenced.
Phylogenetic tree analysis of WAP domains of the elafin ami SLPI
family members To investigate the phylogenetic relationships of the
ovine forms of clafin. we constructed a phylogenetic tree by the
neighbor-joining method (18) using data from multiple alignment of
the amino acid sequences of the whey acidic protein (WAP) domains
ofmembers of the trappin family, the known SLPI sequences (human,
mouse, rat, pig, and sheep), the murine elafin-like proteins 1 and 2 (5),
and the human vasopressin molecule, which contains a rudimentary
WAP motif and can be assumed to be evoltttkttarily related to the
elafin and SLPI families of proteins.
Upopolysaccharide-induced upregulation ofovine elafin and SLPI
in bronchoalveolar lavagefluid. Bronchoalveolar lavage fluid (BALF)
was collected to assess the regulation of ovine elafin and SLPI
following local lung challenge with LPS. Briefly, 12 crossbred sheep
(10 female and 2 male) were anesthetized with 20 mg/kg intravenous
thiopentone (Intraval sodium; Maria I Animal Health, Harlow, Essex,
Physiol Genomics • vol • www.physiolgCTioinics.oig
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UK), intubated, and maintained on 2-3% lialotbane m oxygen and
nitrous oxide. Lipopolysaccharide (LPS), 1 nig. from E. coli 026; B6
diluted in 5 ml distilled water was instilled via bronchoscope into
random segments. All experimental animal procedures were approved
by Uie Ethical Review Committee of the University of Edinburgh.
Bronchoalveolai lavages from these sheep were collected a week prior
to the exixuiment and 6,24, and 168 h aficr the administration of I.PS.
The lavages were spun at 400 g for 7 nun, and 200 |tl of the resultant
supernatant was used in a dot blot onto GeneScreen membrane and
blocked with 5% milk powder in PBS + 0.1% Twccn-20 (TPBS). The
membrane was then probed with either polyclonal antihuman SLP1
antibody (24) or monoclonal TRAB20 antielafin antibody (HyCult
Bioteclmology, Uden. tlie Netherlands). Resultant films after exposure
to X-Omat radiograph-quality film were scanned, and densitometry
measurements taken using a white-light transilluminator (UVP, lip-
land. CA). Control membranes probed witli secondary antibody alone
showed no detectable protein (not shown).
Construction of adenoviral vector expressing ovine elafin. Full-
length ovine clafin cDNA m pCR 4-TOPO (see above) was used its a
template for two consecutive PCRs with first Bgl-f-el and FLAG-r-el.
followed by Bgl-f-el and Sac-r-FLAG-el (lo yield Bgh 1 -elalin-FLAG-
Sac\). PCR conditions were as for the RACE PCR for elafin. This
product was hgated into shuttle vector pD05I6 [which contains the
murine cytomegalovirus (MCMV) promoter] using standard tech¬
niques.
This plasmid was used to create a replication-deficient adenovirus
(Ad) by cotransfection of type 293 cells with pBI (Gfrt(del)F. 1,3FLP (a
kmd gill from Dr. M. IhU, McMasler University). Ad-ovine elafin
was obtained tlirough homologous recombination between the two
plasmids using the FT P recombinase/frt rnccltanism (15).
The presence of the correctly inserted ovine elafin cDNA into the
viral genome was confirmed by //mdlll digestion followed by South¬
ern blot analysis (not shown). Infection ofA549 cells with tliis virus
confirmed correct processing of the ovine elafin protein (not shown).
Adeno\ 'irus-mediated protection ofA549 cells against proteolytic
enz)we damage A549 cells ( I I) were plated our in 48-well plates at
50,000 cells/well and kept in Dulhecoo s modified Eagle's medium
(DMEM) containing 10% fetal calf scrum (FCS), penicillin G (final
concentration 100 U/ml), .streptomycin sulfate (final concentration
100 jxg/ml), and L-glutaiuluc (final concentration. 2 g.M) overnight at
37°C, Tlic following day the cells were washed with fresh medium
and incubated for 45 mm with Ad-ovinc elafin, Ad-human elafin (25),
Ad-murine SI,PI (6), or Ad-murine eotaxin (6) in fresh medium. The
cells were then washed with serum-free DM EM and medium replaced
witli DMEM containing 2% USG serum substitute (GIBCO-BRL).
After 72 h the medium was removed, the cells were washed twice with
PBS, and medium was replaced with fresh DMEM with no serum or
USG and containing I p.g/ml HNE (F.lastm Products, Owensville,
MO) or PRE (Sigma-Atdrich, Dorset, UK). Plates were incubated
overnight and photomicrographs taken.
To quantify elastase-mediated injury, medium containing detached
cells was spun at 13,000 rpm for 5 mill. Tlie cell pellet was then
washed in sterile PBS twice and resuspended in distilled water,
followed by two successive freeze/thaw rounds. The suspension was
further centriftiged (13.000 rpm, 5 mm), and the supernatant was
assessed for protein content (indirect readout of cell detachment)
using the bioinchomnic acid method (Pierce) using purified albumin
(Pierce) as standards.
Residual HNE and PPF activity in the supematants was assayed 111
96-we11 microliter plates. Ten microliters of supernatant diluted witli
40 p,l assay buffer (50 mM Tris, 0.1% Triton, 0.5 M NaCl, pH 8.0)
was incubated at 37°C with the chromogenic substrates A'-methoxy-
succinyl-Ala-Ala-Pro-Val-p-nitroanilidc (for HNE activity) or AT-suc-
cmyl-Ala-Ala-Ala-/Miitxoanilide (for PPF activity) diluted to I p-g/ml
in assay butler. Both chromogenic substrates were supplied by Sigma-
Aldrich, Dorset, UK. Enzyme activity was shown by a change in
absorbance measured at 405 nm over 90 nun.
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RESULTS
Isolation and sequence, analysis ofovine elafin cDNA. Using
ovine tracheal mucosal RNA, and PCR primers annealing to a
portion of the ovine clatin sequence already available (R.
Misiry. unpublished observations), with 5'-RACE PCR wc
produced a product of 612 bp, which was cloned into pCR
4-TOPO plasmid lbr sequencing. This PCR product contained
the sequence corresponding to the GeneRacer oligo ligated to
the 5' terminus of the tnRNA followed by 18 bp of 5'-
unfranslaled region (TJTR) and the ovine elalin cDNA se¬
quence through to the priming site for the gene-specific primer.
This information allowed 3'-RACE to proceed. This yielded a
product of 887 bp. which was also cloned into pCR 4-TOPO
plasmid for sequencing and was shown to contain sequence 3'
of the stop codon corresponding to 3'-UTR tlirough to the
polyadenylation signal. This product terminated with the se¬
quence corresponding to the GeneRacer oligo-dT sequence
used in the reverse transcription step of the RACE procedure.
Altogether, the 5'- and 3'-RACE procedure allowed us to
identify an open reading frame for a protein of220 amino acids
which showed homology with human, simian, porcine, and
bovine elafin ( see Fig. 1) and will be referred to as ovine elafin.
The protein consists of a putative hydrophobic signal sequence
of 23 amino acids at the NRj terminus followed by a distinct
region of hexapeptide repeats of consensus sequence
PVKGQD, which corresponds to a potential transglutaminase
substrate domain (27), and a COOH-terniiiial portion contain¬
ing a presumed disulfide core region with eight cysteine resi¬
dues in positions corresponding to those in the human elafin
protein WAP domain.
Sequence analysis of the ovine elafin gene. Screening of an
ovine BAG library was performed at INRA using probes
generated by PCR (sec t-xriauMCtTAL procedures). This screen¬
ing identified one clone for clafin. Southern blot analysis using
1 pg of BAG clone DNA allowed identification of a positive
iTcoRl baud of 10 kb from the elafin clone. This band was
purified and subcloned into PDC516 for sequencing with
sequential internal primers through to the polyadenylation
signal at the 3' end and proximally tlirough toward the pro¬
moter region. This approach only enabled us to obtain full 3'
sequence information (up to the poly-A signal) and no 5'
information. Indeed, because the BAG library was generated
by partial HimMW digestion, and since the elafin 5' promoter
region contains a //i'/idUI site, wc were unable to obtain 5'
information using this methodology and only obtained se¬
quence from this restriction site forward. The elafin promoter
region sequence was obtained by using PCR (with ovine
genomic DNA as template obtained locally; see experimental
procedures) with a primer designed to anneal to the 5' end of
the human clafin promoter along with a reverse primer anneal¬
ing to a portion of the first iniron of the ovine elafin gene. This
PCR product was cloned into pCR 4-TOPO and sequenced.
This allowed us to show that the elalin gene spans —2.5 kb and
is split into three exons and two introns (Fig. 2, GenBank
accession no. AY344541).
Tissue distribution ofovine elafin. Total RNA was extracted
from multiple ovine tissues and analyzed by Northern blot. A
750-bp ovine elafin RNA species was detected in tongue,
trachea, small intestine, large intestine (strongest signal), and
skin (see Fig. 3A).
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Fig. I. Sequence foi the gene coding for ovine clafin. The "TATA" box, 5' Kozak sequence, and 3' polyadcnylation signal
sequence ate boxed. Lxons arc underlined. Predicted signal cleavage site is between amino acids 23 and 23 (between A and A).
Annealing sites lor the primers GSP1, (1SP2, r-el (used in RACE-PCR), fBAC, rBAC (used in PCR screening of BAG library*),
and r-inv-cl (used to amplify the promoter region) arc indicated.
RT-PCR reaction using primers GSP2 and r-cl for ovine
elafin was performed using the same RNA samples (see Fig.
3B). Consistent with the Northern blot analysis, we found RNA
to be present in tongue, trachea, small intestine, large intestine,
and skin. Interestingly, products of two different lengths were
obtained, —660 bp (the expected size as predicted from the
gene sequence) and 800 bp.
Genomic PCR Jor ovine elafin using a combination of
non-tntron-spanning and imron-spanntng primers. On account
of isolating two different ovine elalin niRNA products by
RT-PCR (see Fig. 3/?), although only one gene was isolated
from the BAC library screening, we performed additional PCR
reactions using non-intron-spanning primers and a variety of
templates to determine whether these RNA products arc splice
variants from a single gene or products of diffcrcnt/allclic
genes. Figure 4A shows the PCR products when fBAC and
rBAC primers arc used with various templates: genomic ovine
DNA (obtained locally), cDNA synthesized by RT-PCR from
ovine skin RNA (shown to be positive for elafin expression;
see Fig. 3). DNA extracted from the clafin-positivc B.AC clone,
and finally DNA extracted from the expression plasmid pIRES-
GFP3 containing the cDNA for ovine elafin isolated by RACE-
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1 15 16 30 31 45 46 60
Bimian VWPLI AGKLWEAA
human MRASSFLI -VWFLI AGTLVLEAA - --
porcine MRSRSFLVLVWFLI CGTLVAQAAGRIRRP KGKGTKKILALV
bovine —
ovine MKTRSFLVQVWLLI LGTLVAEAAIIRGRP KGQGTKKTNVLVNEK GPINGQYPVKRPNPV
61 75 76 90 91 105 106 120
Bimian VTGV PVKGQDTVKGRVPF NGQDPVKGQVSVXGQ DRVKGRGPVKG
human VTGV -PVKGQDTVKGRVPF NGQDPVKGQVSVKGQ DKVKAQEPVKG
porcine KGQGPVRGKDQVKGQ GPVKGQDLGKSQDPV KAQLPDKGQDLGKGE DSVKGQDPFKAQ
bovine --QEPVKGQDPVKGQ DPVKGQDPVKGQDPV KDQNPVRGQEPVKGQ DPVKGQDPVKGQDPV
ovine IGQGPVKGQDPVKGQ DPVKGQDPVKGQDPV KGQDPVKGQDPVKGQ DPVKGQDPVKGQDPV
121 135 136 150 151 165 166 180
simian PVSTKPGSCP
human - PVSTKPGSCP
porcine LPD KLQDPVKAQPAIK RLILLTKPGSCP
bovine KGQ - - EPV KGQDPVKGQDPVKRQ GRIGGPLLTKPGSCP
ovine KGQGPVKGQDPVKGQ DPVKGQGPVKGQDPV KGQDPVKGQDPVKGQ DRVRSPLLTKRGSCP
*
181 195 196 210 211
Bimian NILIRCAMLNPPNRC LKDTD 89
human IILIRCAMLNPPNRC LKDTDCPGIKXCCEG SCGMACFVPQ 117
porcine RILIRCLMVNPPNRC LSDAQCPGLKKCCEG FCGKACMDPK 167
bovine RVLIRCAMMNPPNRC LRDAQCPGVKKCCEG SCGKTCMDPQ 134
ovine RVLIRCAMMNPPNRC LRDAQCPGAKKCCES SCGKTCMDPQ 220
Fig. 2. Comparison of the known clafin protein
sequence between species. The shaded area cor¬
responds to the region of hcxapcptidc repeats
with the consensus sequence PVKGQD. Ihe
eight conserved cysteine residues within the
whey acidic protein domain (WAP) are indi¬
cated by asterisks. Where there is sequence
overlap (i.e., ignoring the size difference be¬
tween the proteins), the ovine elafin sequence
shows 70% homology at the amino acid level
with the simian, 68% with the human. 49% with
the porcine, and 80% with the bovine clafin
sequence
PCR (see above). Two bands were seen with the first two
templates (—400 bp and 525 bp). The low-molecular weight
band corresponded to the ovine clafin cDNA product isolated
by RACE-PCR (coding for a 220 amino acid protein) and
present in the plRES-GPP3 plasmid containing the ovine elafin
cDNA. The higher-molecuiar-weight band was of unknown
origin. The two products obtained with the genomic DNA
template were isolated and cloned into pCR 1 TOPO and
sequenced. As predicted, the low-molecular-weight product
sequence matched exactly the sequence from the ovine elafin
original sequence, whereas the high-molecular-wcight product




Ovine elafin specific band j \
at approximately 750bps ' ✓
/./V /// / /
B
{J-actin
Fig. 3. Tissue distribution of ovine elafin
RNA as assessed by Northern blot and RT-
PCR A. for Northern blot, 20 of total
RNA was loaded for each tissue Ribosomal
18S and 28S RNA subumts arc indicated by
arrows, The membrane was priced with tl*c
full-length cDNA (660 bp) corresponding to
the coding portion of the gene for ovine
clafin. B RT-PCR for (i-actin and ovine
elafin from RNA extracted from the various
organs indicated. The position of molecular
weight markers is indicated (I-kb ladder).
Primers used for amplification ofovine e latin
were GSP2 ami r-el, yielding two products of
•660 bp and 800 bp.
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Fig. 4. The relationship between the two ovine ciafin alleles
(trappin ovine molecules TOM-1 and TOM-2) coding for
proteins of 220 amino acids and 262 amino acids, respec¬
tively. A: PCR was performed using the non-intron-spanning
primers IBAC and rBAC as detailed in the text. Templates
used were ovine genomic DNA, cDNA synthesized by re¬
verse transcription of RNA isolated from ovine skin, DNA
isolated from an ovine BAC clone positive by PCR for the
elafin gene, and the expression plasm id ptRES-GFP3 con¬
taining the cDNA for ovine clafin (220 amino acid form).
The lowcr-molccular-weight product of —400 bp is due to
amplification of exon 2 of the ovine elafin gene or cDNA
(and also inserted into plRBS-GFP3); the longer product of
—525 bp corresponds to amplification of a longer form of
ovine elafin. B: the promoter sequence and 3' sequence is
known for the TOM-1 gene only. There is 100% homology
between the known portion ofTOM-2 and the corresponding
portion of TOM-1, except for the fact that TOM-2 contains
seven extra repeats with the consensus PVKGQD as shown.
Numbers below the representation of TOM-1 denote base
pairs from the start of the gene sequence. TOM-2 has been
sequenced after PCR of ovine genomic DNA using the








(26 instead of 19). The existence of two different genomic
forms was further confirmed using a different set of PCR
primers (the intron-spanning primers GSP2 and t-el), yielding
two distinct products of —1,500 and 1,600 bp (not shown).
These products were cloned into pCR 4-TOPO and sequenced
and confirmed the presence of a second, heavier form of the
ovine elafin otherwise identical to the original gene isolated by
BAC library screening. The original form of the gene described
will hereafter be referred to as TOM-1, and the higher-molec¬
ular-weight form, coding for the longer form of ovine elafin of
262 amino acids, will be referred to as TOM-2. Alignment of
TOM-1 and the known region of TOM-2 are shown in a
diagrammatic representation in Fig. 4B.
Southern blot analysis of ovine genomic DNA (from the
same animal as the RNA used in the RT-PCR; Fig. 3#) is
shown in Fig. 5 and indicates the presence of only one ovine
elafin gene, showing that indeed TOM-1 and TOM-2 are two
allelic forms of the same gene.
In vivo upregulation ofovine SLPI and elafin in response to
bacterial LPS. Bronehoalvcolar lavage samples were collected
1 wk prior to and 6. 24, and 168 h after LPS administration.
Dot blots were performed using these lavages and probed with
cither a polyclonal antibody against human SLPI or the mono¬
clonal antibody TRAB20 to detect ovine elafin (Fig. 6).
Although both SLPI and elafin concentrations in the BALF
from LPS-treated sheep increase with time compared with
prccxpcriment values, the kinetics and degree of elafin and
SLPI upregulation are different. SLPI increases significantly
(1.5-fold) at 6 h {P < 0.0005) and at 24 h (P < 0.005), whereas
the increase in elafin levels is much more dramatic (8-fold)
(.P < 0.005 at 24 h).
Protection of A549 cells against proteolytic damage. To
show potential antielastase activity attributable to the protein
encoded for by the ovine elafin eDNA, A549 cells were
infected with Ad-ovine elafin. To compare its activity with
other known antiproteascs, cells were also infected with Ad-
human elafin and Ad murine SLPI (Fig. 7). Ad-murinc cotaxin
6000bps[
i5oobpsi y
Fig. 5. Southern blot of ovine genomic DNA probed for ovine ciafin. Genomic
ovine DNA. 20 p.g. was digested with restriction enzymes {Xba I. Sad, £coR I.
and DamW 1), fractionated on a 0.8% agarose gel. then blotted onto a nylon
membrane. The membrane was probed with radiolabeled full-length cDNA
corresponding to the coding sequence ofTOM-1. The sizes of the bands seen
are indicated.
4? Crf <£ <f
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Fig. 6. Secretion of secretory leukocyte protease inhibitor (SLPI)
and elafin in bronchoalveolar lavage collected from sheep lung
segments exposed to lipopolysaccharide (LPS). E. coli LPS, 1
mg, was administered to discrete lung segments of 12 sheep.
Bronchoalveolar lavage was collected a week prior to and 6, 24,
and 168 h after administration of the LPS. Then, 200 p,l of
bronchoalveolar lavage from each animal at each time point was
used in a dot blot and probed with either human anti-SLPI
polyclonal antibody (A) or TRAB20 monoclonal antibody de¬
tecting ovine elafin (B). Results are shown as median arbitrary
densitometry units against time after dosage of LPS, with error
bars showing inter-quartile ranges. Also shown are representative
dot blot results for each protein. "*P < 0.005 and < 0.0005
compared with preexperimental values when Mann-Whitney
analysis was performed. All results are based on n = 12.
Pre 6 hours 24 hours 168 hours
was used as a negative control. Ad-ovine elafin and Ad-human
elafin conferred protection of the A549 cells, irrespective of the
enzyme used. Ad-murine SLPI protected the ceils against HNE
only, whereas, as anticipated, die negative control Ad-murine
eotaxin was ineffective against either enzyme.
This array of results was obtained using qualitative (fig. 7A)
and quantitative (fig. IB) methods. In agreement with the
above, the protection by Ad constructs against HNE and PPE
activity was paralleled by measuring residual enzymatic activ¬
ity in the supernatants (fig. 7C).
DISCUSSION
Neutrophil elastase inhibitors have been shown to be impor¬
tant endogenous molecules involved in limiting the extent of
neutrophil-induced inflammation in humans, as well as in a
variety of animal models (4, 10, 17, 30). Among these inhib¬
itors, our group is particularly interested in the study of elafin,
a member of the tr&ppin multigene family (27). The "trappin"
name has been coined by Schalkwijk and collaborators (27) as
an acronym for "transglutaminase substrate and WAP domain
containing protein," to illustrate its property ofbeing "trapped"
in a tissue (at least in the skin; Refs. 13 and 29) and therefore
potentially acting as an anchored protein. Trappins consist of
an NH^-term inal transglutaminase substrate domain with
hexapeptide repeats (PVKGQD) and a COOH-terminal four-
disulfide core, containing, in some members, the antielastase
activity (27). Members of this family share the WAP domain
with another elastase inhibitor, SLPI. Trappin members have
been isolated from a number of animal species, including
humans, but, until now, no studies had identified the ovine
ortholog of elafin.
We have in the present study isolated both the genes and
cDNA coding for this protein and have analyzed the antielas¬
tase activity of the translated product.
We have isolated from a trachea sample a cDNA encoding
for ovine elafin (o-elafin) which is composed of 220 amino
acids, inclusive of a 23 amino acid signal peptide indicating
that the protein is, like other species orthologs, a secreted
protein (Fig. 1 and 2). Following this signal peptide, we
identified a region containing 19 hexapeptide repeats of the
consensus sequence PVKGQD. A very similar region of re¬
peats has been termed "cementoin" (14) in the trappin family
of proteins (27), to which the elafin members belong (see
above). This glutamine- and lysine-rich region is thought to be
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Ad-h elafin Ad-o elafin Ad-m SLPI Ad-Eotaxin Ad-h elafin Ad-o elafin Ad-m SLPI Ad-Eotaxin
Fig. 7. Adenovirus (Ad)-ovine elafin protection of A549 cells against human naitrophil elastase (HNE) and porcine pancreatic
elastase (PPE): correlation with inhibition of enzymatic activity. Ad-ovine elafin was shown to protect A549 cells against HNE and
PPE (1 |Ag/ml) (A). By contrast, the negative control Ad-rrurine eotaxin provided no protection against either enzyme. Ad-human
(Ad-h) elafin protected cells against both HNE and PPE, whereas Ad-murine (Ad-m) SLPI was efficient only against HNE (A).
These data were confirmed quantitatively, when protein concentration was assessed as a surrogate marker of cell damage (B; and
experimental procedures). The protection (or lack of) conferred (A and B) by the Ad constructs against proteolytic enzymes was
paralleled by the residual enzymatic activity recovered in cell culture supernatant (C). **P < 0.005 and ***p< 0.0005 compared
with Ad-murine eotaxin with Mann-Whitney analysis; n = 5 (HNE) or 6 (PPE).
involved in a transglutaminase reaction resulting in e-(y-glu-
tamyl)lysine covalent bonds between the repeat region and
matrix proteins such as loricrin and keratin-1, to promote the
anchorage of the molecule to the interstitium, at least iri the
skin (13, 29). The second domain of o-elafin is composed of a
WAP domain (27), which has strong homology with o-SLPI,
which we sequenced (accession no. AY346135), and based on
the sequence contains the antielastase site (see below).
Using both the ovine genomic BAC library described above
and genomic DNA obtained locally, we isolated the o-elafin
gene TOM-1 (Fig. 1, accession no. AY344541), the sequence
ofwhich predicted exactly the cDNA sequence obtained from
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tracheal RNA. The gene structure is similar to tliat for human
elatin (23) in that the gene contains 3 exons and 2 introns with
similar intron/exon boundaries.
The promoter region shown contains a "TATA" box at bp -163
but no sequence identifiable as a "CAAT" lx>x. An ATG initiation
codon was detected, directly 3' of a consensus Kozak sequence
(9). The o-elafin leader sequence coding for the signal peptide
was found to be very similar to other species' orthologs.
RT-PCR and Northern blot analysis using RNA from vari
ous ovine tissues showed o-elaliii to be present in tongue,
trachea, small intestine, large intestine, and skin. This is similar
to porcine elaftn's distribution, where claim lias been shown by
in oitu hybridization to be accreted by goblet eellii in the
tracheal mucosa and large intestinal crypts (31), and to human
elafin, which has been detected in bronchial mucus (19) and
psoriatic skin (26, 35) at the protein level and in the epiglottis,
pharynx, vocal fold, and psoriatic skin ai die mRNA level (16).
Of note, higher levels of expression of ovine elafin were seen
in die huge intestine when analyzed by Northern biol analysis
compared with RT-PCR. This is possibly due to degradation of
the RNA, which would limit RT-PCR yield but may not have
such a marked effect on Northern blot analysis.
To summarize tissue distribution of mRNA, o-ciafin is
transcribed in the upper respiratory tract, oral cavity, skin, and
gastrointestinal tract. 1'he mainly mucosal tissue distribution of
o-elafin is consistent with it being, like its human ortbologs, an
antimicrobial "defensin-like" molecule (20). Indeed, evidence
is forthcoming that, in addition to their antiprotcasc activity,
SLPI and elafin have important functions in innate immune
responses (20).
Interestingly, we obtained either one or two o-clafin cDNA
producta, depending on the tissues (Fig. 3). The origin of the
two bands lias been shown to lie two allelic forms oftlie same
gene (TOM-1 and TOM-2) (Fig. 4). The reason for the varied
expression of TOM-1 and TOM-2 in different tissues is unex¬
plained at present, although it is most likely due to differential
allele-spceific expression, a phenomenon recognized in other
systems. The reason why wc only obtained TOM-1 from die
BAC library analysis while both TOM-1 and TOM-2 were
obtained from genomic DNA probably lies with the origin of
the samples: indeed, the BAC library used(INRA, France) was
derived from a different ovine breed (Romanov; Ref. 34) from
the one used for the RNA and subsequent RACE analysis
(Suffolk crosses from the UK). Our results suggest that the
Romanov breed animal used to construct the BAC library only
has TOM 1, whereas the Suffolk breed has both TOM 1 and
TOM-2. It is therefore [KKsible that the two allelic forms of
o-clafin may be caused by the interbreeding of the commercial
Suffolk lowland flock.
Tile large transglutaminase substrate domain present within
the o-elalin molecule is of interest with regard to its potential
interaction with other tissue components. As mentioned above,
this region is thought to be involved in cross-linking to extra¬
cellular matrix proteins at least in the skin. Human elafin has
boon shown tu bo cross linked in litis way to the oornified
envelope of keratinocytes (13, 29). Human ciafin contains five
repeats loosely based on the consensus sequence PVKGQD.
The o elafin orthologs discussed here (TOM 1 and TOM 2)
contain 19 or 26 repeals with far higher conservation of the
consensus sequence, suggesting, potentially, higher levels of
transglutaminase mediated cross linking. Interestingly, recent
19
work has implicated transglutaminase repeats to be of impor¬
tance in competitively inhibiting tissue transglutaminase and in
turn phospholipasc A2, hence leading to a downrcgtilarjon of
proinflammatory mediators in a hypersensitivity model (2S).
This link between members of the trappin family and down-
regulation of phospholipasc Aj leads to the fascinating possi¬
bility that Hie extensive transglutaminase substrate region of
the o-clafin proteins may provide a particularly high anti¬
inflammatory activity to the secreted protein compared with
those already studied. The transglutaminase substrate domain
has also been identified as one of the c/'s-acling elements
implicated in the gene multiplication seen in the members of
the trappin family [Furutani et al, (3) identify a correlation
between number of repeats and iiutvibci of trappin family
members, i.e., the fewest repeats are seen in human and
peccary, in each of which only one trappin family member has
been described]. 3uiprisingly, given the high niuubei ofrepeats
identified here, we only isolated one trappin, ovine elafin,
which was shown to exist in two allelic ibrins. Tiiis is the first
time a trappin family member gene lias Ix-cn shown lo be
present in more than one allelic form.
The phylogcnctic Ircc analysis (Fig. 8) shows the close
relationship between the WAP domain of TOM-1 and TOM-2,
iutd lite other trappin family members, with the second WAP
domain of the SLPI orthologs. This suggests a divergence in
evolution of the trappin WAP motifs and the second SLPI
WAP motif from a common ancestral protein subsequent lo the
divergence of the first and second WAP motifs of the SI.PI
family from each other. Interestingly, the hominid trappins
(human elafin and simian elafin) have diverged from the rest of
the known trapping (Bovidac, Hippopotamidao, Taya3auidac,
and Suidae). The two o-elafin proteins (TOM-1 and TOM-2)
are most closely linked with bovine elafin and bovine trappins
4 and 5.
To ascertain whether the ovine elafin protein is behaving like
a local acute phase rcactant. wc assessed the levels of ovine
elaiin in a model of lung inflammation triggered by local
bronchoscopic administration of I.PS. The dramatically in¬
creased level of elafin in inflammatory conditions such as
described here finds an eelto in some of our previous in vitro
and in vivo human work. We showed (33) that elafin levels
were sharply increased in BALF from human patients with
farmer's lung disease. By contrast, in the same patients, and in
lite present study, ST.PI levels increased less dramatically. Ttlis
may be due to the increased sensitivity of ciafin to proinflam¬
matory cytokines such as 1L I and TNF (22). The time courses
ofelafin and SI.PI expression presented iiere add further to that
concept, in agreement with murine SLPI in vivo studies (1, 7).
Western blot analysis ofBALF lor ovine elafin and SLPI using
tlie antibodies utilized in the dot blot analysis above was
unsuccessful at detecting protein, presumably because of the
low concentration ol these antiprotcases nt the BAIT .
In summary, the identification and cloning of the gene
encoding for the ovine orthologs of human elafin have allowed
us to postululo important and exciting functions of this protein
in addition to the antiprotcasc functions. Furthermore, the in
vivo demonstration that ovine elafin is an acute inflammatory
reaetanl in the lung indicates that it can be considered as an
"alarm inhibitor" in that organ. Its efficiency as a neutrophil
elastase inhibitor makes it an attractive candidate for use in
adenovirus mediated gene transfer in ovine models of ncutro
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Fig. S. Whey acid protein (WAP) comparison (SLPI, trapping mouse clafin-likc proteins, vasopressin). A: alignment of the 1st and
2nd WAP domains of the currently known SLPI proteins, along with die WAP domains for a variety of trappins including die ovine
forms of elafin derived from die alleles TOM-1 and TOM-2, and including the WAP domains of the murine clafin-likc proteins 1
and 2 (Hagiwara et ah, Ref. 5) and human vasopressin. The WAP motifs for all the proteins were aligned by using ClustaJW
software available online. Conserved cysteine residues are indicated by asterisks. The boxed region indicates the putative active
antiprotease active site in the second WAP domains of the SLPI family and in die WAP domain of die trappin family. B:
phylogcnctic tree constructed using a neighbor-joining tcchniejuc with Poisson corrected data from the above alignment. Bootstrap
values above 40 arc indicated. Branch length is proportional to evolutionary distance.
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phils-driven lung injury, currently being explored in our labo¬
ratories. Additionally, specific and potentially very important
effects of the transglutaminase substrate domain in this protein
warrant further investigation.
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